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Abstract
The enormous burden and threat to global health posed by the spread of malaria
is well documented and forms an extensive field of study. With over 250 mil-
lion new cases per annum and close on a million deaths, mostly in Sub-Saharan
Africa, [5], the role of pharmacokinetics in determining the contribution of drugs
to the prevention and cure of malaria is of evident importance. During preg-
nancy, those stricken with the disease are at increased risk of severe morbidity
and both maternal and foetal mortality.
As part of the current WHO recommendations, pregnant women in areas of
high intensity malaria transmission are given intermittent preventative treat-
ment (IPT), using Sulfadoxine-Pyrimethamine (SP). Despite this recommenda-
tion and widespread implementation of the policy, there is very limited informa-
tion on the disposition of the compounds during pregnancy, information which
is critical for the development of informed and justified dosing regimens.
Using a similar protocol, studies were conducted in Mozambique, Zambia, Mali
and Sudan, where serially measured concentration data was collected for healthy
self-matched pregnant subjects on SP-IPTp. The objective of the studies was
to enable characterization of the processes underlying the concentration-time
relationship, and to determine the impact of pregnancy and pregnancy-related
factors on individual specific deviations from these processes. Data was collected
for 98 pregnant women, 77 of whom returned postpartum to act as self-matched
controls.
The mixed effect or hierarchical model, is an appropriate methodology in the
analysis of longitudinal data, in that it copes with the repeated measures per
subject through the addition of subject-specific random effects, [6]. It thus pro-
vides a flexible framework and structure for dealing with multiple sources of
variation, [6, 3]. In addition, by pooling information from all sampled individ-
uals, it effectively accommodates sparsely sampled data.
This thesis discusses the techniques involved in the fitting of nonlinear mixed
effect (NLME) models. In particular, it looks at the application of these tech-
niques to the analysis of concentration-time data for the aforementioned anti-
malarial compounds, and details the necessary extensions to the basic modeling
process that were required in order to accommodate multiple responses and
multiple observation phases (pregnant and postpartum).
The existence of serial measurements for two phases on each individual neces-
sitated the inclusion of an additional level of random effects, occasion-specific,
nested within the individual-specific effects. This multi-level model was devel-
oped for each of the individual compounds, using a structural model based on
additive poly-exponential expressions.
In addition to the quantification of the systematic impact of pregnancy, results
from the multi-level models were contrasted with those achieved using single
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level models with an explicitly specified correlation structure for the random ef-
fects. Various structures were explored for the modeling of heterogeneous resid-
ual variance (a complication not unusual in nonlinear repeated measurement
data), and the impact of various different parameterizations on the convergence
and stability of the models was also assessed.
The co-administration of the two drugs raises the possibility of an interaction
or interdependence. Sequential and simultaneous modeling procedures tradi-
tionally used in the context of investigating the dose response relationship were
adapted to the analysis of the joint absorption and distribution of these drugs.
The sequential modeling approach involved the use of the predicted values of
one response in the covariate model of the other as a time-varying predictor.
This approach was contrasted with two simultaneous model formulations, one
in which different structural model forms were specified using a binary indicator
for response type, and one wherein the same structural form was applied to both
responses, and the response type was included as a covariate.
Bi- and triple- exponential models were deemed appropriate for Sulfadoxine
and Pyrimethamine respectively, which are loosely analogous to traditionally
defined one- and two-compartment pharmacokinetic model forms. Both single-
level models with correlated random effects and multiply-nested models achieved
the same results, and the parameterization of the random effects (fit in both an
additive and multiplicative (or proportional) context, the latter using logged
parameters), appeared to play a significant role in the ease and speed of con-
vergence, and in the estimation of robust variance-covariance matrices for the
random effects.
The Delta method was then employed in order to acquire estimated standard
errors for clinically useful parameters, obtained via back transformation from
the exponential specification. The pharmacokinetic parameters obtained via
this approach were compared and contrasted with those previously obtained
using a traditional two-stage approach to the analysis of this longitudinal data
set, that is, those obtained by averaging results obtained from individual- and
occasion-specific models. Additional comparisons were also made between the
parameters obtained from the exponential specification, and those from a mech-
anistically specified NLME model.
Results from the individual models indicated that physiological changes in preg-
nancy play a differing role for the two compounds in the determination of both
the range of concentrations reached following the standard dosage regimen, and
in the elimination of the drug from the system.
Pregnancy appeared to increase the range of concentrations reached for Sul-
fadoxine, whilst simultaneously increasing the rate of decline over time. The
overall clinical impact of this was a reduction in the total drug exposure, as
measured by the area under the concentration-time curve (AUC), a reduction
in the volume of distribution, and an increase in the clearance. Site also had
an impact on the concentration-time profile of Sulfadoxine, with subjects in
Mozambique and Zambia having the highest and lowest range of concentra-
II
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tions, irrespective of pregnancy phase, and subjects in Mozambique having a
slower rate of decline when compared to other sites, again irrespective of preg-
nancy phase.
The impact of pregnancy on Pyrimethamine concentrations was to similarly
increase the range, although no direct effect could be ascertained for the various
rate constants. Clinically, this translated to an increase in total drug exposure,
again as measured by the AUC, and a decrease in clearance for pregnant sub-
jects versus those postpartum. The impact of pregnancy was dependent on the
study site of the subject: pregnant subjects had higher peak concentrations in all
sites except Sudan, where pregnancy status appeared to have a limited impact.
Additionally, there was a separate site effect, with subjects in Mozambique and
Zambia having the highest and lowest concentrations respectively, regardless of
pregnancy phase.
Pharmacokinetic parameters obtained from the exponential specification were
similar to those obtained via the two-stage approach and the mechanistic NLME
model.
In the sequential modeling, the impact seen was that of the predicted Pyrimeth-
amine concentrations on the absorption properties of Sulfadoxine, rather than
any effect vice versa. Both this sequential model and the simultaneous model in
which different functional forms were accommodated for the different responses
were of limited usefulness in determining the true nature of the interaction be-
tween the drugs.
The simultaneous model in which the same structural form was applied for both
responses allowed for the formal statistical testing of the “correct” structural
model form for the different responses, and bi- and triple-exponential models
were again indicated for Sulfadoxine and Pyrimethamine respectively.
For this model specification, the parameter estimates for the response type in-
dicator variable were effect modifiers, specifying changes to the parameters and
thus the concentration-time curve for the baseline response (Pyrimethamine).
The parameters defining the second compartment for Sulfadoxine were not sig-
nificantly different from zero. Additionally, the impact of pregnancy could be
directly determined only for parameters related to the range of concentrations
reached.
Concerns arose with the determination of accurate starting estimates for the
more general empirical specification of the model in terms of poly-exponential
equations, which initially led to problems with convergence. These were later
overcome using curve-stripping algorithms.
An additional problem area resulted from the multiply-nested structure of the
data, in that the determination of the degrees of freedom was not possible, un-
less approximated using formulae appropriate in the linear mixed effect model
context, which did not appear to be applicable in the non-linear context.
Covariate model building also presented several challenges, due in part to the
III
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complexity of the base model specification, and also because of the loss of clinical
information regarding the placement of covariates resulting from the exponential
parameterization. Convergence and stability issues resulted in fewer covariates
being considered for inclusion, despite indications that covariates not included
might still play a role in determining the relationship between the two drug
concentrations and the influence of pregnancy, such as anaemia.
This thesis demonstrates that the use of nonlinear mixed effect modeling tech-
niques provides a flexible framework for the estimation of separate, sequential
and simultaneous models of drug-concentration over time. We have been able
to draw conclusions regarding the impact of pregnancy on the concentration-
time profiles of the individual compounds, as well as examine the sequential
and simultaneous approaches to the modeling of the interaction between the
two drugs, although further work is required to obtain a specification for the
simultaneous modeling approach that allows for different structural forms and
also makes sense for drug-drug interactions.
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Chapter 1
Problem Statement and
Introduction to Data
1.1 Study Design
The data specific to the analyses presented in this thesis are from a prospec-
tive multi-center study, consisting of 98 self-matched pregnant women from four
different countries, where self-matched refers to return of the same subjects
postpartum for the purpose of providing a non-pregnant control group.
Data was initially collected for 31 pregnant women in Mozambique, with the
same women returning postpartum to act as their own controls. Using a simi-
lar protocol, a study was undertaken in Sudan, with 25 self-matched pregnant
women, and again in Mali and Zambia with 18 and 25 self-matched pregnant
women respectively.
All subjects were healthy volunteers, with maternal age 18-45 and gestational
age 15-36 weeks, receiving intermittent preventative treatment during pregnancy
(IPTp) with Sulfadoxine-Pyrimethamine (SP), antimalarial compounds that are
routinely administered as part of pre-natal care in areas of high malaria preva-
lence.
Three tablets of SP (1500 mg of Sulfadoxine and 75 mg of Pyrimethamine)
were orally administered to each subject once during pregnancy and again post-
partum.
The main purpose of the study was to determine the impact of pregnancy and
pregnancy related factors on the disposition and characterization of the SP drug
concentration-time profiles.
This is referred to as the study of Pharmacokinetics (PK), whereas the study
of the impact of the drug on the disease is termed Pharmacodynamics (PD).
Of the original 98 subjects, 77 returned to complete the postpartum phase of
the study, and hence the data is unbalanced.
1
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Figure 1.1: Sulfadoxine Concentration-Time Curves Grouped by Pregnancy
Phase and Site
Figure 1.2: A Sample of Individual Sulfadoxine Concentration-Time Curves
Grouped by Pregnancy Phase and Site
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Blood samples were collected from women in Mali and Zambia at 3, 6, and 12
hours, and again at 1, 3, 7, 14, 21 and 28 days, and from women in Mozam-
bique and Sudan on days 1, 3, 7, 14, 21 and 28 only. Postpartum samples in
Mozambique and Sudan were taken on days 0 and 7 only, which was deemed
adequate at the time owing to the reported high correlation between day 7 drug
concentrations and overall drug exposure [5].
There are thus differing measurement occasions for different sites, and extremely
sparse sampling for the postpartum phase in two of the sites where concentra-
tions are only measured twice. There is also very limited information for the
absorption phase, as data is only collected for the first 24 hours in two of the
four sites.
This sparsity of information is demonstrated by Figure 1.1, which shows (mul-
tiple) Sulfadoxine concentration-time curves for each pregnancy phase grouped
by site, and by Figure 1.2, which looks at a subset of the data, and allows for the
examination of several individual subject profiles by pregnancy status and site.
Large variation in the shape of the curves is observed both between individuals
and within individuals between phases.
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Figure 1.3: Decomposition of Bi-Exponential Curve
The methods involved in the evaluation of these curves must thus account for
the sparseness of the data, the inherent correlation structure induced not only by
the serial measurements per subject but by the multiple nested levels of group-
3
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
ing, (specifically: the measurements within observation phases within subject),
and also the variable shape of the curves.
This latter aspect is addressed with the use of sums of exponentials, a rou-
tinely applied empirical methodology for curves such as these [7]. We chose to
fit empirical rather than mechanistic models because we focused on the smooth-
ing and interpolation of these incomplete observed concentration-time curves,
approaching the analysis from a mathematical rather than pharmacological ap-
proach.
The suitability of the use of sums of exponentials is demonstrated graphically in
Figure 1.3, which shows the decomposition of a particular bi-exponential equa-
tion into its requisite parts, superimposed over the lowess plot of the observed
Sulfadoxine concentrations at the different time points.
In addition to accounting for all of the aforementioned aspects, the method-
ology must also accommodate the possible inter-dependent relationship of the
two responses (the Sulfadoxine and Pyrimethamine concentrations over time),
as the drugs are co-administered.
The correct quantification of this relationship is necessary in order to accom-
modate the simultaneous modeling of PK/PD data, although the focus of this
thesis is on the PK component only. The concentration-effect relationship deter-
mined by the PK/PD analysis has yet to be accurately elucidated for SP in vivo,
due in part to the lack of information regarding the interaction of the two drugs.
Table 1.1 is an excerpt of the data, highlighting the structure and the vari-
ous factors under consideration as potential covariates.
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Participant Day Sulfadoxine Pyrimethamine Pregnant Gestational Age Trimester Site Haemaglobin Anaemic (HB <10d/l) Weight Dosage
(ug/ml) (ng/ml) (wks) (g/dl) (Yes/No) (kg) (mg/kg)
MALI 002 0 0 0 1 24 2 Mali 9 1 60 1.25
MALI 002 0.125 83.2 354 1 24 2 Mali 9 1 60 1.25
MALI 002 0.25 83.9 310 1 24 2 Mali 9 1 60 1.25
MALI 002 0.5 86.8 311 1 24 2 Mali 9 1 60 1.25
MALI 002 1 80.7 266 1 24 2 Mali 9 1 60 1.25
MALI 002 3 69.4 178 1 24 2 Mali 9 1 60 1.25
MALI 002 7 49.7 71 1 24 2 Mali 9 1 60 1.25
MALI 002 14 25.3 11 1 24 2 Mali 9 1 60 1.25
MALI 002 0 0 0 0 0 0 Mali 14.2 0 56 1.34
MALI 002 0.125 55.3 350 0 0 0 Mali 14.2 0 56 1.34
MALI 002 0.25 55.9 277 0 0 0 Mali 14.2 0 56 1.34
MALI 002 0.5 66.2 245 0 0 0 Mali 14.2 0 56 1.34
MALI 002 1 63.4 201 0 0 0 Mali 14.2 0 56 1.34
MALI 002 3 59.9 112 0 0 0 Mali 14.2 0 56 1.34
MALI 002 7 39.2 24 0 0 0 Mali 14.2 0 56 1.34
MALI 002 14 34 12.3 0 0 0 Mali 14.2 0 56 1.34
MALI 002 21 19.7 0 0 0 0 Mali 14.2 0 56 1.34
MALI 002 28 11.3 0 0 0 0 Mali 14.2 0 56 1.34
SUDN 029 0 0.501 127 1 17 2 Sudan 10 1 78 0.96
SUDN 029 1 56.1 318 1 17 2 Sudan 10 1 78 0.96
SUDN 029 2 66.7 262 1 17 2 Sudan 10 1 78 0.96
SUDN 029 3 48.2 186 1 17 2 Sudan 10 1 78 0.96
SUDN 029 7 28.4 66.1 1 17 2 Sudan 10 1 78 0.96
SUDN 029 14 11.9 11.8 1 17 2 Sudan 10 1 78 0.96
SUDN 029 21 7.7 0.37 1 17 2 Sudan 10 1 78 0.96
SUDN 029 28 3.95 4.56 1 17 2 Sudan 10 1 78 0.96
SUDN 029 42 0.625 2.95 1 17 2 Sudan 10 1 78 0.96
SUDN 029 0 0 0 0 0 0 Sudan 7 1 53 1.42
SUDN 029 7 44.6 79 0 0 0 Sudan 7 1 53 1.42
Table 1.1: Subset of Data: Example
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Chapter 2
Methodology
2.1 Introduction to Pharmacokinetics
2.1.1 Background
In order to motivate the use of Non-Linear Mixed-Effect (NLME) modeling
techniques, it is pertinent to define the broad goals behind the analysis of phar-
macokinetic data, and to explore the characteristics of the data which render
these techniques necessary.
Pharmacology may be defined as the science dealing with the fate and effects
of the drugs or substances on the processes of the body and mind, where drugs
are defined as a chemical agent, typically foreign or exogenous to the body, [8].
The branch of pharmacology dealing with the fate of drugs in the body, or
the processes of absorption, distribution, metabolism and elimination (ADME),
is known as pharmacokinetics (PK), and is more formally defined as the study
of the time course of substances in the body, [2, 8, 9, 10, 11, 12, 13, 14].
Pharmacodynamics (PD) is defined as the study of the pharmacological re-
sponse to a drug (the effect of the drug in the body), and it is typically studied
together with pharmacokinetics in order to determine whether or not there is a
concentration-effect relationship [8, 9, 10, 11, 12, 13, 14].
The goal behind the analysis of pharmacokinetic data is to provide a better
understanding of how the concentrations of the drugs under evaluation (and
the underlying processes which govern these concentrations) vary over time and
across individuals. The quantification of systematic variation is critical for the
development of sub-population specific dosing regimens, [6, 14, 15].
2.1.2 General Data Characteristics
In general, pharmacokinetic data consists of serially measured drug concentra-
tions on several individuals, that is, the data consists of repeated measurements
over time which are grouped according to one or more classification factors, and
is thus termed hierarchical, [6, 15].
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The variation in the response (drug concentration) is non-linear over time,
and from multiple sources: there is both within group variation (i.e. intra-
individual), and between group variation (i.e. inter-individual), [3, 6, 15].
The usual ordinary least squares (OLS) assumptions of independent observa-
tions are thus no longer applicable because of the within-individual correlation
between measurements, i.e. observations within a particular group are expected
to be more similar than observations from different groups. Between group
variation refers to the individual-specific deviation from the common or typical
profile.
We expect the same basic nonlinear profile for drug concentrations over time,
but the peak, rise and decay and the corresponding model parameters will differ
slightly for each person, [3, 6, 15]. This deviation can be attributed to, and
explicitly modeled as a function of both systematic and random components,
where systematic refers to the impact of an individual or grouping level specific
covariate pattern, [3, 6, 15].
2.2 Basic Pharmacokinetics
An in depth discussion of pharmacokinetics is beyond the scope of this thesis,
but the rudimentary principles are introduced here in order to familiarize the
reader with terms and concepts later referenced.
Since Sulfadoxine-Pyrimethamine is administered orally in a single dose, and
the intention behind the collection of the data was to determine the impact of
pregnancy induced changes on the disposition of SP, processes specific to oral
administration, SP, and the impact of pregnancy have been highlighted. Calcu-
lations for parameters of interest are detailed in later sections.
In general, the aim of drug therapy is to achieve efficacy without toxicity, [16].
Figure 2.1 [1] represents the typical concentration profile for a single orally ad-
ministered dose, where the minimum effective concentration (MEC) and toxic
threshold are clearly demarcated.
The objective is thus to determine a regimen for dosing such that concentrations
reach and exceed the MEC as quickly as possible, remaining in the therapeutic
window for as long as required, without toxicity, [9, 10, 11, 12, 13, 14].
Pharmacokinetics allows us to determine the factors behind the variation of
the concentration over time, and thus to create dosing regimens tailored to take
into account changes in pertinent PK parameters brought about by physiologi-
cal or environmental factors, (for example), [16].
From a dosing perspective, the most important parameters are the clearance,
volume of distribution and elimination half-life of the drug, defined as [16]:
 Clearance (Cl): the volume of plasma cleared per unit time,
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 Volume of Distribution (Vd): the volume of space the drug would be
distributed in at a concentration equal to that observed in the plasma
(blood), given uniform and instantaneous distribution,
 Elimination half-life (t1/2): the time for the concentration of the drug to
be halved.
Figure 2.1: Typical Profile with Therapeutic Window Indicated [1]
The movement of drugs through the biological system is a complex process,
and the models used to assess this movement are hence based on simplifying
assumptions, [13, 14].
The schematic below is a much simplified version of the actual processes oc-
curring in the body following the administration of a drug, [13]:
DrugIn −→ Gastro − Intestinal T ract
↓
Blood ⇐⇒ T issues
↓
Elimination
Essentially, a drug is administered for the purposes of producing a therapeutic
effect, which is achieved through the absorption and subsequent distribution of
drug molecules to what is known as the site of action, [14], which may broadly
be described as a binding site for the drug, consisting of cells or tissues that in-
teract with the drug to bring about the desired (or adverse) effects, [8, 17, 18, 19].
These target sites can be receptors or enzymes, where receptors are a kind
of terminal on the cell surface which are able to detect stimuli, and through the
transmission of signals (dependent on the type of stimulus), are able to bring
about a type of reaction. Drugs can bind to these receptors, which will induce
a certain effect, or to enzymes, which regulate the rate of chemical reactions,
thereby altering this rate, either increasing (activators or inducers) or decreas-
ing it (inhibitors), [8, 17, 18, 19].
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Agonists are defined as drugs which stimulate the receptor in the same way
that the body’s natural substances would, and antagonists as drugs that block
the action of the natural substance. Receptors may have several subtypes, and
drugs may act on one or several, [8, 17, 18, 19].
Blood usually provides the method of transport from the site of administra-
tion to the surrounding tissues and organs (including the site of action), and is
thus one of usual mediums of measurement of concentrations in the body (along
with urine), [2, 11, 14].
For malaria, blood is the main site of action, and Sulfadoxine and Pyrimethamine
are both folic acid antagonists, which in combination as SP, act as a two-fold
interference in the synthesis of tetrahydrofolic acid in malaria parasites, which is
essential for DNA synthesis and cell multiplication, i.e. they prevent the repli-
cation of the parasites at a crucial stage in their development cycle, [18, 20].
In intravenous administration, the administered drug is immediately and instan-
taneously absorbed into the systematic circulation, (i.e. no absorption is neces-
sary) and 100% of the administered dose is available for distribution, [14, 16].
SP is, however, orally administered, and must therefore follow a process of ab-
sorption, (defined as the movement of the drug from the site of administration
into the systematic circulation/site of measurement (in the case of SP, the blood
or plasma), [2, 9, 10, 11, 12, 13, 14], or in biological terms, as the ”uptake of
materials from cells’ external environment”, [19]).
In general, following absorption into the system, i.e. once in the bloodstream,
there is both bound and unbound (free) drug, which is circulated throughout
the body, [9, 10, 11, 12, 13, 14]. Concentrations measured from plasma are as-
sumed to be total drug concentrations (from both free and bound drug, which
are assumed to be in equilibrium). Bound drug is that which is (e.g.) reversibly
bound to either red cells or plasma proteins, such as albumin, and the protein-
binding acts like a slow-release system from a reservoir, [9, 10, 11, 12, 13, 14].
The free drug is that which is allowed to travel across cell membranes, (semi-
permeable barriers around cells, composed of phospholipids (fat molecules), pro-
teins and aqueous pores), and distribute into peripheral tissues, [8, 9, 10, 11,
12, 13, 14, 19].
Tissue bound drug eventually leaves and re-enters the bloodstream. This re-
versible transfer of drug to and from the site of measurement (i.e. from the
blood or plasma to the surrounding tissues and back again) is known as the
process of distribution, [2, 9, 10, 11, 12, 13, 14].
From the bloodstream, the drug is able to perfuse the liver and kidneys, the
main organs responsible for the elimination of drug from the system, where
elimination is the irreversible transfer of drug from the site of body. this in-
cludes metabolism, where the parent drug or initial substance is converted into
a slightly different chemical substance, and excretion, [2, 9, 10, 11, 12, 13, 14].
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This is not a simple linear process: drug metabolized by the liver can be excreted
in bile/faeces, but it can also be reabsorbed, (this re-absorption is referred to as
the entero-hepatic cycle). Both the parent drug and any un-excreted metabo-
lites are later filtered by the kidney, and again either reabsorbed or excreted
from the body, [9, 10, 11, 12, 13, 14] and there are other routes of elimination
e.g. sweat/tears, although these are generally minor.
In the subsections that follow, (which describe the individual processes of ab-
sorption, distribution, metabolism and elimination (ADME) in greater detail),
the information presented is a para-phrasal and concatenation of work presented
by Wagner [14] and Begg [16].
2.2.1 Input factors: Absorption
There are several possible routes of administration, which may loosely be cate-
gorized into intra- and extra-vascular routes.
In oral administration, (as is the case with most of the extra-vascular routes),
following drug administration a small depository is formed, and some form of
transport must occur from this site of administration to the systematic circula-
tion. This transport usually involves the traversing of a cell membrane.
Oral absorption in particular usually occurs via passive diffusion of the drug
through the small intestine, i.e. the process is one which requires no energy,
and movement flows with the concentration gradient (from an area of high con-
centration to that of a lower concentration). Drug absorption may also occur
via active transport (as opposed to passive diffusion) whereby transportation
across the cell membrane is facilitated by an energy dependent membrane car-
rier mechanism such that transport can occur against the concentration gradient
(transfer from low to high concentration).
The completeness (or extent) of the absorption of the drug reaching the sys-
tematic circulation (bioavailability) is ordinarily less than 100%. Most orally
administered drugs must pass through the portal vein to the liver, which means
that the drug is exposed to metabolizing enzymes; this is known as the first pass
effect.
A number of factors, mechanical, physicochemical, and physiological, may im-
pact on the absorption of a particular drug, including, (but not limited to), the
surface area of the particles, or the size and shape of the granules, the pH of
gastric secretions, the presence or absence of food in the gut, the blood flow rate
to the site of administration, the individual’s temperature etc.
2.2.2 Disposition factors
Disposition factors as a whole refer to all the processes of drug movement from
the time that the drug appears in the systematic circulation until the time that it
exits the body. They thus encompass the processes of distribution, metabolism
and elimination.
10
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Distribution
Distribution in particular has already been defined as the reversible transfer
of drug to and from the site of measurement (the systematic circulation) into
different “volumes”: extra vascular, interstitial and intracellular spaces.
The systematic circulation carries the drug to all the tissues of the body, but the
rate and extent of the distribution is determined by the ability of the drug to
perfuse these tissues, which again depends on the blood flow rate to the tissue
(the perfusion rate), and the pH of the drug.
Tissues fall into several groups: those that are highly perfused, less highly per-
fused tissues (muscle and skin), a negligible perfusion group which consists of
ligaments and cartilage, and a fat group (adipose tissue and bone marrow).
Drugs distribute most easily into porous tissues with high blood flows, (such
as the liver/kidney) and less easily into e.g. the brain, which is protected by the
blood-brain barrier, a lipid membrane with very few aqueous pores.
Un-ionized, lipophilic (fat-loving) drugs are more widely distributed, and po-
lar drugs (ionized, hydrophilic drugs i.e. dissolving more easily in water) less so
because of the difficulty encountered in crossing non-porous lipid membranes.
The polarity of a drug thus limits the rate of distribution and basic compounds
tend to distribute more easily into tissues than acidic.
Distribution is also influenced b plasma-protein and tissue binding: at equi-
librium (which is assumed to exist at all times because of the speed of rates
of association and the disassociation of the reversible binding process) protein-
and tissue-bound drugs are not available for distribution.
Metabolism and Elimination
Metabolism, or biotransformation, typically forms part of elimination in that
the parent substance is, by way of enzyme-catalyzed reactions, converted to
metabolites, either in the gut wall during absorption, in the liver, or in certain
tissues, such as the lung and kidney.
The rate and extent of metabolism is influenced by genetic, environmental and
physiological factors. The form of metabolism that is of the most interest with
oral absorption is that occurring in the gut wall, and the so called first pass
effect already discussed, which reduces the overall bioavailabilty of the drug.
The route of elimination is largely dependent on the polarity and molecular
weight of the drug. Sufficiently lipophillic components excreted in bile are re-
absorbed in the GI Tract (entero-hepatic cycle), and cleared again by the liver,
before finally being excreted. Some polar drugs are biotransformed by bacteria
and the products reabsorbed, and they are usually eliminated via the kidneys.
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Renal excretion, which occurs via the kidneys, and is the route of elimination for
SP, is quantitatively the most important route, although excretion also occurs
via bile/faeces and sweat and tears also play a minor role.
There are 3 processes of renal elimination:, Glomerular filtration, passive tubu-
lar reabsorption, and active tubular secretion. Glomerulur filtration refers to
unbound drug only (and is thus dependent on the extent of plasma-protein
binding). The rate of filtration (125ml/min) referred to as the GFR can be
approximated by creatinine clearance. Passive diffusion in the kidney is depen-
dent on the polarity and degree of ionization of the drug at the urinary pH: an
increase in pH promotes the excretion of acids and inhibits that of bases. Total
renal elimination is given by filtration plus secretion, minus reabsorption.
2.2.3 Pharmacokinetic Parameters of Interest
There are a number of pharmacokinetic parameters of interest, most particu-
larly, the three previously mentioned: the volume of distribution, clearance and
half-life.
Distribution is estimated by the volume of distribution (Vd), (the volume into
which the drug appears to be distributed with a concentration equal to that
measured in the plasma). Volume of distribution is most commonly expressed
in litres, but may also be normalized for weight and measured in litres per kg.
The Vd is not a physiological volume, but may approximate to one of either
plasma volume (3L), extracellular volume (13-16L), or total body water (40-
46L). Values in excess of total body water indicate a high tissue uptake (in-
creased uptake of drug by tissues leaves smaller concentrations in the circula-
tion, and thus results in larger volumes of distribution).
It ranges from approximately 7 to 50000L.
Since we do not know the fraction (f) of the dose that was actually absorbed
following extravascular administration, we express the volume as V/f , where
f is a measure of bioavailabilty. We refer to V/f as the “apparent” volume of
distribution.
The clearance (Cl) or apparent clearance (Cl/f) of a drug refers to the amount
of plasma that is cleared of drug per unit time, and both renal clearance and
total clearance are defined, where total clearance is the sum of clearance from
all routes. for calculations of the maintenance dose rate, the clearance of the
drug is the most important parameter of interest, (while the loading dose is
calculated based on the volume of distribution) [16].
The plasma elimination half-life provides an “index of the time-course of drug
elimination”, [16]. It may be expressed in terms of ke, the elimination rate
constant, which may sometimes be determined from the log-linear plot of the
concentration-time profile as the slope of the line following Cmax (for a single
compartment model, defined in section 2.5.)
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There are several PK parameters relating to the absorption of the drug: the
bioavailabilty, (the percentage of the dose available for distribution into the sys-
tematic circulation), is a measure of the extent of absorption. The Cmax is the
maximum concentration reached, and the Tmax the time after dosing that this
maximum is achieved. Tmax is related to the rate of absorption, along with the
absorption constant (ka), [16].
The Cmax and Tmax may be obtained from the observed or predicted con-
centration versus time curves.
Additional parameters of interest are the AUC (the area under the plasma
concentration-time curve), which is a measure of the extent of drug exposure.
AUC is calculated using either the trapezoidal rule, should only the observed
data be available (model-independent approach), or derived from parameters
determined using appropriate models. Calculations for the AUC may be seen
in section 2.8.3, along with those for the volume of distribution and clearance.
The mean residence time (MRT), interpreted as the average time taken for the
drug to transition from administration to elimination, may also be determined,
and is defined as the first statistical moment where the concentration-time curve
is defined as a probability curve.
2.2.4 SP and the Impact of Pregnancy
Changes in maternal physiology influence the processes of absorption, distribu-
tion, metabolism and elimination. In some instances, pregnant subjects may
experience significantly higher or (more often) lower concentrations. For drugs
with a narrow therapeutic window, there is thus an increased risk of toxicity
for higher concentrations, or reduced efficacy for lower concentrations or total
exposure, [21, 22, 23].
In general, information on the absorption and disposition of drugs during preg-
nancy is limited and largely based on theoretical principles and observational
studies, as the ethical and practical constraints implicit in taking samples from
such a vulnerable subpopulation prevents the collection of large amounts of data,
[21, 22, 23].
During pregnancy, hormonal changes (such as elevated progesterone) may re-
duce gastric emptying and small intestine mobility, resulting in an increase in the
time taken to reach maximum concentration, and a decrease in the actual maxi-
mum achieved. These effects are most pronounced during the third trimester, as
it is during this time that the levels of progesterone are highest, [16, 21, 22, 23].
Changes in the gastric pH may also reduce the absorption of weak acidic drugs,
but the most pronounced absorption related impact of pregnancy for orally ad-
ministered drugs is that of nausea and vomiting, [22].
Pregnancy induces expansion of intra- and extra-vascular water content, and
hence increases total body water by approximately 8 litres. It also increases
body fat (approximately 4 kgs). This increase in body water and fat essentially
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provides a larger space for drugs to distribute into, resulting in a decrease in
the maximum concentrations reached and a larger volume of distribution. De-
creases in protein binding, (specifically albumin), result in the displacement of
protein-bound drug, which results in an increase in the amount of free drug
available, [16, 21, 22, 23].
An increase in hepatic blood flow means that more drug passes through the liver
and is thus available for metabolizing. Additionally, hormonal changes may in-
duce or inhibit metabolizing enzymes, thus increasing or decreasing metabolism
and hence elimination. The exact effect is dependent on the mechanism of
change and the drug itself, [16, 21, 22, 23].
Elimination of drugs is expected to increase during pregnancy, due to an in-
crease in renal blood flow of approximately 50 to 80%, and an increase in GFR
of about 40 to 65%. This increase, together with the increase in the volume
of distribution, indicates that there are lower concentrations during pregnancy,
and thus that dosage adjustments may be required, [16, 21, 22, 23].
There may also be a potential build up of drug in the foetal-placental unit:
drugs that may enter the foetal compartment with relative ease are occasionally
unable to return, resulting in an accumulation of drug in the foetus. Addition-
ally, because the umbilical cord feeds straight into the cardiac and systematic
circulation of the foetus, bypassing the liver, and enzymatic activity is low in
early development, elimination via liver-based metabolism is limited, (8).
In the case of SP, although the exact mechanism of effect as intermittent pre-
ventive treatment in pregnancy (IPTp) is not clearly understood, the general
consensus indicates that efficacy is dependent on sustained effective concentra-
tions, i.e. for the entire dosing interval, [5].
Despite the extensive use of SP in IPTp, the understanding of its performance
and disposition during pregnancy is limited. As of July 2009, there were fewer
than 150 enrolled participants in published pharmacokinetic studies, [23, 24, 25],
data which is urgently required for the review and optimization of current IPTp
strategies [26, 27].
In the non-pregnant population, both compounds are well absorbed, have greater
than 90% bioavailability and are 85-90% protein bound. Both compounds are
excreted primarily in urine, although Pyrimethamine is metabolized to several
metabolic products, and only 15 to 30% of the drug is excreted unchanged,
[5, 28, 29].
The average terminal elimination half-lives are 200 and 100 hours for Sulfadox-
ine and Pyrimethamine, respectively, in healthy non-pregnant adults, [5, 28, 29].
SP concentrations are expected to be lower during pregnancy, relative to after
the postpartum period (6 to 8 weeks after delivery), as a result of pregnancy-
associated changes in drug absorption, distribution, metabolism (notably hep-
atic metabolism), and renal elimination. This may result in a reduction in SP
efficacy, particularly given the widespread resistance to this drug, [5, 23].
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Table 2.1 summarizes the data currently available for SP pharmacokinetic pa-
rameters in the non-pregnant population, while Table 2.2 indicates the impact
of covariates such as age and pregnancy on these parameters determined from
several sources.
For Sulfadoxine, the overall drug exposure appears to decrease during pregnancy,
(as indicated by the majority of sources), and the clearance appears to increase.
Conflicting results are seen for the volume of distribution. For Pyrimethamine,
there does not appear to be a common consensus on the impact of pregnancy
for any of the three parameters.
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Antimalarial (metabolite) Ref. Cmax Tmax AUC Ka V/F CL/F t1/2
(hr) (mg/mL.hr) (/hr) (L/hr.kg) (days)
Pyrimethamine [23, 30, 31] 193-591 (ng/mL) 12-19.8 25.2-72.7 3.8-7.2 (L/kg) 0.03-0.07 2.8-3.4
Sulfadoxine [23, 30, 31] 57.92 (ug/mL) 5.7-13.5 11040-66192 0.3 372-660 (ml/kg) 1.4-3.0 4.1-8.9
Table 2.1: Summary of Available Data on Sulfadoxine and Pyrimethamine Pharmacokinetic Parameters
Antimalarial Covariate Clearance Volume of distribution Exposure (e.g. AUC, day 7)
↑ ←→ ↓ ↑ ←→ ↓ ↑ ←→ ↓
Sulfadoxine Age (young children) [30] [30] [30] [30, 31]
Pregnancy [5, 23] [23] [5] [5, 23, 24, 32]
Pyrimethamine Age (young children) [30] [30] [30] [30]
Pregnancy [23] [5] [23] [5] [5] [24] [23]
Table 2.2: Summary of Available Data on the Effect of Demographic Factors on Sulfadoxine and Pyrimethamine Pharmacokinetic
Parameters
1
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2.3 Introduction to NLME Models
2.3.1 Role of NLME model: Background
In the traditional two stage or marginal approach to the analysis of PK data,
separate models are fitted to each individual, and population parameters (mean,
variance and covariance) may then be obtained through the averaging of param-
eters from several individuals.
The suitability of this method is reliant on the availability of rich sampling
data, which is not always possible (e.g. in infants or similarly vulnerable sub-
populations such as pregnant women), [3, 6, 12, 33].
The mean parameter estimates resulting from this approach are usually un-
biased, but for sparsely sampled data, the estimates of the variance and co-
variance across subjects are not. Estimates of the inter-individual errors are
overestimated as residual error is increased, [15, 34, 35].
The alternative population or mixed effect modeling approach, in which a model
is simultaneously fitted to data from all subjects (thereby pooling information),
was thus originally proposed as a solution to the aforementioned issues in the
analysis of sparsely sampled data [3, 6, 15, 36].
The basic NLME model is expressed in terms of both fixed and random ef-
fects, where fixed effects are those parameters associated with the population as
a whole: they express the basic shape of the concentration-time curve. Random
effects are parameters associated with individual experimental units randomly
drawn from population at large, (for the general case: individual subjects).
By associating common random effects to observations from the same level, (e.g.
subject specific random effects), population averages and estimates of variation
are obtained whilst simultaneously quantifying the between (inter)-individual
variation separately to the within (intra)-individual variation, [3, 6].
This separation is important: deviations from the typical profile are usually
expected to vary constantly within individuals, whereas elements of residual
error, (deviations from the individual profile), change for every observation,
[3, 6, 33, 37, 38, 39, 40, 41].
The different levels of variation (inter-individual and intra-individual) need to
be independently dealt with in order to correctly account for the inherent co-
variance structure of the data, and to quantify the inter-individual variation
attributable to systematic components.
In the pharmacokinetic context, we need to not only characterize the basic
ADME processes which govern the concentrations, (the underlying features or
mechanisms of individual profiles), but also explore how these processes vary
in the population of subjects, [3, 6, 15], in order to elucidate the proportion
of variance attributable to individual-specific characteristics (e.g. pregnancy,
weight, age) and to thus develop appropriate and therapeutically beneficial dos-
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ing strategies/regimens, tailored for specific population subgroups, [2, 9, 10].
General inference about the typical population profile is not adequate, because
of the differential impact of the drugs on different individuals.
2.3.2 Relevance of Study Design
The details presented earlier in section 1.1 introduced the multiply-nested struc-
ture of the data: that of measurements taken within observation phase within
subject, where the observation phases are determined by the pregnancy status.
These multiple levels of grouping result in a correlation structure that is inher-
ently more complicated, as measurements within phases on the same individuals
are more similar than those for different phases, and measurements on the same
individual (irrespective of observation phase) are more similar than those for
different individuals. The phases of observation are henceforth referred to as
occasions. This leads to the following levels of random effects:
 Inter-individual variation (IIV), (level 1)
 Intra-individual, inter-occasion (IOV), (level 2)
 and Intra-individual, intra-occasion (WIV), (level 3: the innermost level
or residual measurement error)
The non-linear mixed effect model allows for a flexible representation of this
covariate structure.
In summary: we therefore have the basic deterministic model, consisting of
fixed effect parameters only, which provides us with the average non-linear
concentration-time profile for the population as a whole (the structural model),
and that of strata within the population (the covariate model, which takes into
account systematic deviations from the typical parameters). Non-systematic or
random deviations are dealt with via the use of nested random effects- one for
each level of grouping. These random effects are dealt with separately from the
residual variation (level 3), and are quantified in terms of their deviation from
the typical parameters through specific covariance matrices.
The development of the theoretical model may thus loosely be categorized into
three sections: structural, covariate and stochastic, although these are not easily
separated out.
2.3.3 Conceptual Framework
Overall, the application of the NLME model may be conceptually illustrated
using the general structure of an ordinary least squares model (OLS), [39]. In
this, and in the remainder of the thesis, the subscript i refers to subjects, j to
specific measurements or observations, and k to pregnancy status and thus to
observation phase or occasion.
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OLS Model:
For the usual ordinary least squares (OLS) model, the goal is invariably to
model the effects of independent variables or predictors on a particular response.
Assuming one predictor variable for the sake of simplicity, and thus the vector
of intercept and slope parameters θ, then for observations j = 1 . . . n, the vector
of independent responses, Y = [Y1 . . . Yn]
′, is associated with the vector of
predictor values, X = [X1 . . .Xn]
′, through the vector of model parameters, θ,
which may be schematically represented as follows:
Xj Yj
θ
2-Level Random Effects Model:
For the 2-level random effects model, i.e. for the situation in which there are
multiple individuals and observations are grouped according to these individu-
als, the OLS assumptions of independent observations no longer apply.
We now have i = 1, . . . ,m individuals, with j = 1, . . . , ni observations on each
individual.
Again assuming a single predictor variable, the vector of responses for the ith
individual, Yi = [Yi1 . . .Yini ]
′ is now associated with the vector of predictor
values, Xi = [Xi1 . . .Xini ]
′ and a vector of individual specific random parame-
ters, bi = [b1 . . . bm]
′, through a vector of shared parameters θ, and a parameter
matrix Σ governing inter-individual variability:
Xi Yi
Σ bi
θ
This relationship may be represented equivalently by the simple schematic above,
and the more fully expanded version:
X1j Y1j
Σ b1 ...
bm
...
Xmj Ymj
θ
θ
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3 Level Random Effects Model:
Similarly, for the 3-level random effects model where we have multiple obser-
vations on several individuals for each of several possible occasions (given by
pregnancy status), we have i = 1, . . . ,m individuals, k = 1, . . . , ni occasions
on each individual, and j = 1, . . . , nik observations for each occasion on each
individual.
For the ith individual on the kth occasion, the vector of j = 1 . . . nik responses,
Yik = [Yik1 . . .Yiknik ]
′ , is associated with the vector of predictor values (for a
single predictor), Xik = [Xik1 . . .Xiknik ]
′, the vector of individual specific ran-
dom effects, bi = [b1 . . . bm]
′, and the vector of occasion specific random effects,
bik = [bi1 . . . bini ]
′ through the vector of common parameters, θ, a parameter
matrix governing inter-individual variability, Σi, and a parameter matrix gov-
erning intra-individual inter-occasion variability, Σik.
Xik
Σi bi Yik
Σik bik
θ
2.4 Linear Mixed Effect Models
This section introduces mixed effect models in a purely linear fashion for a single
level of grouping only, (observations j grouped by subjects i). The purpose of
this apparent digression is to actually demonstrate how the technique of mixed
effect models accounts for the hierarchical structure of the data, in the simplest
algebraic terms possible. Whilst this could be achieved for the non-linear case,
the linear version is simpler, and contributes to the natural progression of un-
derstanding. The information presented in this section is based on lecture notes
by Jack Weiss, [40, 41].
As was the case for the conceptual schematics, the mixed effect model is again
contrast to the usual OLS model, where the model for the jth response is given
by:
Yj = Xjβ + ǫj
where ǫj ∼ N(0, σ2).
Now looking at p predictor-variables, and thus at the vector of model parameters
β, and expressing the above model in matrix notation:
Y = Xβ + ǫ
where ǫ ∼ N(0, Iσ2e),
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or (now including an intercept term):


y1
...
yn

 =


1 x11 . . . x1p
...
...
. . .
...
1 xn1 . . . xnp




β0
...
βp

+


e1
...
en


The expectation and variance, and the distribution of the responseY, are given
by:
E(Y) = Xβ
V ar(Y) = V ar(ǫ) = σ2eI
Y ∼ N(Xβ, σ2eI)
The above OLS specification is that of a model with fixed effects only. We can
now comfortably segue into the notation for a model in which j = 1, . . . , ni
observations are grouped according to i = 1, . . . ,m individuals, (such that we
have N = Σmi=1ni data points in total).
This new model may be expressed in two stages, the 1st encompassing the
structural model form and the within-individual variation, and the second deal-
ing with the inter-individual variation.
Thus stage I may be written as:
Yi = Xiβ + Zibi + ǫi
for the ith individual (suppressing subscript j for convenience), where β is the
p-dimensional vector of fixed effects, bi is the q-dimensional vector of random
effects, Xi and Zi are the fixed and random effects regressor matrices of dimen-
sion (ni × p) and (ni × q) respectively, and ǫi is the ni-dimensional vector of
residual (within-group) errors.
Or (again now including an intercept):


yi1
...
yini

 =


1 x11 . . . x1p
...
...
. . .
...
1 xni1 . . . xnip




β0
...
βp

+


1 z11 . . . z1q
...
...
. . .
...
1 zni1 . . . zniq




b0i
...
bqi

+


ǫi1
...
ǫini


Where the marginal expectation and covariance of Yi are given by:
E(Yi|bi) = Xiβ + Zibi
Cov(Yi|bi) = Ri
and thus ǫi ∼ N(0,Ri).
The development of the inter-individual variability, (stage II), involves the ad-
dition of covariates and random effects. Focusing on the random effects, and
defining q random effects where q ≤ p, we can then define a covariance matrix
Dq×q, such that bi ∼ N(0,D), (assuming normality).
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If the bi are independent of the ǫi and of each other for different individuals,
the unconditional expectation and covariance of Yi are as follows:
E(Yi) = E{E(Yi|bi)}
= E{Xiβ + Zibi}
= Xiβ
Cov(Yi) = E{Cov(Yi|bi)} + Cov{E(Yi|bi)}
= Ri + ZiDZ
′
i
= Vi
where Vi is dependent on a vector ̟ of variance parameters.
If we look at an example where we have a model that includes an intercept
term, and has random effects on both the intercept and slope parameters, stage
I could be expressed as:
yij = f(xij ,βi) + ǫij
= β0i + β1ixij + ǫij
where βi = (β0i, β1i)
′, f(xij ,βi) = β0i+β1i× tij , for a single predictor variable
xij = tij , and i = 1, . . . ,m, and j = 1, . . . , ni where m is the number of individ-
uals and ni is the number of observations for individual i.
Assuming that the covariance matrix Ri is given by σe
2 × I, the distribution of
the residual errors may be written as ǫij ∼ N(0, σe2).
Stage II could then be written as:
β0i = β0 + b0i
β1i = β1 + b1i
Then assuming a compound symmetric correlation structure and using assump-
tions of independence for the elements of bi and ǫij , and for bi for different
individuals:
Cov(b0i, b0k) =
{
τ0
2 i = k
0 i 6= k
Cov(b1i, b1k) =
{
τ1
2 i = k
0 i 6= k
Cov(b0i, b1k) =
{
τ01 i = k
0 i 6= k
Cov(b0i, ǫij) = 0
Cov(b1i, ǫij) = 0, ∀i, j
Thus, covariance matrixD and the distribution of the random effects bi is given
by: [
b0i
b1i
]
∼ N(
[
0
0
]
,
[
τ0
2 τ01
τ01 τ1
2
]
)
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although the assumptions of normality may later be relaxed.
Simplifying the above for the purposes of illustration, and thus looking back
at the OLS case where:
β0i = β0
β1i = β1
if we were to include random effects on the intercept parameter only for the
mixed effect model:
β0i = β0 + b0i
β1i = β1, for b0i ∼ N(0, τ02)
the form of the composite model would then be as follows:
yij = β0 + b0i + β1tij + ǫij
= β0 + β1tij︸ ︷︷ ︸+ b0i + ǫij︸ ︷︷ ︸
fixed effects random effects
Then using the properties of covariance for the sum of random variables (X,Y,W,Z)
with a and b depicting constants:
Cov(a+X, b+ Y ) = Cov(X,Y )
Cov(W +X,Y + Z) = Cov(W,Y ) + Cov(W,Z) + Cov(X,Y ) + Cov(X,Z)
and looking at observations from different groups (i, k) and at different times or
for different observations (j, l):
yij = β0 + β1Xij + b0i + ǫij
ykl = β0 + β1Xkl + b0k + ǫkl
Cov(yij , ykl) = Cov(β0 + β1Xij + b0i + ǫij , β0 + β1Xkl + b0k + ǫkl)
= Cov(b0i + ǫij , b0k + ǫkl)
= Cov(b0i, b0k) + Cov(b0i, ǫkl) + Cov(b0k, ǫij) + Cov(ǫij , ǫkl)
= Cov(b0i, b0k) + Cov(ǫij , ǫkl)
where
cov(b0i, b0k) =
{
τ2 if i = k
0 if otherwise
cov(ǫij , ǫkl) =
{
σ2 if i = k & j = l
0 if otherwise
we can show that:
cov(yij , ykl) =


0 if i 6= k
τ2 if i = k & j 6= l
τ2 + σ2 if i = k & j = l
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i.e. observations in the same group have a positive covariance (and are therefore
more similar), and observations in different groups are uncorrelated.
In correlation terms, for distinct observations (j 6= l):
ρ(yij , ykl) =
Cov(yij , ykl)√
V ar(yij)
√
V ar(ykl)
=
Cov(yij , ykl)√
Cov(yij , yij)
√
Cov(ykl, ykl)
Thus
ρ(yij , ykl) =


τ2
τ2+σ2 if i = k
0 if otherwise
If we specify (e.g.) 4 subjects, with N = 15 observations, (n1 = 4, n2 = 4, n3 =
3, n4 = 4), i.e. an unbalanced randomized block design; using the example from
before with random effects on the intercept parameter only, we can show the
form of the variance-covariance matrix more explicitly. Thus, (again suppressing
subscript j for convenience):
Yi = Xiβ + Zibi + ǫi
β = [β0, β1]
′
bi = [b0i].
Assuming V ar(ǫi) ∼ N(0,R) where
R = σ2eI
R =


σ2e . . . 0
...
. . .
...
0 . . . σ2e


(15×15)
and
ZDZ′ =

1 0 0 0
1 0 0 0
1 0 0 0
1 0 0 0
0 1 0 0
0 1 0 0
0 1 0 0
0 1 0 0
0 0 1 0
0 0 1 0
0 0 1 0
0 0 0 1
0 0 0 1
0 0 0 1
0 0 0 1


15×4


σ2s 0 0 0
0 σ2s 0 0
0 0 σ2s 0
0 0 0 σ2s


4×4


1 0 0 0
1 0 0 0
1 0 0 0
1 0 0 0
0 1 0 0
0 1 0 0
0 1 0 0
0 1 0 0
0 0 1 0
0 0 1 0
0 0 1 0
0 0 0 1
0 0 0 1
0 0 0 1
0 0 0 1


′
4×15
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Thus
ZDZ′ +R =



σ2s + σ
2
e . . . σ
2
s
...
. . .
...
σ2s . . . σ
2
s + σ
2
e


4×4
. . .


0 . . . 0
...
. . .
...
0 . . . 0


...
. . .
...

0 . . . 0
...
. . .
...
0 . . . 0

 . . .


σ2s + σ
2
e . . . σ
2
s
...
. . .
...
σ2s . . . σ
2
s + σ
2
e


4×4


We have thus shown the overall model formulation for this particular case, with
the focus on the hierarchical covariance structure.
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2.5 Structural Model Formulation
Before continuing with the development of the theory behind nonlinear mixed
effect models and the various extensions to the general techniques required for
the analysis of our particular data set, we need to introduce the basic structural
model formulation, and in so doing, the terminology used in the remainder of
this chapter.
2.5.1 Background
In the traditional clinical approach to the modeling of pharmacokinetic data,
linear compartment models form the basis for the structural model form.
In compartmental modeling, the input and disposition of “substances in the
body are assumed to occur in a series of consecutive processes or steps” [14, 42],
and the body is thus divided into a series of compartments (not representative
of “real physical spaces” [7]), where the rates of transfer of the drug from one
compartment to another are assumed to follow a first order process, (i.e. the
rate is proportional to the amount of drug in the system), [2, 14].
These“compartmental”models are described by L.Aarons in the British Journal
of Clinical Pharmacology [7] as semi-mechanistic, in that although the parame-
ters are relatively easily related to physiological processes, and are thus easier to
interpret, the assumption of compartments is a simplification of the biological
system, and is in fact referred to as an “abstraction” by Wagner et al, [14], nec-
essary for the development of practical mathematical relationships which can
be used to describe the kinetics of the drug’s movement, [14].
The model itself is given by the equation or set of equations which describes the
system, and the one and two compartment open models for oral absorption may
be represented using schematic diagrams, from which the differential equations
and resulting integrated solutions may be derived. The input, distribution and
elimination rates are all assumed to be first order.
An alternative and more comprehensive approach would be to use the so-called
physiologically based pharmacokinetic model (PBPK), wherein the compart-
ments represent actual tissue and organ spaces with real physical volumes [7].
The uptake and elimination of substances may be linked to specific organs, and
drivers of uptake and absorption such as the perfusion-rate limitation of differ-
ent tissues may also be incorporated [7]. These models may be described by a
series of differential equations. The use of these models is, however, limited by
a lack of sufficiently complex quality data.
2.5.2 Semi-Mechanistic: Schematics and Derivation
The section below deals with the derivation of the equations used for the semi-
mechanistic one- and two-compartmental models introduced above. Although
these models are not those employed in the majority of the analyses presented in
this thesis, they are described here for the purposes of contrast and comparison.
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One Compartment Model
The schematic for the one compartment model with oral absorption is given by,
[2, 14]:
Xg Xp
ka ke
where Xg is the amount of drug in the gastro-intestinal tract immediately fol-
lowing administration, and Xp = V × Cp is the amount of drug in the central
compartment, where V is the volume of distribution (in Litres) and Cp (usually
in ug/ml or ng/ml) is the concentration of the drug. The rates of absorption
and elimination are given by ka and ke respectively, both measured in units of
reciprocal time (usually 1/hour).
Both ka and ke are assumed to be first order process, despite the oral absorption
and resultant possible issues with dissolution and possible multiple absorption
sites, [2, 43].
This model assumes that there is rapid equilibrium between the drug in the
blood/plasma, and the surrounding extra vascular tissues, i.e. that the drug is
immediately and evenly distributed, such that the body is made up of a single
“well-mixed” (central) compartment.
Using this schematic, we can define differential equations for Xg and Xp, [2, 14]
such that:
dXg
dt
= −ka×Xg
dXp
dt
= ka×Xg − ke×Xp.
Then taking the Laplace transformations we get:
L(
dXg
dt
) = s× X¯g −X0g = −ka× X¯g
(s+ ka)X¯g = X
0
g .
Thus
X¯g =
X0g
(s+ ka)
(2.1)
and:
L(
dXp
dt
) = s× X¯p −X0p = ka× X¯g − ke× X¯p
L(
dXp
dt
) = L(
V×dCp
dt ) = s× V × C¯p − V × C0p
= ka× X¯g − ke× (V × C¯p).
We therefore have:
V × C¯p × (s+ ke) = ka× X¯g
V × C¯p = ka×X¯g(s+ke)
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and substituting 2.1:
V × C¯p = ka× F ×D
(s+ ka)× (s+ ke)
C¯p =
ka× F ×D
V × (s+ ka)× (s+ ke)
where X0g = F ×D and F is the fraction of dose D absorbed, Xp = V ×Cp and
C0p = 0 at time t = 0.
The general partial fraction (fingerprint) method is given by equation:
L−1(
N(s)
D(s)
) = Σni=1
N(λi)
D(λi)
× eλi×t
where the λ terms are the roots of the polynomial term in the denominator on
the left, and with limitations that the degree of the denominator is higher than
that of the numerator, with no repeating terms, we can backtransform in order
to get the concentration of drug in the central compartment, Cp.
Thus, for:
C¯p =
ka× F ×D
V × (s+ ka)× (s+ ke) ,
the roots of the denominator are −ka and −ke, and:
L−1(C¯p) = Cp =
ka× F ×D
V × (ke− ka) × e
−ka×t +
ka× F ×D
V × (ka− ke) × e
−ke×t
Therefore:
Cp(t) =
ka× F ×D
V × (ka− ke) × [e
−ke×t − e−ka×t]. (2.2)
Two Compartment Model
For the two compartment oral absorption model with i, j = 1, 2, the schematic
is as follows:
X1 X2
ka kij
ke
Solution of the resulting differential equations makes use of both the partial
fraction method outlined above, and convolution theory, [14].
The two compartment model allows for the specification of both a central and
peripheral compartment, (the assumption of rapid and immediate distribution
between the plasma and surrounding tissues is deemed to be overly simplistic),
[14].
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While exact anatomic assignment to these compartments is not possible, those
tissues most rapidly perfused are assumed to be associated with the central
compartment, [14].
Input, disposition and elimination rates are still assumed to be of first order,
and further, terminal elimination is assumed to occur from the central compart-
ment only, [14].
The anticipated number of phases of decline and thus the correct compartment
model may be determined by examination of plots of the logged concentration
over time, such as those in Figure 2.2: should the plot be linear, the decline is
determined to be monophasic, whereas an additional deviation (i.e. a secondary
altered rate of decline), would indicate the presence of an additional compart-
ment, [2, 7, 14].
Figure 2.2: Mono- and Biphasic Decline: Log-Linear Scale
The derivation of the equation for the two compartment model is done in two
stages, as described by Wagner [14].
Stage 1 determines the amount of drug in the central compartment (X1) follow-
ing an IV Bolus dose, i.e. for the second schematic (i, j = 1, 2):
X1 X2
kij
ke
The differential equations for the amount of drug in X1 and X2 are as follows:
dX1
dt
= k21 ×X2 − k12 ×X1 − ke×X1
dX2
dt
= k12 ×X1 − k21 ×X2
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Taking the Laplace transformation of the equations:
L(
dX1
dt
) = s× X¯1 −X01 = k21 × X¯2 − k12 × X¯1 − ke× X¯1
L(
dX2
dt
) = s× X¯2 −X02 = k12 × X¯1 − k21 × X¯2
and rearranging, given that X01 = F ×D where F = 1, and X02 = 0:
(s+ k12 + ke)× X¯1 − k21 × X¯2 = D
(s+ k21)× X¯2 − k12 × X¯1 = 0
Now applying Cramer’s Rule, X¯1 is given by:
X¯1 =
|determinant obtained by replacing 1st column by column of constants|
|determinant of system|
=
∣∣∣∣∣∣
D −k21
0 (s+ k21)
∣∣∣∣∣∣∣∣∣∣∣∣
(s+ k12 + ke) −k21
−k12 (s+ k21)
∣∣∣∣∣∣
Thus:
X¯1 =
D × (s+ k21)
(s+ α)× (s+ β)
where
α = 1/2× [(k12 + k21 + ke) +√(k12 + k21 + ke)− 4× k21 × ke ]
β = 1/2× [(k12 + k21 + ke)−√(k12 + k21 + ke)− 4× k21 × ke ]
Stage 2 uses the principle of convolution. Defining ins as the Laplace transform
of the input function for a given compartment, and ds as the Laplace transform
of the disposition function:
X¯1 = ins × ds
For a two compartment model with oral absorption,
ins =
F ×D × ka
(s+ ka)
,
ds =
(s+ k21)
(s+ α) × (s+ β)
Thus
X¯1 =
F ×D × ka× (s+ k21)
(s+ ka)× (s+ α)× (s+ β) .
Taking the inverse, using the partial fraction method, we get:
C1(t) =
ka× F ×D
V1
×
[
k21 − α
(ka− α)× (β − α) × exp(−α× time)
+
k21 − β
(ka− β)× (α− β) × exp(−β × time)
+
k21 − ka
(α − ka)× (β − ka) × exp(−ka× time)
]
(2.3)
where α and β are defined as before, for X1 = V1 × C1.
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2.5.3 Empirical Approach
The clinical parameterization derived and outlined above, that of the semi-
mechanistic compartmental model, is based on assumptions regarding the ac-
tual (albeit simplified) underlying processes of drug absorption and disposition.
This can be simplified by expressing the concentration-times curves as an addi-
tive series of exponential terms, such that the concentration at time t is given
by:
C(t) = Σni=1Ci × e(−λit)
where the λi are the rate constants, t = time, the number of terms (i = 1, . . . , n)
is determined by the number of differential phases of decline, and the coefficient
of the exponential term related to the absorption phase is negative.
This model specification reasonably describes the “typical concentration-time
[curves]”, resulting in profiles that are roughly equivalent to those obtained via
the compartmental approach [7]. The parameters themselves however have no
direct physiological interpretation, although pharmacokinetic parameters of in-
terest and dosage regimens may easily be determined.
Thus for example, observing a monophasic decline on the log-linear scale, the
response may be expressed as:
C(t) = β0[−exp(−β1 × time) + exp(−β2 × time)], (2.4)
where β0 gives an indication of the range or level of concentrations reached, and
β1 and β2 are the slopes of the incline and decline phases respectively.
Comparing this model to that previously defined by equation 2.2: the com-
posite parameter β0 may be expressed as:
β0 =
F ×D × ka
V (ka− ke)
and β1 and β2 as ka and ke respectively.
Similarly, for a curve displaying a biphasic log-linear profile, the concentration
may be expressed as :
C(t) = A1 × exp(−α× time) +A2 × exp(−β × time)
+A3 × exp(−k × time)
where (relating this model formulation back to the clinical specification in equa-
tion 2.3):
A1 =
k × F ×D
V1
× [ k21 − α
(k − α)× (β − α)
]
A2 =
k × F ×D
V1
× [ k21 − β
(k − β)× (α− β)
]
A3 =
k × F ×D
V1
× [ k21 − k
(α− k)× (β − k)
]
31
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Here, k = ka, the absorption rate constant, and α and β, defined as before,
represent the initial slope of the curve, corresponding to the distribution phase,
and the slope for the final or terminal elimination phase respectively.
Further, in order to reduce collinearity and achieve a steeper slope for the incline,
using A1 ≈ −(A2 +A3) and defining:
β1 = ka,
β2 = A1
β3 = α,
β4 = A2
β5 = β
we can define the model:
C(t) = β2 × [−exp(−β1 × time) + exp(−β3 × time)]
+ β4 × [−exp(−β1 × time) + exp(−β5 × time)] (2.5)
where β3 and β5 represent the initial and final slope of the decline, β2 and β4
combined represent the overall level of concentration reached, [3]. β1 represents
the slope for the incline.
Figure 2.3: Triple-Exponential Curve (Decline only) [2]
Ignoring the absorption phase of the curve, Figures 2.3 and 2.4 illustrate the
change in slope from the initial to the final phase of decline for the triple ex-
ponential model. Figure 2.4, [3], illustrates the final combined “elimination”
curve (given by equation 2.6 below) and its constituent exponential parts, with
β2, β4, β3 and β5 labeled.
C(t) = β2 × [exp(−β3 × time)] + β4 × [exp(−β5 × time)] (2.6)
The two sets of parameters given by (β2, β3) and (β4, β5) are described as “ex-
changeable” by Pinheiro and Bates [3], in that the values of the pairs can be
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β2exp(− β3t) + β4exp(− β5t) = 1.5exp(− 1t) + 3.5exp(− 4t)
β2 = 3.5
β4 = 1.5
Slope=
Slope=
(β3 = 4) > (β5 = 1)
β5 = 1
Figure 2.4: Bi-Exponential Decline of Triple-Exponential Curve (Absorption
Phase Ignored) [3]
exchanged without altering the predicted value of C(t). Requiring that β3 be
greater than β5 creates an “identifiable” parameterization, [3].
The empirical modeling approach is limited in terms of extrapolation: it is
difficult to determine the impact of underlying physiological changes on the pa-
rameters as specified, and thus the semi-mechanistic models are usually favoured
from a pharmacokinetic perspective.
The more general parameterization is however preferred for use in this thesis, as
the focus was on the smoothing and interpolation of the observed concentration-
time curves, and the methodologies behind the use of non-linear mixed effect
models for a multi-level design.
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2.6 Nonlinear Mixed Effect Models
Now that the terminology for the structural model form has been introduced,
we may procede with the theoretical development of mixed effect modeling pro-
cedures, moving on to the nonlinear case for both single and multiple levels of
nesting.
Similar to the development of the linear mixed effect model, the nonlinear model
(with a single level of subject-specific random effects) may also be defined in two
stages: the first stage again encompassing the structural model form, and the
modeling of the intra-individual variance, and the second stage examining the
inter-individual variability, and modeling it in terms of the impact of covariates
on structural parameters. The extension to multiple levels and then to the case
where we have multiple responses follows from there.
The methods outlined here are modifications of those presented in Mixed Effect
Models in S and S-Plus by Pinheiro and Bates [3], and Nonlinear Models for
Repeated measurement Data, by Davidian and Giltinan, [6].
Hierarchical Model Development
Stage 1: Intra-individual (within-subject)
Ignoring the multiple levels of nesting (i.e. ignoring the occasion-specific ran-
dom effect), and looking at j = 1, . . . , ni observations on each of i = 1, . . . ,m
individuals, such that we have a total of N = Σmi=1ni available data values, we
can then define a model for the jth response as:
yij = f(xij,βi) + eij (2.7)
where eij is a random error term ,given individual i, with E(eij |βi) = 0.
The function f(xij,βi) could be any linear/non-linear function, although for
our purposes it follows one of the exponential forms previously identified (equa-
tions 2.4 and 2.5).
This function, which gives the structural form of the model, governs the within-
individual behaviour through characterization of the systematic variation by a
(p× 1) vector of parameters βi which is specific to each individual i. It models
the inter-subject variability in terms of the impact of covariates xij on structural
parameters.
The data for the ith individual may be summarized as:
yi = f(βi) + ei
where
yi = [yi1, . . . , yini ]
′,
ei = [ei1, . . . , eini ]
′,
and
fi(βi) = [f(xi1,βi), . . . , f(xini ,βi)]
′
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Then
E(ei|βi) = 0,
Cov(ei|βi) = R(β, ξ)
where R(β, ξ) is a covariance matrix which allows for the relaxation of the
usual classical assumptions that the residual error terms eij are i.i.d normally
distributed with mean zero and constant variance σ2, (eij ∼ i.i.d N(0, σ2)),
where ξ is a function of σ, some vector of additional variance parameters θ and
a vector of correlation parameters α. This is explained in more detail for the
case where we have multiple levels of nesting.
Stage 2: Inter-individual (between-subject)
Now specifying a model for the βi, allowing for dependence on both systematic
and random effects;
βi = Aiβ + bi,
Where Ai is an indicator matrix in the case of group effects but can also contain
other types of covariate values, and β is a vector of fixed parameters common
to all individuals.
More generally, allowing the random effects bi to be added to some parame-
ters and not necessarily to others:
βi = Aiβ +Bibi,
where Bi is an indicator matrix, or;
βi = d(ai,β,bi),
The p-dimensional vector d characterizes how the elements of βi vary across
individuals, allowing for both (i) systematic and (ii) random variation:
(i) systematic variation is accounted for through systematic association with
ai, an (a× 1) vector of covariates for the ith subject, modeled through β,
a vector of fixed parameters common to all individuals, and
(ii) random (unexplained) variation in the population is modeled through the
q-dimensional vector of random effects bi, where the bi are i.i.d and often,
bi ∼ (0,ψ), where ψ is a (q × q) covariance matrix.
The linear mixed effects model is a simplified version of the models presented,
where β and bi are defined as before, Xi is a design matrix for individual i, and
Zi is a design matrix linking the random effects to the response.
Since βi is specific to individuals through bi and the known individual charac-
teristics ai,
ei|bi ∼ (0,Ri(β, ξ))
A new vector of parameters,̟ , may then be constructed, consisting of both the
intra-individual parameter ξ, and the distinct elements of the inter-individual
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covariate matrix ψ.
For the structural form dictated by equation 2.4, i.e. that of:
yij = β0i(−e(−β1i×tij) + e(−β2i×tij)) + eij ,
βi = β + bi
where β = [β0, β1, β2]
′, and bi = [b0i, b1i, b2i]
′.
For example, where we have subject-specific random effects on parameters β0
and β1 only, we could define:
A =

1 0 00 1 0
0 0 1


and:
B =

1 0 00 1 0
0 0 0


such that:
βi = Aiβ +Bibi
can be written as:
β0iβ1i
β2i

 =

1 0 00 1 0
0 0 1



β0β1
β2

+

1 0 00 1 0
0 0 0



b0ib1i
b2i

 .
Alternatively, incorporating a subject-specific continuous covariate such as age
(time-invariant) on parameters β0 and β1, we could define:
A =

1 0 0 agei. 00 1 0 0 agei.
0 0 1 0 0


and:
B =

1 0 00 1 0
0 0 0


such that:
βi = Aiβ +Bibi
can be written as:

β0iβ1i
β2i

 =

1 0 0 agei. 00 1 0 0 agei.
0 0 1 0 0




β0
β1
β2
β3
β4

+

1 0 00 1 0
0 0 0



b0ib1i
b2i


where (β0, β3), (β1, β4) are the “intercept” and “slope” parameters respectively
that determine the linear relationship between β0, β1 and age. β2 is defined as
before. This example also assumes random (subject-specific) effects on β0 and
β1 only.
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Extension to Multi-Level
Extension to the case where there are multiple levels of nested random effects
(occasion within subject) is more easily achieved with slight changes to the
notation used in the specification of a single level mixed effect model. Thus,
redefining the model represented by equation 2.7 for the jth response on the ith
individual:
yij = f(xij,βij) + eij
where i = 1, . . . ,m, j = 1, . . . , ni, f and xij are defined as before, and
βij = Aijβ +Bijbi,
where the dependence of Aij, Bij and thus βij on j now allows for the incorpo-
ration of time-varying covariates.
Then for the ith individual:
yi = f(xi,βi) + ei
where
yi = [yi1, . . . , yini ]
′,
ei = [ei1, . . . , eini ]
′,
βi = [βi1, . . . , βini ]
′
and
f(xi,βi) = [f(xi1, βi1), . . . , f(xini , βini)]
′
Now defining the period (occasion determined by pregnancy status) k = 1, 2,
we thus specify the model for the jth measurement in the kth period for the ith
individual as:
yikj = f(xikj,βikj) + eikj
i = 1, . . . ,m, k = 1, . . . , ni, j = 1, . . . , nik
where m is the number of individuals, ni is the number of periods for the ith
individual, and nik is the number of observations in the kth period for the ith
individual.
The (p× 1) vector of regression parameters βikj is then defined as:
βikj = Aikjβ +Bi,kjbi +Bik,jbik,
bi ∼ N(0,ψ1),bik ∼ N(0,ψ2)
Where β is a p-dimensional vector of fixed effects, with design matrix Aikj
which may incorporate time-varying covariates. The first level (subject-specific)
random effects bi are independently distributed q1-dimensional vectors with
variance-covariance matrix ψ1. The second level (occasion-specific) random
effects bik are independently distributed q2-dimensional vectors with variance-
covariance matrix ψ2, assumed independent of the first level random effects.
The random effects design matrices Bi,kj and Bik,j depend on first and second
level groups and possibly on the values of some covariates at the jth observation.
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In the sequential modeling approach (which is explained in more detail later),
the response or concentration of one drug is modeled as a function of the other,
incorporating the predicted time-varying concentration of the other drug as a
covariate. The dependence on j is thus required.
The within group errors eikj are assumed independently and identically nor-
mally distributed, with variance-covariance matrix Rik.
As before, for the particular case represented by equation 2.4, looking at the
model for the jth concentration in the kth period for the ith individual:
yikj = f(xikj,βikj) + eikj
= β0ikj(−e−β1ikj×xikj + e−β2ikj×xikj) + eikj
where the only covariate is time, i.e. xikj = timeikj , we can expand the previ-
ously specified model (suppressing subscript j for convenience) as follows:
β0ik = β0i + b0ik,
β0i = β0 + b0i
β1ik = β1i + b1ik,
β1i = β1 + b1i
β2ik = β2i + b2ik,
β2i = β2 + b2i,
i.e. in composite form
yikj = (β0+ b0i+ b0ik)(−e−(β1+b1i+b1ik)×timeikj + e−(β2+b2i+b2ik)×timeikj )+ eikj .
We can illustrate the incorporation of covariates as follows:
Fitting subject-specific covariate age (time and occasion (period)-invariant) to
β0 would result in equations:
β0ik = β0 + β3 × agei.. + b0i + b0ik,
β1ik = β1 + b1i + b1ik,
β2ik = β2 + b2i + b2ik
Fitting time-invariant covariate weight (or equivalently pregnancy) which varies
by occasion within subject, would result in equations:
β0ik = β0 + β3k × weightik. + b0i + b0ik,
β1ik = β1 + b1i + b1ik,
β2ik = β2 + b2i + b2ik
Re-introducing subscript j, and specifying both subject and occasion specific
random effects on the intercept parameter only (in the linear relationship be-
tween β0 and the covariate), we could fit a time-varying covariate such as in the
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sequential modeling approach using equations:
β0ikj = β0 + β3kj × concentrationikj + b0i + b0ik,
β1ikj = β1 + b1i + b1ik,
β2ikj = β2 + b2i + b2ik
General intra-individual, intra-occasion covariance structures
Individual non-linear data quite often exhibits a distinct departure from the
classical OLS assumptions of independence and homoskedasticticy imposed on
the eikj ,(previously the eij), indicating a need for a generalization of this tra-
ditional approach.
This section deals with the description of the variance-covariance matrix Rik
for the within group errors eikj .
 Variance heterogeneity
In PK data specifically, observations are often serially correlated over time, nor-
mality assumptions do not necessarily hold, and variance is often proportional
to the square of the mean response, i.e. a log normal distribution is assumed,
resulting in error terms which follow a gamma distribution with a mean of zero
and variance:
V ar(e′ikj) = σ
2 × (f(xikj,β))2, (2.8)
where σ is the coefficient of variation.
We could thus specify a model of the form:
log(yikj) = log(f(xikj,βikj)) + eikj
which is alternatively expressed as:
yikj = f(xikj,βikj)× e′ikj
where e′ikj = exp(eikj), and thus eikj ∼ N(0, σ2). This would also alter the
linear relationship we saw before for the subject and occasion-specific random
effects, such that for example (suppressing subscript j):
β0ik = β0 × b0i × b0ik,
as well as changing the additive (linear) relationship between the parameters
and the covariates.
The approach taken here is slightly different, in that a model is explicitly speci-
fied for the characterization of the systematic response variance and correlation
patterns. It is referred to as a “band-aid” [6] approach, in that it only approxi-
mates the proportional error structure usually required for data of this kind.
This is detailed below for the general case, but because the same variance func-
tion is applied for both occasions (periods) in this thesis, only subscript j is
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specified, which represents observations for the kth period for the ith individual.
Thus for a specific individual-occasion grouping, we can define a variance func-
tion g, which is dependent on the vector of regression parameters, β, for that
individual through the mean function f , on constants zj, which may include
some or all of xj and on an additional q-dimensional parameter vector θ:
E(yj) = µj = f(xj,β),
V ar(yj) = σ
2g2(µ, zj,θ)
In the above specification, the variance function g provides the general form of
the variance model, with parameter θ fully specifying the functional form. The
scale parameter σ governs the overall level of precision in the response.
An example of a variance function and in fact the function applied later on
follows the general form of:
g2(µ, zj,θ) = (θ1 + µj
θ2)2, θ1, θ2 > 0,
where µj is the expected value of the jth response and θ = [θ1, θ2], which
allows for measurement error that appears constant at lower response values and
exhibits increasing variance at higher levels of the response, i.e. approximately
proportional errors. This form is preferred to the power function specified above
(equation 2.8), because of the large number of fitted values at or close to zero
in our data.
 Intra-individual correlation
An assumed correlation structure Γ(α) is also specified, where the correlation
matrix Γ(α)is a function of a vector of correlation parameters α(s×1).
In some instances, both heterogeneous variance and a correlation pattern are
evident.
For any individual-occasion grouping ik, we can then define the diagonal matrix
G, where the elements are the same variance function previously defined, which
depends on individually specific information (zj) and on an individual mean
response (µj), given βik, i.e.,
G(β,θ) = diag[g2(µ1, z1,θ), . . . , g
2(µnik , znik ,θ)]
If the correlation pattern is given by matrix Γ(α), then assuming a common
within-individual covariance pattern:
Cov(eij) = Cov(e),
we have:
Cov(e) = σ2G(1/2)(β,θ)Γ(α)G(1/2)(β,θ)
= R(β, ξ)
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ξ = [σ,θ′,α′],
where ξ is the (q1 × q2 + s+ 1)× 1) combined vector of all intra-individual pa-
rameters.
This implies that
V ar(yj) = σ
2g2(µj , zj,θ),
Corr(y1,y2) = Γ(j1,j2)(α)
Thus
eik|βik ∼ N(0,Rik(βik, ξ))
The above specification is general enough to accommodate both heterogeneous
variance and within-subject correlations, where the functional form Rik is usu-
ally common to all subjects and is flexible enough to depend on covariates.
In matrix formulation: since we don’t impose an additional correlation structure
on our eik,(although we could), we essentially have an equal and exchangeable
correlation structure such that:
Cov(eik)(nik×nik) =


σ21(θ1 + µ1
θ2)2 σ1
√
(θ1 + µ1θ2)2 × σ2
√
(θ1 + µ2θ2)2 . . .
σ2
√
(θ1 + µ2θ2)2 × σ1
√
(θ1 + µ1θ2)2 σ
2
2(θ1 + µ2
θ2)2 . . .
...
...
. . .

 .
Alternative approach to Nesting
Multilevel nesting can also be represented as a single level of grouping, using
an explicitly specified correlation structure for the random effects that correctly
accounts for the structure of the data. Computational algorithms used in the
nlme package in R are however deemed more efficient for the nested approach.
The use of the alternative single-level representation of a multi-level model is
best explained via an example:
Assuming that the model for the jth measurement in the kth period for the
ith individual is given by equation:
yikj = β0ikj(−e−β1ikj×xikj + e−β2ikj×xikj) + eikj
where (suppressing subscript j for convenience):
β0ik = β0i + b0ik,
β0i = β0 + b0i
β1ik = β1i + b1ik,
β1i = β1 + b1i
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β2ik = β2i + b2ik,
β2i = β2 + b2i
and:
eikj ∼ N(0,Rik)
bi ∼ N(

00
0

 ,

τ
2
0 0 0
0 τ21 0
0 0 τ22

)
bik ∼ N(

00
0

 ,

τ
2
0k 0 0
0 τ21k 0
0 0 τ22k

)
We can then define random effects b∗i:
b∗i =


b0i + b0i,0
b0i + b0i,1
b1i + b1i,0
b1i + b1i,1
b2i + b2i,0
b2i + b2i,1


where the variance-covariance matrix ψ∗ has a blocked diagonal structure, with
a compound symmetry structure on the diagonals:
b∗i ∼ N(0,ψ∗)
ψ∗ =

[
τ20 + τ
2
0k . . . τ
2
0
τ20 . . . τ
2
0 + τ
2
0k
]
0 0
0
[
τ21 + τ
2
1k . . . τ
2
1
τ21 . . . τ
2
1 + τ
2
1k
]
0
0 0
[
τ22 + τ
2
2k . . . τ
2
2
τ22 . . . τ
2
2 + τ
2
2k
]


The variance for the compound symmetry structure in the top-left block is then
given by:
τ2b = τ
2
0 + τ
2
0k,
and the correlation is:
ρ =
τ20√
τ20 + τ
2
0k
Thus,
τ20 = ρ× τ2b ,
and
τ20k = τ
2
b − τ20 .
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Extension to multiple responses:
Ordinarily in the context of pharmacokinetics, when we talk about the accom-
modation of multiple responses, we refer to the modeling of PK/PD data, un-
dertaken in order to determine the concentration-effect relationship.
Sulfadoxine and Pyrimethamine are both folic acid antagonists which are si-
multaneously orally administered, acting in concert on different enzymes which
are required for folate synthesis in the replication of the malaria parasites [4, 44].
Isobolograms, which look at the 50% inhibitory concentration (IC50) values
for various SP concentrations have been developed in-vitro for different para-
site genotypes, as mutations in the dihydrofolate reductase (DHFR) and dihy-
dropteroate synthetase (DHPS) genes result in resistance to the two drugs and
therefore reduce their efficacy and increase the concentrations required to have
an inhibitory effect, [4, 30].
The in-vitro relationship indicated by these isobolograms is an synergistic one:
for a particular genotype, effective inhibitory concentrations can be achieved
with low levels of one drug if combined with high levels of the other [4, 30], and
the inhibition of parasite growth effected by using the two drugs in combination
is significantly greater than what can be achieved by either drug alone, [44].
Isobolograms for Pyrimethamine and Sulfadoxine combinations are depicted in
Figure 2.5 [4].
This synergistic concentration-effect relationship is more difficult to determine
in-vivo however, due in part to the lack of information regarding the mecha-
nisms of interaction between the two drugs.
This, therefore, was the motivation for exploring the drug-drug interaction for
this dataset, from which the sequential and simultaneous modeling methods
usually used in the PK-PD context were adapted to modeling two drug concen-
trations.
The most common PD model specification is that of the Emax model, given
by:
yikj = E0i +
Emaxi − E0i
1 + EC50iCikj
+ eikj
for the case in which we have multiply-nested random effects, and:
βik = β + bi + bik
where
β = [β0, β1, β2] = [E0, Emax, EC50]
bi = [b0i, b1i, b2i]
bik = [b0ik, b1ik, b2ik]
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Figure 2.5: Isobologram [4]
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and
bi ∼ (0,D1)
bik ∼ (0,D2)
eikj ∼ (0,Rik(βik, ξ))
where Rik(βik, ξ) is some assumed intra-individual, intra-occasion covariance
structure, and D1 and D2 are the covariance matrices associated with the dif-
ferent levels of random effects.
The parameters E0, Emax and EC50 are the effect at zero concentration, the
maximum effect produced, and the concentration at which 50% of the effect
occurs respectively, i.e. they measure the effect of drug concentration Cikj on
the PD outcome (some measurement of effect yikj).
Sequential:
In the sequential approach for PK-PD modeling, the predicted concentrations
from the PK model are used in order to try and reduce the bias in the estimation
of the PD model parameters, since the observed concentrations are measured
with error and the predicted values provide a smooth interpolated curve, albeit
with their own amount of estimation error.
We of course do not have PD data, and are in fact modeling the PK-PK re-
lationship. The PK/PD relationship is mentioned merely as a precursor and
introduction, hence: adapting this approach to model the drug-drug interac-
tion, we replace the Emax model with the additive exponential models used
before, and add the second drug’s predicted concentration as a time-varying
covariate.
Thus, for example, we could model the Sulfadoxine concentration at time j
in period k for individual i as a function of the predicted Pyrimethamine con-
centration at the same point using:
yikj = f(xikj,βikj) + eikj
= β0ikj(−e−β1ikj×timeikj + e−β2ikj×timeikj ) + eikj
where:
βikj = Aikjβ +Bi,kjbi +Bik,jbik,
may be written as:

β0ikjβ1ikj
β2ikj

 =

1 0 0 Cikj 0 00 1 0 0 Cikj 0
0 0 1 0 0 Cikj




β0
β1
β2
β3
β4
β5


+

1 0 00 1 0
0 0 1



b0ib1i
b2i

+

1 0 00 1 0
0 0 1



b0ikb1ik
b2ik


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such that:
β0ikj = β0 + β3 × Cikj + b0i + b0ik
β1ikj = β1 + β4 × Cikj + b1i + b1ik
β2ikj = β2 + β5 × Cikj + b2i + b2ik
where Cikj is the predicted concentration of Pyrimethamine, and:
bi ∼ N(0,ψ1),
bik ∼ N(0,ψ2),
eikj ∼ N(0,Rik).
Of the two drugs, Pyrimethamine is the more quickly absorbed and eliminated,
and the relationship presented above is thus in the hypothesized direction, i.e.
where the Sulfadoxine concentration is impacted by that of Pyrimethamine
rather than vice versa.
Simultaneous:
The simultaneous approach is slightly more involved, as it specifies the two mod-
els at the same time, indicating which response type is appropriate with the use
of a binary indicator variable.
The structure of the data is changed slightly, so that now the response is a
stacked vector of concentrations for both drugs for each individual. The partic-
ular drug type being modeled is determined by a binary indicator variable in
the initial structural model specification.
We thus have the same model specification as before, except that now it is
additionally indexed by l, where l = 1, 2 for the case where we have two re-
sponses.
ylikj = fl(xikj,βikj) + elikj
where ylikj is the stacked vector of responses y1ikj and y2ikj .
l = 1, 2, i = 1, . . . ,ml, k = 1, . . . , nli, j = 1, . . . , nlik
ml is the number of individuals for response type l, nli = 2 is the number of
periods for the ith individual for response type l, and nlik is the number of
observations in the kth period for the ith individual for response type l.
The vector of βikj is now a combined vector of regression parameters β1ikj
and β2ikj defined as before, the components of which correspond to those in
the separate models for each response type.
The covariance matrixRik is now a (nik×nik) covariance matrix, where the up-
per left (n1ik×n1ik) submatrix corresponds to the covariance structure for y1ik,
the lower right (n2ik × n2ik) submatrix corresponds to the covariance structure
for y2ik, and the remaining elements may correspond to a model for within-
individual correlations between the elements of y1ik and y2ik.
Rik(nik×nik) =
[
Rik(11) Rik(12)
Rik(21) Rik(22)
]
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The covariance matrix for the residuals now accommodates the covariance struc-
ture for each individual response type, and allows for within-individual within-
phase correlations between the different responses.
For combined vectors bi = [b
′
1i,b
′
21]
′ and bik = [b
′
1ik,b
′
2ik]
′:
bi ∼ N(0,ψ1),bik ∼ N(0,ψ2)
where ψ1 and ψ2 are now joint covariance matrices, allowing correlations among
group-specific regression parameters for the two different response types.
For the PK-PD model, βikj is then a vector of both the PK parameters and
the PD parameters. Thus for example, for a bi-exponential PK model and an
Emax PD model similar to that previously specified:
β = [β0, β1, β2, β3, β4, β5] = [β0, β1, β2, E0, Emax, EC50]
bi = [b0i, b1i, b2i, b3i, b4i, b5i]
bik = [b0ik, b1ik, b2ik, b3ik, b4ik, b5ik]
where the random effects at each level are assumed to be jointly distributed
with an appropriate covariance matrix.
Now looking at the case in which the responses are the Sulfadoxine and Pyrimeth-
amine concentrations, the approach outlined above is appropriate for the case
in which we have different structural forms for the different responses, so for
example bi- and triple-exponential models for Sulfadoxine and Pyrimethamine
concentrations respectively.
Using these specifications, we would thus define a model such that:
f(xlikj,βlikj) =
[
β0likj(−e−β1likj×timelikj + e−β2likj×timelikj )
]
︸ ︷︷ ︸
×δl...
Bi-Exponential Model Form
+
[
β3likj × [−exp(−β5likj × timelikj) + exp(−β6likj × timelikj)]
+ β4likj × [−exp(−β5likj × timelikj) + exp(−β7likj × timelikj)]
]
︸ ︷︷ ︸
Triple-Exponential Model Form
× (1 − δl...)
where δl... is a binary variable indicating the response type as Pyrimethamine
(δl... = 0) or Sulfadoxine (δl... = 1).
Since the triple-exponential model is merely an extension of the bi-exponential
specification, a possible alternative approach would be to specify the larger and
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more complicated of the two structural forms, and differentiate between the two
responses by including the response type as a binary covariate.
Thus for example, for the triple-exponential model specification, we could fit:
ylikj = f(xlikj,βlikj) + elikj
= β2likj × [−exp(−β1likj × timelikj) + exp(−β3likj × timelikj)]
+β4likj × [−exp(−β1likj × timelikj) + exp(−β5likj × timelikj)]
+elikj
where:
β1likj = β1 + β6 × δl... + b1i + b1ik
β2likj = β2 + β7 × δl... + b2i + b2ik
β3likj = β3 + β8 × δl... + b3i + b3ik
β4likj = β4 + β9 × δl... + b4i + b4ik
β5likj = β5 + β10 × δl... + b5i + b5ik
where δl... is a binary variable indicating the response type as Pyrimethamine
(δl... = 0) or Sulfadoxine (δl... = 1), and:
bi ∼ N(0,ψ1),
bik ∼ N(0,ψ2),
eikj ∼ N(0,Rik)
The regression parameters associated with the binary variable δl... act as effect
modifiers, describing the changes in the shape of the concentration-time curve,
(as described by the number of exponential terms), for Sulfadoxine when com-
pared to Pyrimethamine. For the above model specification, the conditional
t-test for parameter β4 thus provides a formal statistical test for the suitability
of the bi- or triple-exponential model for the two responses.
Sequential and/or simultaneous procedures allow for the accommodation of pos-
sible correlations between the different response types: they take into account
the possible interdependence and relationship between the responses.
In the case of the simultaneous approach in particular, the combination of the
two models accommodates the association among factors corresponding to the
two responses, and allows for greater precision in the estimation of common
elements (the mixed-effect model relies on the pooling of data, and with the
simultaneous approach more information is available).
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2.7 Estimation and Inference
Inferential procedures for the nonlinear regression model are based on the usual
principles of least squares, and are analogous to the methods applied for the
linear case, i.e. the iteratively re-weighted least squares approach, where the
usual normality distributional assumptions are relaxed in order to account for
heterogeneity and autocorrelation. The main difference lies in the use of numer-
ical methods in the solving of the resulting estimating equations.
The main class of estimation techniques for nlme models is constituted by meth-
ods based on the linearization of the hierarchical model formulation presented
earlier. Several methods of linearization are available, including first order lin-
earization, which makes use of joint maximum likelihood and generalized least
square methods and first order conditional linearization (FOCE), which is the
estimation algorithm used in the nlme function in R, (R version 2.11.1 (2010-
05-31) Copyright (C) 2010 The R Foundation for Statistical Computing), and
thus the estimation procedure used in the attainment of all results presented
in this thesis. The FOCE approach is a refinement of first order linearization,
which takes the inter-individual variability into account, [6].
Inference is largely based on standard normal asymptotic theory: in the non-
linear case, since the solution of the estimating equations may not be explicitly
obtained, exact distributional results for the OLS estimator are not available.
Hence, approximations are developed using asymptotic theory, which hold even
when the underlying normality assumptions are violated, and are easily adapted
to take into account the existence of non-constant variance. Standard errors are
obtained from the inverse of the information matrix, evaluated at the appropri-
ate estimates. Confidence intervals and hypothesis tests are thus based on these
approximations, and likelihood ratio tests and information criteria are used in
model comparison, [6, 45].
A full description of these procedures may be found in Nonlinear Models for Re-
peated Measurement Data by Davidian and Giltinan [6] for both the linear and
nonlinear mixed effect models, together with alternative inferential approaches
for nlme models not described here. Extensions to the multi-level (nested) case
may be found inMixed Effect Models in S and S-Plus by Pinheiro and Bates [3].
The theoretical development of the multi-level NLME model is fundamental
to the specification and understanding of the correct model structure for this
data, and was thus presented in detail. Since the theoretical estimation and
inferential procedures are widely available and would remain largely unchanged
if detailed here, we chose to focus instead on the two aspects which impacted
most on the analyses, namely, the starting estimates and degrees of freedom.
2.7.1 Starting Values
The estimation of parameters in the context of the nlme model and specifically
in R requires solution of computationally intensive estimation algorithms. The
ease of convergence of these algorithms and the reliability of the results is heav-
ily dependent on the accurate specification of initial values.
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Determining reasonable estimates is difficult, and depends largely on an un-
derstanding of the structure of the model. Techniques described by Bates and
Watts [46] include the use of graphical or mechanistic interpretations of the pa-
rameters, and the refinement of particular estimates through an iterative pro-
cedure in which all other parameters are held fixed. Alternative options are to
base the starting values on relevant previously published literature, or to obtain
them from examination of the data on hand (via curve-stripping or method of
residuals) or through simulation.
Another common strategy is to specify a simpler version of the model, and
use the results to further refine the starting estimates for the intended analysis.
Pinheiro and Bates [3] suggest specifying a diagonal variance-covariance matrix
for the random effects, which, although not necessarily realistic, often speeds up
the iteration process and allows for successful convergence of the algorithms.
Lack of appropriate initial values may cause the iteration procedure to loop, re-
sulting in a lack of convergence, or should the model converge, results obtained
may not be stable or robust. For the latter case, slight changes in starting values
may result in different final parameter estimates.
Although different parameter estimates may result in the same predicted curve,
particularly when dealing with sums of exponentials, unstable parameter values
impact on the model building procedure, as they alter the potential positions of
covariates, and hence the impact of these covariates on specific features of the
curves.
Generally, the easiest way to ensure good starting estimates in the NLME model
is to “update” from the individual model fits, [3], i.e. to use the aggregates of the
predicted individual-specific parameter values as new starting values. Although
this procedure is usually automated in the nlme package in R, for multi-level
models it must be manually programmed.
For the separate Sulfadoxine and Pyrimethamine models, starting estimates
for the least squares and individual-specific models were obtained from previ-
ously published literature (Nyunt et al., [5]) and from a curve-stripping proce-
dure, although the latter methodology was only applied for the bi-exponential
model specification. The estimates of the fixed effects parameters from the least
squares models, and the averaged estimates from the individual-specific models
were then used to inform the initial values used in the NLME model.
For the Pyrimethamine case, there were insufficient data points available to
support the fitting of individual-specific triple-exponential models, and so for
this specification, the literature-based starting values were used in a simpler
single-level NLME model, and the final parameter estimates from this model
were then used in the multi-level version.
Nyunt et al [5] provided starting estimates for PK parameters only, which were
then transformed in order to get the values for the beta parameters in the expo-
nential parameterization. The values for the PK parameters in their paper, [5],
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were the averaged estimates from individual-specific one and two-compartment
models run on the same dataset used here.
Curve stripping or peeling, (also known as the method of residuals), uses the
observed data to provide starting estimates by essentially resolving the concen-
tration time curve into a series of exponentials (much the same as the parameter-
ization employed in the structural model forms used here). The curve-stripping
procedure used for the bi-exponential model was that described in Mixed Ef-
fect Models in S and S-Plus [3] for a first order single compartment model,
which again resulted in estimates for the clinical parameterization of the model
in question, albeit a different version to that obtained from the literature (the
model was specified in terms of clearance rather than volume of distribution).
Transformation to our exponential parameterization was straightforward.
The method is described as follows by Pinheiro and Bates [3]:
Writing the equation for a first order open compartmental model as:
y(x) =
D × exp(φ1)× exp(φ2)
exp(φ3)× [exp(φ2)− exp(φ1)]×[exp(−exp(φ1)×x)−exp(−exp(φ2)×x)]
where D is the dose, φ1 is the log of the elimination rate constant, φ2 is the log
of the absorption rate constant, and φ3 is the log of the clearance, the starting
estimates for φ1, φ2,and φ3 are obtained by following the following steps:
 The position time of the maximum response is determined, and the re-
gression model log(y) = a+ bx is fit to the data with values of x that are
greater than or equal to the position of the maximum response. Following
this, φ01 and φ
0
2 are defined as φ
0
1 = log|b| and φ02 = φ01 + 1 respectively.
 An algorithm for partially linear models is used to fit the nonlinear regres-
sion model:
y(x) = k[exp(−exp(φ1)× x)− exp(−exp(φ2)× x)],
refining the estimates of φ1 and φ2
 The current estimates of φ1 and φ2 and an algorithm for partially linear
models are used to fit
y(x) = kD × exp(−exp(φ1)× x)− exp(−exp(φ2)× x)
exp(φ1)− exp(φ2) ,
and we define φ3 = φ1 + φ2 − log(k).
The curve-stripping procedure that would be used in order to obtain starting
estimates for the two-compartment model is not described here.
2.7.2 Degrees of Freedom
InMixed Effect Models in S and S-Plus, Pinheiro and Bates, [3], recommend that
the conditional t- and F-tests provided in the model output be used to evaluate
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the inclusion of a fixed effect term rather than the output from the likelihood-
ratio tests, and show the likelihood ratio-tests to be slightly “anticonservative”,
in that the “nominal p-values are smaller than the empirical p-values”. The
likelihood-ratio tests may still be used however in the evaluation of the random
effects structure.
The algorithm for the calculation of the denominator degrees of freedom for
the conditional t- and F-tests used in the nlme package is described by Pinheiro
and Bates [3] for the linear mixed effect model. The algorithm was designed
to reproduce the results of the “BETWEENWITHIN” option in SAS PROC
MIXED, [3, 47].
The degrees of freedom are determined by the level of grouping (subject or
occasion-within-subject) at which the term is estimated. A term is classified as
“inner” to a grouping level, if its value can change within the levels of the group.
If not, it is classified as “outer”, [3].
Applying this to our dataset, pregnancy would be classified as “inner” to the
individual level of grouping indexed by i (level 1), and “outer” to the occasion
level of grouping indexed by k, (level 2).
Similarly, a factor such as site (constant for individuals and not dependent
on the occasion/period of observation determined by pregnancy status), would
be determined as “outer” to both levels of grouping, and would thus, like the
intercept, be estimated at level 0, and its denominator calculated at level Q+1,
where Q is the total number of levels.
If we define mf as the total number of groups in nesting level f , with m0 = 0,
(where f = 1, . . . , Q, and for the results presented here, Q = 2), then the de-
nominator degrees of freedom for the conditional t- and F-tests in the regression
models should be given by:
denDFf = mf − (mf−1 + pf ),
where pf is the sum of the degrees of freedom corresponding to the terms esti-
mated at level f .
Defining level 1 as observations indexed by individual i, level 2 as observations
indexed by occasion k, and the inner-most level (Q + 1) = 3 as observations
indexed by j respectively, the degrees of freedom for a parameter corresponding
to a covariate ‘inner” to grouping level 1 and “outer” to grouping level 2 (such
as pregnancy) should then be given by:
denDF1 = 97− (0 + 1)
= 96
where m1 = 97 is given by the number of individuals. The degrees of freedom
calculated and reported in the model output for the various covariate models
do not however appear to follow the above specification.
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For the case of the linear mixed effect model, the degrees of freedom calcu-
lated by the algorithm are described as “approximate at best” [48] by Douglas
Bates, who has also since debated whether this algorithm is“appropriate or not”
[47].
For the nonlinear case, there does not as yet appear to be a reliable way to
calculate the values required, although several approximations are suggested as
potential solutions.
Paraphrasing from several responses to questions posed in the R mixed effects
mailing list, primarily by Douglas Bates [47, 49, 50] and Bert Gunter (Genen-
tech Nonclinical Biostatistics, [51]):
“ Assuming that degrees of freedom (df) are defined as the“dimension of the null space when the data are projected on the
linear subspace of the model matrix of a linear model”, there should
thus be no df for the case in which there is no linear model.
Since nonlinear models are however fit by successive linear
approximations, approximate df may be obtained. The problem
appears to be that there is no “guarantee that the relevant residual
distributions are sufficiently [chi-squared] with the approximate df
to give reasonable answers”.
There does not appear to be a lot of consensus on the correct
approach to take (with little mention of specifically nonlinear mixed
effect models), with suggestions from (1) using the trace of the ‘hat’
matrix to (2) Satterthwaite and Kenward-Roger corrections.
For (1), the suggestion is based on the degrees of freedom
calculated for an unpenalized least squares problem (n minus the
trace of the hat matrix). This approximation is “frequently applied
in penalized least squares problems, which may be viewed as the
basic calculation in mixed effect models”. For (2), one of the
biggest reasons cited for why these corrections are not feasible is
that they rely on a normal distribution assumption, which is not
necessarily correct, and the other is that the actual calculations are
computationally intensive and difficult to institute.
Bootstrapping has also been suggested as a good way of over-
coming the degrees of freedom problem, but this is also not ideal,
as the non-diagonal covariance matrix makes re-sampling whilst
maintaining the covariance structure difficult.
Douglas Bates has discussed the problem extensively, and for
the lmer package, which is a “re-implementation” [49] of the nlme
package, no degrees of freedom or p-values are printed in the model
output, as he has yet to determine a reliable calculation for them.
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While the text, Mixed Effect Models in S and S-Plus, [3], in-
dicates that the linear algorithm described above is used in the nlme
estimation procedures, Bates goes on to describe the denominator df
as all being the same (as seen in the model output in this thesis) [50]:
“The denominator [of the F-test] is the penalized residual sum of
squares divided by the REML degrees of freedom, which is n-p
where n is the number of observations and p is the column rank of
the model matrix for the fixed effects. All the F ratios use the same
denominator . . . This is why I have a problem with the assumption
that the reference distribution for these F statistics should be an
F distribution with a known numerator degrees of freedom but a
variable denominator degrees of freedom and we can answer the
question of how to calculate a p-value by coming up with a formula
to assign different denominator degrees of freedom for each test.
The denominator doesn’t change.”
The current recommendation is to use a Markov Chain Monte
Carlo sample to evaluate the properties of individual coefficients, or
to calculate the F-ratio and assign a lower bound to the denominator
df. ”
The above discussion illustrates the lack of consensus regarding the appropri-
ate calculation for the degrees of freedom in NLME models. Hence, we decided
not to rely on the degrees of freedom and associated p-values reported in the
model output, instead basing our decisions regarding model evaluation and com-
parison on diagnostic assessments and initial hypotheses supported by graphical
output.
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2.8 Pharmacokinetics and the Delta Method
2.8.1 Introduction
The output from the models outlined in previous chapters enables us to achieve
smooth predicted curves, both for individuals and for covariate profiles of inter-
est (e.g. pregnant subjects vs. non-pregnant subjects).
It also provides us with estimates of the fixed effect parameters and their rel-
evant standard errors. These fixed effect parameters are of limited use to the
clinician however, as they are composite transformations of the pharmacokinetic
parameters that are usually of interest, as discussed in section 2.5.3.
In the evaluation of the impact of pregnancy on the disposition of SP, cer-
tain pharmacokinetic parameters are more relevant than others, (e.g. Apparent
Volume of Distribution and Clearance), because of previously formulated hy-
potheses regarding physiological changes during pregnancy and the resultant
anticipated impact on the movement of drugs through the system. These pa-
rameters are also required for the purposes of dosage calculations.
Whilst back-transformation from the beta parameters used in these models to
the mechanistic PK parameters is relatively straightforward, some measure of
variability is also required.
The delta method, which was chosen to obtain these estimates of variability,
is outlined and explained in this chapter. Additionally, calculations for the PK
parameters of interest are provided.
2.8.2 The Delta Method
The delta method essentially enables us to derive an approximation for the mean
value and variance of some nonlinear function, which is a transformation of one
or more random variables, [52, 53].
It uses the first-order Taylor expansion of the function about its mean, ignoring
higher order terms, following which the variance of the function can be calcu-
lated, [52, 53].
Thus, given a nonlinear function G(X), where X is an asymptotically normal
random variable with mean µ and the function is differentiable (i.e. the deriva-
tive exists and is non-zero), the approximate Taylor expansion of G(X) is given
by:
G(X) = G(µ) + (X − µ)×G′(µ)
The approximate variance of this function is thus given by:
V ar(G(X)) = V ar[G(µ) + (X − µ)×G′(µ)] = V ar(X)× [G′(µ)]2,
using:
V ar(a) = 0
V ar(a+ b×X) = b2 × V ar(X)
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where a and b are constants, [52, 53].
It should be noted that the accuracy of this approximation depends on the
the variance of the random variable X : the larger this variance, the worse the
approximation, [52, 53].
Extending this to the multivariate case, where X is a (1 × m) vector-valued
function, [53]:
G(X) = G(µ) + (X− µ)×G′(µ)T
And thus:
V ar(G(X)) = V ar[G(µ) + (X− µ)×G′(µ)T ]
= V ar[G′(µ)T ×X]
= G′(µ)T × V ar(X) ×G′(µ)
2.8.3 PK Parameters
The PK parameters of interest, namely, the AUC, clearance (Cl), volume of
distribution (Vd), elimination half-life (t1/2), Cmax, Tmax and the absorption
and elimination rates ka and ke, have already been introduced and defined in
the section on basic pharmacokinetics.
The exponential specification of the structural models necessitates that these
parameters be calculated, and as such, the calculations required for these back-
transformations are presented here. These calculations are based on those found
in the user guide for the software PK Solutions 2.0 [54].
The area under the concentration-time curve, or AUC, can be calculated us-
ing the trapezoidal rule below (for either observed or predicted concentrations):
AUC0−t = Σ
n
i=1
(Ci+1 + Ci)
2
× (ti+1 − ti)
where n is the total number of data points, and extrapolated to infinity using
ke:
AUC0−∞ = AUC0−t +AUCt−∞
AUCt−∞ =
C
ke
where C is the (observed or predicted) concentration at time t, the last observed
data point.
Alternatively, based on the general model specification used in this thesis:
C(t) = Σni=1Ci × exp(−λi × t)
where λi is the rate parameter as before, n is the number of differentiable phases
and thus the number of exponential terms, and t is time, the AUC may be
calculated as:
AUC = Σni=1
Ci
λi
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Thus for the bi-exponential model given by:
yikj = (β0ikj)[−e−(β1ikj)×timeikj + e−(β2ikj)×timeikj ] + eikj ,
where(for example)
β0ikj = β0 + b0i + b0ik
the AUC is calculated as:
AUC = Σ2i=1
Ci
λi
=
β0
β1
+
β0
β2
The vector of the mean parameter estimates, β = [β0, β1, β2]
′, which are the es-
timates of the fixed effects from the model output, and the variance-covariance
matrix of these parameter estimates would then be required in order to deter-
mine the standard error for the AUC using the Delta method.
Similarly, volume of distribution and clearance can be calculated as:
V d =
F ×D
λz × Σni=1Ciλi
Cl =
F ×D
Σni=1
Ci
λi
where λz is the elimination rate constant, and F is the fraction of dose D ab-
sorbed.
Hence, assuming F = 1, for the bi-exponential model specification:
V d =
Dose
β2 ×AUC =
Dose
β2 × (β0β1 +
β0
β2
)
=
Dose× β1 × β2
β2 × β0 × (β2 + β1)
=
Dose× β1
β0 × (β2 + β1)
and:
Cl =
Dose
AUC
=
Dose× β1 × β2
β0 × (β2 + β1)
Cmax and Tmax are calculated as:
Tmax =
2.303
λa − λz × log(
λa
λz
)
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Cmax =
F ×D
V d
× exp(−λz × Tmax)
where F , D, and λz are defined as previously, λa is the absorption rate param-
eter, and V d is the volume of distribution as calculated above. Thus:
Tmax =
2.303
β1 − β2 × log(
β1
β2
)
and:
Cmax = (Dose× 1/V d)× exp(−β2 × Tmax)
= (Dose× β2 ×AUC
Dose
)× exp(−β2 × Tmax)
= (β2 ×AUC)× exp(−β2 × Tmax)
Plasma half-life is calculated as:
t1/2 =
0.693
λn
=
0.693
β2
.
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2.9 Model Building
In general, several methods are available in the development of the covariate
model, which may be loosely divided into “candidate covariate” and “regression
based” procedures, [33].
In “regression-based” procedures, an initial NLME model is fitted ignoring co-
variates other than the primary time covariate, (which is already included in the
relevant structural model specification). This basic model is used in order to
obtain the individual- or occasion-within-individual-specific predicted parame-
ter values, for each parameter, [33, 55].
For each parameter, this vector of predicted parameter values is then used as
the vector of (independent) responses, and ordinary least squares regression of
each estimated parameter against the potential covariates determines which co-
variates, and in what form, are most appropriate for that parameter. Model
building procedures such as stepwise model selection may be used in order to
obtain the “best” model for each parameter, [33, 55].
The methods used in this thesis are, however, what would be referred to as
“candidate covariate” techniques. Unlike in the “regression-based” procedures,
the selection of covariates is not determined by the (for example) stepwise re-
gression of each individual parameter against prospective covariates.
The inclusion of covariates on a particular parameter, on several parameters,
and in combination with other covariates or otherwise, is determined via com-
parison of the appropriate NLME models, i.e. comparison of the model fits for
the appropriate non-linear models of the concentration over time.
For this thesis, prior to the development of the NLME models, least squares
models (ignoring random effects) and individual-specific models were fitted, the
latter being used in order to identify parameters which might require random
effects, and to identify potentially influential individuals.
Various structural model forms were compared, and the models were fitted for
the full dataset and for both pregnant and postpartum subsets. These models
were used to inform starting estimates for use in the NLME models.
Starting from a basic NLME model which included all possible random effects,
albeit with the most simplified variance-covariance structures, subsequent mod-
els were built in increasing and then decreasing levels of complexity, where the
inclusion of random effects, covariates and variance structures was re-evaluated
at each juncture.
This iterative re-assessment was required in order to accurately determine the
effect of the inclusion or removal of a covariate, since the various components
of the model all impact on one another. All possible combinations of model
features that could feasibly be assessed were thus considered.
Model evaluation included the usual assessments of model improvement, such
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as the stepwise addition and deletion of covariates based on the comparisons of
log-likelihood ratios and the Akaike (AIC) and Bayesian Information Criteria
(BIC) and the assessment of the appropriate model diagnostics.
Various other factors were also considered, including the successful convergence
of model runs, the time taken for them to converge and the obtainment of robust
variance-covariance matrices. Model fits were individually assessed in order to
watch for the emergence of multi-collinearity and other signs of model instability.
While this seems straightforward, there were several difficulties in the identi-
fication of the appropriate covariate relationships, not unusual in the case of
nonlinear mixed effect models.
In the stepwise approach outlined, the number of combinations of covariates
and parameters was unfeasibly large. The number of possible covariate com-
binations, compounded by the required iterative model building procedure and
finally, by the presence of correlated covariates, (the inclusion of which resulted
in unstable models with nonsensical results), resulted in a reduction in the num-
ber of covariates assessed for inclusion in the models. The focus was deemed
to be the impact of pregnancy/trimester, the inclusion of which followed the
procedure outlined above.
An hypothesis-based model building procedure was required in order to as-
sess the impact of the remaining covariates. However, the specification of the
models in terms of multiple exponential terms ignores the usual compartmen-
tal breakdown and clinical parameterization, which in turn hampers the use of
hypothesis-based covariate selection; since several beta parameters are compos-
ite parameters, despite the clearly defined relationships between the PK and
beta parameters, the hypothesized clinical impact of a covariate on a specific
parameter is no longer clear.
Acting without information regarding clinically feasible relationships for the
beta parameters made the covariate selection more complicated, and alterna-
tive means of identifying potential parameter -covariate relationships were thus
required. To this end, graphical techniques were employed, whereby plots of
the random effects of each of the parameters against various covariates were
assessed at every step of the model building procedure in order to determine
possible associations. These plots were also used in the assessment of the preg-
nancy and trimester covariates.
The graphical approach to covariate selection may be affected by shrinkage:
individual parameter estimates may tend to shrink towards the typical popula-
tion or average value, in comparison with the true individual parameter values,
particularly for sparse data, [33, 55]. This shrinkage may distort the actual
parameter-covariate relationships, hiding real associations or even falsely induc-
ing them (a correlation between structural model parameters may result in a
false correlation between individual specific parameters, and thus, the relation-
ship between a covariate and one parameter may falsely create the impression
of a relationship between that covariate and several other parameters), [33, 55].
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This is even more noticeable for individual parameter values that are not plau-
sible or have little information (such as the absorption phase in our case), and
this approach is not possible at all for parameters that have no random effects,
[33].
The exponential parameterization makes this all the more likely: using the
bi-exponential structural model as an example, β0 is seen to be a composite
function of β1 and β2. Thus, systematic patterns observed in the subject or
occasion-specific variability about this parameter, which might ordinarily indi-
cate the effect of some covariate on β0, may in fact be more accurately captured
through one of the other parameters.
The graphs were thus used as a guideline only.
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Chapter 3
Analysis and Results
3.1 Data Preparation and Exploration
Data preparation and exploration was performed using Stata/MP 11.0 (Stata-
Corp, College Station, Texas 2005) and R (R version 2.11.1 (2010-05-31) Copy-
right (C) 2010 The R Foundation for Statistical Computing).
Continuous covariates prospectively considered to be of interest included the
subject’s weight (kg), and gestational age (in weeks). Trimester, pregnancy and
site were to be explored as categorical variables, with the cut off for 2nd and
3rd trimester determined as 14-26 weeks and 27-35 weeks respectively. Subjects
with haemoglobin levels less than 10g/dl, were considered to be anaemic, [5],
and the impact of anaemia was to be investigated as both a continuous and
dichotomous variable with the above cut-off.
Postpartum Pregnant P-value
Variable N Median (IQR) N Median (IQR) (Kruskal-Wallis)
Weight (kg) 73 59.4 (53.3,67) 98 61 (56,67) 0.0016
Haemaglobin (g/dl) 74 11.75 (11,13.1) 98 10.7 (9.2,11.7) <0.0001
N % N % (Chi-Square)
% Haemaglobin < 10g/dl 74 9.46% 98 41.84% <0.0001
Table 3.1: Baseline Characteristics by Pregnancy (I)
Baseline characteristics for the study participants were compared for different
phases of pregnancy (Table 3.1) and across sites (Table 3.2 and Table 3.3) us-
ing appropriate tests, Kruskal-Wallis for continuous variables and Chi-squared
tests of association for counts.
Although we do have paired samples, the design is unbalanced, since some of
the participants did not return for the postpartum phase of the study. As such,
the Kruskal-Wallis and Chi-squared tests appropriate for independent samples
were used, albeit as a basic guideline only.
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Parameter Total Mali Mozambique Sudan Zambia P-value
Median (IQR) N=97 N=18 N=31 N=24 N=25
Age (years) 26 (23,32) 26 (22,32) 24 (22,27) 28 (26,32) 31 (25,36) 0.003
Weight (kg) 61 (56,67) 60 (56,65) 61 (56, 65) 66 (57,71) 60 (56,66) 0.37
Gestational age (wks) 27.5(24,29) 28 (25,29) 27 (24,29) 27 (21,33) 26.5 (24,28) 0.87
2nd Trimester (n (%)) 44 (45%) 7 (39%) 13 (42%) 12 (50%) 12 (48%) 0.9
Haemoglobin (g/dl) 10.7 (9.2,11.7) 9.9 (9.4,11.4) 10.8 (9.6, 12) 9.2 (8.5, 10.9) 11.3 (10.5, 12.1) 0.0002
Anaemic (n (%)) 41 (41.84%) 10 (55.6%) 11 (35%) 17 (71%) 3 (12%) 0.001
Dosage (mg/kg) 1.2 (1.1,1.3) 1.3 (1.2, 1.3) 1.2 (1.2,1.3) 1.2 (1.1, 1.3) 1.3 (1.1,1.3) 0.35
Table 3.2: Baseline Characteristics for Pregnant Subset
Parameter Total Mali Mozambique Sudan Zambia P-value
Median (IQR) N=74 N=18 N=22 N=15 N=18
Weight (kg) 59.4 (53.3,67) 59 (52,64) 55 (51,63) 71 (61,82) 60.8 (55,66) 0.003
Haemoglobin (g/dl) 11.8 (11.0,13.1) 12.4 (11.6,13.2) 11.6 (11.2,12.9) 10.8 (10.2,11.5) 13.1 (11.6,14.9) 0.0003
Anaemic (n (%)) 7 (9.5%) 1 (5.6%) 3 (13.6%) 3 (20%) 0 0.2
Dosage (mg/kg) 1.3 (1.1,1.4) 1.3 (1.2,1.4) 1.4 (1.2,1.5) 1.06 (0.9,1.2) 1.2 (1.1,1.4) 0.003
Table 3.3: Baseline Characteristics for Non-Pregnant Subset
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Pregnant subjects appeared to weigh significantly more (p=0.0016) and be
significantly more anaemic (p<0.0001) when compared to postpartum subjects
for all sites, although the actual difference between the pregnant and postpar-
tum median weights (59.4 versus 61) did not appear to be too large.
Within the pregnant and postpartum subsets, significant differences were seen
across sites for age and anaemia (in the pregnant subset) and for anaemia and
weight (and thus mg/kg dosage) in the postpartum subset.
Weight (kg), dosage (mg/kg) and gestational age (in weeks) were similar across
sites for pregnant subjects, and moderate anaemia was observed for approxi-
mately 41.8% of pregnant subjects.
Subjects in Zambia appeared to be older and less anaemic than those in the
remaining sites, with a median age of 31 and only 12% of subjects with anaemia
in the pregnant subset, and no anaemic subjects in the postpartum subset.
Subjects in Sudan were most often anaemic for both the pregnant (71%) and
postpartum subsets (20%).
Individual concentration-times curves were examined for both Sulfadoxine and
Pyrimethamine, in order to identify concentrations that might be deemed bio-
logically implausible.
Subjects with all concentrations less than 10ug/ml for Sulfadoxine and 10ng/ml
for Pyrimethamine could not be included in the analysis, as the limits of quan-
tification for the assay methods were 10ug/ml and 10ng/ml for the two drugs
respectively. Concentrations greater than 0ug/ml or 0ng/ml prior to dosing
and those outside of the range of plausible values were also excluded. Table 3.4
details the subjects and/or concentrations that were not included in the analysis
(for both Sulfadoxine and Pyrimethamine).
Subject Site Pregnancy Status Concentration Measurements
11 Sudan Pregnant/Postpartum All
10 Mozambique Pregnant Days 2 and 21
26 Mozambique Postpartum Day 0
28 Mozambique Pregnant Days 1, 2 and 3
23 Mozambique Pregnant Day 1
Table 3.4: List of Subjects/Concentration Measurements Excluded from Anal-
yses
Figures 3.1 and 3.2 show graphs of Pyrimethamine concentrations over time
for subjects in Sudan and Mozambique, with the implausible points labeled by
subject and by day of observation. Figures 3.3 and 3.4 show these same plots
for the Sulfadoxine concentrations over time. These figures illustrate the gen-
eral structural form of the observed drug concentration-time profiles, in addition
to identifying those biologically implausible points removed prior to modeling.
Similar curves were examined for subjects from Mali and Zambia, for which no
implausible points were identified, (Appendix A, Figures A.1 to A.4).
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Figure 3.1: Identification of Biologically Implausible Pyrimethamine Concen-
trations: Sudan
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Figure 3.2: Identification of Biologically Implausible Pyrimethamine Concen-
trations: Mozambique
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Figure 3.3: Identification of Biologically Implausible Sulfadoxine Concentra-
tions: Sudan
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Figure 3.4: Identification of Biologically Implausible Sulfadoxine Concentra-
tions: Mozambique
66
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The distributions of individual covariates were examined using histograms (con-
tinuous covariates) and tables (categorical covariates). The relationships be-
tween continuous covariates were explored using pairs plots, and those between
categorical covariates using appropriate tests of association. Box plots of the
continuous variables by pregnancy status, site and anaemia were also used to
indicate potential confounders (Appendix A, Figures A.5 and A.6).
As seen in Figure 3.5, relatively symmetrical distributions were indicated for
weight (kg), haemoglobin measurement and dosage (mg/kg). The histogram
for gestational age (gage) reflects zero’s for the non-pregnant subjects and an
approximately symmetrical distribution for pregnancy. Age appeared to be
slightly skewed to the right. Weight and mg/kg dosage are directly correlated,
as anticipated.
Day 7 concentrations were used to indicate relationships between concentra-
tions and covariates; day 7 concentrations have previously been shown to be
highly correlated with total drug exposure (as measured by the area under the
concentration-time curve) for both Sulfadoxine and Pyrimethamine, and have
also been shown to be associated with therapeutic efficacy, [5, 30].
gage
8 10 12 14 16
0.49 0.083
50 70
0.14
0
10
20
30
0.15
8
10
12
14
16
haemd0
0.12 0.17 0.17
age
0.20
20
30
40
0.22
50
70
weight
0.98
0 10 20 30 20 30 40 1.0 1.4 1.8
1.
0
1.
4
1.
8
dosage
Figure 3.5: Pairs Plots
Box plots of day 7 concentrations by pregnancy status, site and anaemia indi-
cated that the relationship observed between Pyrimethamine day 7 concentra-
tion levels and pregnancy phase appeared to differ dependent on whether or not
subject was anaemic (Figure 3.6). For Sulfadoxine, the impact of pregnancy on
the day 7 concentrations appears to be greater for anaemic subjects.
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Figure 3.6: Boxplots of Day 7 Concentrations by Pregnancy and Anaemia
0
10
0
20
0
30
0
D
ay
 7
 P
yr
im
et
ha
m
in
e 
Co
nc
en
tra
tio
n 
(ng
/m
l)
Mali Mozambique Sudan Zambia
PP Pregnant PP Pregnant PP Pregnant PP Pregnant
0
20
40
60
80
D
ay
 7
 S
ul
fa
do
xin
e 
Co
nc
en
tra
tio
n 
(ug
/m
l)
Mali Mozambique Sudan Zambia
PP Pregnant PP Pregnant PP Pregnant PP Pregnant
Figure 3.7: Boxplots of Day 7 Concentrations by Pregnancy and Site
The relationship between the day 7 concentrations and pregnancy did not ap-
pear to be altered by site for either of the two compounds (Figure 3.7), although
for Pyrimethamine, more of an overlap is observed for subjects in Sudan than
for those in the remaining sites, and for Sulfadoxine, the impact of pregnancy
on the day 7 concentrations appears to be greater for subjects in Mozambique
and Sudan than for those in Mali and Zambia.
Figure 3.8 demonstrates the different scales and units for Pyrimethamine and
Sulfadoxine. Higher peak concentrations and a longer observation period were
observed for pregnant subjects for both compounds, (Figure 3.9). For Sulfadox-
ine, a steeper elimination period was also seen in for pregnant subjects.
3.2 Sulfadoxine Models
Following the model building procedure outlined in section 2.9, least squares
models (referred to as NLS models), that ignore the grouping structure of
the data, and individual-specific models were fitted to the the Sulfadoxine
concentration-time data prior to any nlme models.
This section presents some of the pertinent results from the NLS and individual-
specific models, and compares the results from models using different starting
values (those from Nyunt et. al [5] and from the curve-stripping procedure for
the bi-exponential model).
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Figure 3.8: Scatter plots of Sulfadoxine and Pyrimethamine Concentrations over
Time
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Figure 3.9: Lowess plots of Sulfadoxine and Pyrimethamine Concentrations over
Time by Pregnancy Status
The covariate model-building procedure used in the development of the non-
linear mixed effect model is also detailed, along with the results from the final
NLME models. Predicted curves from the exponential model specification are
shown, and clinical parameters are presented and contrasted with those obtained
using the more traditional two stage approach to the analysis of PK data, for
several models.
Results from the basic bi-exponential model, ignoring covariates, and the model
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adjusted for pregnancy are also contrasted with those obtained from correspond-
ing clinically (mechanistically) specified one-compartment models.
The results obtained from the NLME multi-level model adjusted for pregnancy
only are compared to those achieved with a single-level representation of the
grouping structure, and a model with proportional (multiplicative) random ef-
fects is also presented.
3.2.1 NLS Models
Nonlinear least squares models ignore the hierarchical grouping structure of the
data, assuming independent observations. We are thus fitting a model of the
form:
yj = f(xj ,β) + ej (3.1)
where yj is the concentration at time j, xj = timej , and β is a p-dimensional
vector of fixed effects.
Both the bi- and triple-exponential structural model forms were fitted, such
that:
f(xj ,β) = β0 × [−exp(−β1 × timej) + exp(−β2 × timej)] (3.2)
or:
f(xj ,β) = β2 × [−exp(−β1 × timej) + exp(−β3 × timej)] (3.3)
+β4 × [−exp(−β1 × timej) + exp(−β5 × timej)]
The models were fitted for the full dataset and for pregnant and postpartum
subsets; in the case of the bi-exponential model, comparing the results obtained
from starting values based on the article by Nyunt et. al [5] with those from
the curve-stripping procedure.
Table 3.5 compares the starting values from the different sources for the full
dataset and the various subsets. The units in table 3.5, and in the remainder
of the results section, for the beta parameters corresponding to the range of
concentrations (for example β0) and the rates of incline/decline (for example
β1) are concentration, and concentration per hour respectively.
Parameter Data Curve Stripping Nyunt et. al
β0: Full 86.7 80.89 (60.88; 96.88)
Pregnant 91.3 86.8 (68.6; 101.5)
Postpartum 67.3 62 (50.2;70.7)
β1: Full 5.92 14 (4.2; 39.8)
Pregnant 6.58 15.7 (4; 45)
Postpartum 8.76 11.5(5.3;20.7)
β2: Full 0.1476 0.088 (0.069; 0.1)
Pregnant 0.1476 0.094 (0.081,0.11)
Postpartum 0.0978 0.07(0.062;0.079)
Table 3.5: Comparison of Starting Values for Bi-Exponential Model
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The values obtained from the curve-stripping procedure appear to lie within the
ranges calculated from the Nyunt et. al [5] results, with the exception of those
for β2 (analogous to the elimination rate), which are consistently higher using
curve-stripping for all subsets.
The suggested starting values for the pregnant subset indicate a higher range of
concentrations than for the postpartum subset, together with a slower rate of
incline and faster decline.
The large degree of uncertainty for the β1 parameter observed for all subsets
(indicated by the wide interquartile ranges from the Nyunt et al. analysis) may
be attributable to the the limited amount of information available for the ab-
sorption phase of the data.
Estimate Std. Error Pr(>|t|)
β0 72.90 0.96 0.00
β1 10.11 0.67 0.00
β2 0.07 0.003 0.00
Table 3.6: Model Output for Sulfadoxine Bi-Exponential NLS model
Estimate Std. Error Pr(>|t|)
β1 17.95 5.23 0.00
β2 -21.73 6.05 0.00
β3 1.89 0.79 0.02
β4 77.62 1.98 0.00
β5 0.08 0.004 0.00
Table 3.7: Model Output for Sulfadoxine Triple-Exponential NLS model
Tables 3.6 and 3.7 are the results obtained for the full dataset from NLS models
using the bi- and triple-exponential structural model forms respectively. The re-
sults were the same regardless of which set of starting values were applied. Com-
parisons of these models based on Aikaike (9395.81 vs. 9377.96) and Bayesian
Criteria (9415.97 vs. 9408.20) indicated that the triple-exponential model was
preferred.
For the pregnant subset, comparisons of the Aikaike criteria of the bi- and
triple-exponential models indicated that the inclusion of the additional expo-
nential term improved the general model fit, (6131.44 vs. 6123.79), although
the Bayesian criteria favoured the simpler model (6149.9 vs. 6151.47). For
the postpartum subset however, the triple-exponential model resulted in dispro-
portionately large standard errors indicative of multi-collinearity, and so was
discarded. This may in part be attributed to the very sparse sampling observed
for postpartum subjects in Mozambique and Sudan (concentrations were mea-
sured on days 0 and 7 only for these subjects).
The validity of these triple-exponential models was brought into question by
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a paper published in the Journal of Pharmacokinetics and Biopharmaceutics
in 1998, entitled “Pitfalls in Pharmacokinetic Multicompartment Analysis”, by
Liang and Derendorf [56]. Using simulation techniques, the authors explored the
potential for erroneous model specification, and determined that for the model
formulation below:
C = A1 × exp(−α× time) +A2 × exp(−β × time)
+A3 × exp(−k × time)
the values of parameters A1 and A2 played a more significant role in the accurate
determination of a truly biphasic elimination profile than the rate constants α
and β.
They determined that a monophasic elimination profile was indicated for situ-
ations in which both parameters were negative, or if otherwise, for the case in
which |A2| > |A1|. Biphasic elimination profiles were indicated for situations
where |A1| > |A2|.
Using the triple-exponential model specification given by equation 3.3, param-
eters β2 and β4 are those corresponding to parameters A1 and A2 respectively.
Examination of the parameter estimates presented in Table 3.7 shows that
β4| > |β2|, which is thus indicative of a misspecification.
For the NLS models then, the bi-exponential models were deemed more appro-
priate for both the full dataset and the pregnant subset. Results from this model
specification indicated that when compared to postpartum subjects, pregnant
subjects exhibited higher values for β0 (78.4 vs. 61.5), a slower rate of incline
(10.36 vs. 12.26), and faster rate of decline (0.084 vs. 0.054), as observed in the
initial data exploration and indicated by the starting values obtained from the
curve-stripping procedure, (Appendix B, Tables B.1 and B.2).
Plots of the standardized residuals against the subject ID (Figure 3.10), showed
residuals for several subjects that were either strictly positive or negative, indi-
cating the need for the subject-specific random effects.
3.2.2 Individual-Specific Models
Individual-specific model fits for both structural model specifications provided
us with alternative starting values: parameter estimates from the individual fits
were averaged across all individuals for later use in the nlme models.
Individual-specific fits could not be achieved for subjects in Mozambique or
Sudan due to sparsely sampled data, since for pregnant subjects no samples
were taken for the first 24 hours following dosing, and samples were taken for
days 0 and 7 only in the postpartum subjects.
Plots of the parameter estimates and their 95% confidence intervals for each
subject may usually be used in order to ascertain which of the parameters might
require random effects. A basic range may also be established for each of the
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Figure 3.10: Residuals by Subject ID: Sulfadoxine Bi-Exponential NLS Model
parameters, and individual subjects with mean values and confidence intervals
outside of this range may be identified for further examination as potential out-
liers. In this instance, because of the large number of individuals for whom
these model fits and estimates could not be obtained (approximately half of the
individuals in the dataset), the graphs are not overly informative.
Figure 3.11 shows the parameter estimates and 95% confidence intervals for
the bi-exponential model specification. The lack of overlapping intervals seen
for β0 indicated the potential need for random effects on this parameter. This
was not so easily determined for β1 or β2, as comparatively wide confidence
intervals for some of the individuals obscured the scale and intervals for the
remaining subjects. Removal of two of the individuals with overly large con-
fidence intervals resulted in Figure 3.12, which indicated that random effects
were required for β2, but not necessarily for β1.
The graphics for the triple-exponential model were not useful, as so few indi-
vidual fits could be obtained for this specification.
3.2.3 Multi-Level NLME Models
The specification of starting values for the nlme models played a significant role
in both the convergence and stability of the model.
Basic nlme models (ignoring the impact of covariates) were again fit for both the
bi- and triple-exponential model specifications for the pregnant and postpartum
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Figure 3.11: Parameter Estimates and 95% Confidence Intervals for Individual
Model Fits (I)
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Figure 3.12: Parameter Estimates and 95% Confidence Intervals for Individual
Model Fits (II)
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subsets. These subset analyses were done in order to double check the impact
of pregnancy on the beta parameters, and thus to better inform the starting
values used later when incorporating pregnancy as a covariate in the model for
the full dataset.
Stable versions of the models were achieved using starting values for the fixed
effects based on the parameter estimates from the appropriate NLS models, and
a positive-definite diagonal covariance matrix for both levels of random effects
(subject and occasion specific).
We were unable to fit a triple-exponential model for the postpartum subset,
and the results from this formulation for the pregnant subjects indicated mis-
specification of the structural model form, since the parameter estimates for β2
and β4 were such that |β4| = 81.04 > |β2| = 0.157.
Table 3.8 shows the Aikaike and Bayesian information criteria for the com-
parison of the bi- and triple-exponential models for the pregnant subset: the
model comparison supported the conclusion that the simpler model was pre-
ferred. The bi-exponential model form was thus selected to continue the model
building process.
Model df AIC BIC
Bi-Exponential 7 5599.207 5631.501
Triple-Exponential 11 5624.219 5674.966
Table 3.8: Model Comparison for Bi-Exponential NLME Models: Pregnant
Subset
Model 1:
The initial model fit to the Sulfadoxine concentration-time data was thus given
by equation:
yikj = f(timeikj ,βikj) + eikj
where yikj is the jth measurement in the kth period for the ith individual, and
f(timeikj ,βikj) = β0ikj [−exp(−β1ikj × timeikj) + exp(−β2ikj × timeikj)]
= (β0+b0i+b0ik)×[−exp(−(β1+b1i+b1ik)×timeikj)+exp(−(β2+b2i+b2ik)×timeikj)]
Thus, in the specification of the stage II equations:
βikj = Aikjβ +Bi,kjbi +Bik,jbik,
the p-dimensional vector of fixed effects β is given by
β = [β0, β1, β2],
the q1− and q2-dimensional vectors of the subject and occasion-specific random
effects are given by:
bi = [b0i, b1i, b2i]
bik = [b0ik, b1ik, b2ik]
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Parameter Value Std.Error DF P-value
βˆ0 79.09 1.99 977.00 <.0001
βˆ1 13.95 1.07 977.00 <.0001
βˆ2 0.08 0.002 977.00 <.0001
Table 3.9: Bi-Exponential Model Output: Sulfadoxine NLME Model 1
and the design matrices Aikj, Bi,kj, and Bik,j are (3× 3) identity matrices.
Table 3.9 summarizes the results from this model, showing the fixed effects pa-
rameter estimates together with their standard errors, the degrees of freedom
and associated significance.
The within group errors eikj are assumed independently and identically nor-
mally distributed, with variance-covariance matrix Rik for every ik combina-
tion, whereRik is the positive-definite (nik×nik) matrix with diagonal elements
σˆ2 = (7.36)2.
The subject and occasion-specific random effects are also assumed to be nor-
mally distributed:
bi ∼ N(0,ψ1),bik ∼ N(0,ψ2)
with variance-covariance matrices, (ψ1 and ψ2) given by:
ψˆ1 =

14.85
2 0 0
0 3.062 0
0 0 7.77e− 062

 , ψˆ2 =

13.72
2 0 0
0 5.852 0
0 0 0.0182


The diagnostic plots for this model (Appendix B, figures B.1 to B.5) indicated
that the normality assumptions for the random effects and residual errors ap-
peared to be reasonable. QQ plots of the random effects for the respective
grouping levels showed very little subject or occasion-specific variation for the
β1 parameter. Pairs plots of the random effects for the different levels showed
no distinct correlation patterns, (Appendix B, figures B.6 and B.7).
Figure 3.13 is a plot of the standardized residuals against the fitted values (with
outliers identified by the labelled points), and indicated that the assumption of
constant variance for the residual errors was invalid, as demonstrated by the
outward fanning of the residuals which shows increasing variance for larger fit-
ted values. The model thus appears to be over- or under-estimating the peak
concentrations.
The overall fit of the model was examined using plots of the fitted values
versus the observed, (Appendix B, figure B.8) , and plots of the predicted
concentration-time curves for the population, individual-specific and occasion-
specific levels versus the observed values for each individual-occasion grouping.
Figure 3.14 shows the latter plots for a subset of the dataset; the blue lines rep-
resent the population curve obtained using the fixed effects parameter estimates,
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Figure 3.13: Standardized Residuals vs. Fitted Values: Sulfadoxine NLME
Model 1
i.e. the predicted concentrations yˆikj given by:
yˆikj = βˆ0 × [−exp(−βˆ1 × timeikj) + exp(−βˆ2 × timeikj)],
= 79.09× [−exp(−13.95× timeikj) + exp(−0.08× timeikj)]
The pink and green lines are the predicted curves for the subject and occasion-
specific grouping levels respectively, i.e. the predicted concentrations given by:
yˆikj = (βˆ0 + bˆ0i)× [−exp(−(βˆ1 + bˆ1i)× timeikj) + exp(−(βˆ2 + bˆ2i)× timeikj)]
and
yˆikj = (βˆ0+bˆ0i+bˆ0ik)×[−exp(−(βˆ1+bˆ1i+bˆ1ik)×timeikj)+exp(−(βˆ2+bˆ2i+bˆ2ik)×timeikj)]
The peak concentration value is under-estimated for several individuals (e.g.
subject SUDN 012/1), and the overlapping of the blue, pink and green lines for
the absorption phase of the curves demonstrates the lack of subject or occasion-
specific variability for the parameter representing the slope of this line.
The small subject-specific variability for the β2 parameter (τˆ
2
2 = 7.77e− 062) is
also illustrated by the overlapping blue and pink lines in the elimination phase
of the curves.
As described in the section on model building, for each grouping level and pa-
rameter, plots of the random effects versus covariates were used as a guideline
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Figure 3.14: Population, Subject and Occasion-Specific Predicted Curves (Sub-
set: Sudan): Sulfadoxine NLME Model
in deciding on the placement of covariates.
Figures 3.15, and 3.16 are plots of the subject-specific random effects for β0
and β1 vs. trimester, weight, site and anaemia. Figure 3.17 is the plot of the
occasion-specific random effects vs. the same covariates for β2. The plots for
the parameters and grouping levels not shown here may be found in Appendix
B, figures B.9 to B.11.
Using study site Mali as a reference category, subjects in study sites Mozam-
bique and Zambia appear to have higher and lower median β0 values respectively.
Anaemic subjects, and those in their 2nd or 3rd trimester appear to have higher
median β0 values (when compared to non-anaemic and postpartum subjects re-
spectively. There does not appear to be any weight effect for this parameter.
The systematic patterns detectable in the subject-specific variation for β0 are
not as evident for the occasion-specific grouping level, with the exception of
Anaemia, (Appendix B, figure B.10).
Figure 3.16 illustrates the limited amount of subject-specific variability for the
β1 parameter, (representing the slope of the incline, and analogous to the ab-
sorption rate constant ka), although this may not necessarily indicate a true
lack of variability; it is more likely a consequence of the limited data available
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Figure 3.15: Subject-Specific Random Effects for β0 vs. Covariates: Sulfadoxine
NLME Model
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Figure 3.16: Subject-Specific Random Effects for β1 vs. Covariates: Sulfadoxine
NLME Model
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for this part of the curve. No systematic patterns are observed.
The same observations could be made for the plot of the occasion-specific ran-
dom effects vs. covariates (Figure B.11 in Appendix B) for β1.
There do not appear to be any large differences in the value of β2 attributable
to study site, anaemia or weight, where β2 is the parameter giving the slope of
the decline and is analogous to the elimination rate constant ke, (Figure 3.17).
Subjects in their 2nd and 3rd trimester do appear to have higher median values,
which would indicate a faster rate of decline. This systematic pattern in the
occasion-specific variability is not observed in the plots of the subject-specific
random effects for this parameter.
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Figure 3.17: Occasion-Specific Random Effects for β2 vs. Covariates: Sulfadox-
ine NLME Model
Since the main objective of the study was to determine how the concentration-
time relationship of the drugs was affected by pregnancy, we started the covariate
model building procedure by looking at pregnancy and its proxy measurements,
trimester and gestational age (plots not shown).
The graphs presented in figures 3.15, 3.16 and 3.17 and the initial data ex-
ploration indicated a possible systematic pregnancy effect for parameters β0
and β2. These graphs were used as a guideline only however, and the inclusion
of pregnancy as a covariate on the fixed effect parameters was examined through
an iterative stepwise model building procedure, in which pregnancy was added
to each parameter in turn and to various combinations of parameters in increas-
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ing levels of complexity.
Model comparisons using the Aikaike and Bayesian information criteria and
the (“anti-conservative”) likelihood ratio test (for nested models) indicated a
preference for the initial model (excluding covariates) at every step.
Model 2:
The removal of the subject-specific random effect for parameter β2 (τˆ
2
2 = 7.77e−
062) appeared to improve the model fit, (AIC: 8484.19 vs. 8482.19, BIC: 8534.59
vs. 8527.55), and we were then able to fit pregnancy to both β0 and β2.
Model 3:
The resulting stage 2 equations are given by:
βikj = Aikjβ +Bi,kjbi +Bik,jbik,
where:

β0ikjβ1ikj
β2ikj

 =

1 0 0 pregik. 00 1 0 0 0
0 0 1 0 pregik.




β0
β1
β2
β3
β4

+

1 0 00 1 0
0 0 0



b0ib1i
b2i

+

1 0 00 1 0
0 0 1



b0ikb1ik
b2ik


such that:
β0ikj = β0 + β3 × pregik. + b0i + b0ik,
β1ikj = β1 + b1i + b1ik,
β2ikj = β2 + β4 × pregik. + b2ik.
The distributional assumptions for the eikj and the subject and occasion-specific
random effects remain unchanged, and the results for the fixed effects are sum-
marized in Table 3.10.
Parameter Value Std.Error DF P-value
βˆ0.(Intercept) 71.91 2.58 975.00 <.0001
βˆ3.(Pregnancy) 8.89 2.50 975.00 <.0001
βˆ1 14.22 1.10 975.00 <.0001
βˆ2.(Intercept) 0.06 0.003 975.00 <.0001
βˆ4.(Pregnancy) 0.03 0.004 975.00 <.0001
Table 3.10: Model Output for Sulfadoxine NLME Model 3
The variance-covariance matrices for the random effects for each grouping level
are given by:
ψˆ1 =

14.52
2 0 0
0 3.322 0
0 0 0

 , ψˆ2 =

11.98
2 0 0
0 5.802 0
0 0 0.0152


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and the diagonal elements of Rik are given by σˆ2 = (7.32)
2.
This model was determined to be significantly better than model 2 (AIC: 8482.19
vs. 8427.35, BIC: 8527.55 vs. 8482.8 and lrtest p-value (anti-conservative):
<0.0001).
Examination of the diagnostic plots for this model (Appendix B, figures B.12
to B.18) indicate no departure from the assumptions aside from the assumption
of constant variance, as demonstrated by Figure 3.18.
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Figure 3.18: Standardized Residuals vs. Fitted Values: Sulfadoxine NLME
Model 3
A variance model of the form:
g2(µ, zj,θ) = (θ1 + µj
θ2)2, θ1, θ2 > 0,
was therefore specified for the residual errors (eikj), where µj is the expected
value of the jth response (for each ik combination) and θ = [θ1, θ2], which re-
sults in approximately proportional errors.
The inclusion of this variance model appeared to greatly improve the model
fit, (AIC: 8427.35 vs. 7867.06, BIC: 8482.8 vs. 7932.59, and lrtest p-value:
<0.0001).
Model 4:
The results for the fixed effects from this model are summarized in Table 3.11,
and the variance-covariance matrices for the subject and occasion-specific ran-
82
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
dom effects, (ψ1 and ψ2 respectively) are now given by:
ψˆ1 =

13.63
2 0 0
0 3.362 0
0 0 0

 , ψˆ2 =

11.22
2 0 0
0 5.022 0
0 0 0.0142


The (nik × nik) variance-covariance matrix Rik for the residual errors is now:
Rˆik =

σ2(θ1 + µ1
θ2)2 σ1
√
(θ1 + µ1θ2)2 × σ2
√
(θ1 + µ2θ2)2 . . .
σ2
√
(θ1 + µ2θ2)2 × σ1
√
(θ1 + µ1θ2)2 σ
2(θ1 + µ2
θ2)2 . . .
...
...
. . .


where σˆ2 = 0.0772, and θˆ = [20.37, 1.14].
Parameter Value Std.Error DF P-value
βˆ0.(Intercept) 70.69 2.47 975.00 <.0001
βˆ3.(Pregnancy) 8.62 2.45 975.00 <.0001
βˆ1 13.37 1.07 975.00 <.0001
βˆ2.(Intercept) 0.06 0.003 975.00 <.0001
βˆ4.(Pregnancy) 0.03 0.003 975.00 <.0001
Table 3.11: Model Output for Sulfadoxine NLME Model 4
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Figure 3.19: Standardized Residuals vs. Fitted Values: Sulfadoxine NLME
Model 4
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Figure 3.19 illustrates the reduction in the variance of the residuals for the larger
fitted values for Model 4. As seen before, pregnant subjects in models 3 and 4
appeared to have systematically higher values for β0 and β2 compared to post-
partum, illustrated by the positive effect modifiers β3 and β4 respectively. This
indicates that pregnant subjects have a higher range of concentrations and a
faster rate of decline than those postpartum.
This is illustrated in Figure 3.20 which is a plot of the mean predicted concentration-
time curves for the pregnant and postpartum subjects.
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Figure 3.20: Predicted Mean Concentration-Time Curves by Pregnancy Phase:
Sulfadoxine NLME Model 4
Examining the plot of the subject-specific random effects vs. covariates for the
β0 parameter fromModel 4, (Figure 3.21), we see that the trimester and anaemia
effects previously noted have been somewhat reduced, although the site effect
remains.
No patterns can be seen for the occasion-specific random effects for this param-
eter, (Appendix B, figure B.19).
Looking at the occasion-specific random effects for the β2 parameter, (Fig-
ure 3.22), both the trimester and anaemia effects are no longer in evidence.
No further adjustments to the random effects were deemed necessary, and the
inclusion of trimester in place of pregnancy did not improve the model fit, (as an-
ticipated since no differences were observed between the 2nd and 3rd trimesters
for any of the parameters). Model 4 is therefore the final pregnancy model for
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Figure 3.21: Subject-Specific Random Effects for β0 vs. Covariates: Sulfadoxine
NLME Model 4
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Figure 3.22: Occasion-Specific Random Effects for β2 vs. Covariates: Sulfadox-
ine NLME Model 4
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Sulfadoxine.
Figure 3.23 is the plot of the fitted values vs. observed for this model, which
indicates a relatively good fit.
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Figure 3.23: Fitted Values vs. Observed: Sulfadoxine NLME Model 4
The results for the fixed effects for model 4 presented in Table 3.10 have the
same degrees of freedom for every parameter (df=975), which seems intuitively
incorrect if we assume that the algorithm for the calculation of these degrees of
freedom described for the linear mixed effect model is applicable here.
Due to the ongoing discourse regarding the correct method of calculating the
degrees of freedom, we have chosen not to interpret the statistical significance
of the individual parameters. This impacts on the model building procedure,
and as such, an hypothesized model building approach was adopted for the
remaining covariates.
Model 5:
The visible site effect seen in Figure 3.21, the plot of the random effects vs.
covariates for β0, would suggest that site be incorporated as a categorical co-
variate on this parameter. However, models of this form would not converge.
Based on the supposition that effects seen for β0 might be incorporated through
either β1 or β2, (since β0 is a composite of these parameters), a model was fitted
with site as a categorical covariate on β2.
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Since the inclusion of site on β2 alone did not reduce the effects seen in the
graphs, site was then added to the β0 parameter. Following examination and
adjustment of the random effects included in the model, the stage 2 equations
for Sulfadoxine model 5 may be given by:
β0ikj = β0 + β3 × pregik. + β6 ×mozambiquei.. + β7 × zambiai.. + b0i + b0ik,
β1ikj = β1,
β2ikj = β2 + β4 × pregik. + β5 ×mozambiquei..
The distributional assumptions for the eikj and the variance model form remain
unchanged. The fixed effects are summarized in Table 3.12, where the degrees
of freedom and significance have been excluded from the model output, (see
Section 2.7.2).
Parameter Value Std.Error
βˆ0.(Intercept) 73.43 2.49
βˆ3.(Pregnancy) 8.05 2.62
βˆ6.(Mozambique) 8.88 3.25
βˆ7.(Zambia) -21.61 2.79
βˆ1 13.9 0.91
βˆ2.(Intercept) 0.06 0.002
βˆ4.(Pregnancy) 0.03 0.002
βˆ5.(Mozambique) -0.01 0.003
Table 3.12: Model Output for Sulfadoxine NLME Model 5
The distributions for the random effects for each grouping level are given by:
b0i ∼ N(0, 0.0092), b0ik ∼ N(0, 13.072)
and the parameters determining the elements of variance-covariance matrix Rik
are given by:
θˆ = [6.073, 0.871], σˆ2 = 0.262
Models with subject- and occasion-specific random effects on parameters other
than β0 resulted in non-positive definite variance-covariance matrices. The
grouping of the site categories such that both Mali and Sudan form the base-
line for the interpretation of the β6 and β7 parameters and Mali, Sudan and
Zambia the baseline for the interpretation of the β5 parameter reduced the
multi-collinearity observed in the model with site Mali as the baseline in all
cases.
The inclusion of site as a covariate on β0 and β2 appears to have significantly
reduced the effects previously visible in the plots of the random effects versus
the covariates. This is illustrated in Figure 3.24. No further patterns of system-
atic variability appear to be unaccounted for, and as such, no further covariates
were added to the model.
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Figure 3.24: Subject-Specific Random Effects for β0 vs. Covariates: Sulfadoxine
NLME Model 5
Examination of diagnostic plots (in Appendix B, figures B.20 to B.26) indicate
that the assumptions of normality for the residuals and random effects are valid,
as is the assumption of homoskedasticity. The model appears to fit reasonably
well.
Figures 3.25 and 3.26 show the mean predicted curves by site and pregnancy
phases generated from the final Sulfadoxine model, (model 5).
Faster rates of decline are observed for pregnant subjects in all sites, with higher
peak concentrations for pregnant subjects in Mali and Zambia, (Figure 3.25).
Subjects in Mozambique and Zambia had the highest and lowest concentrations
respectively, regardless of pregnancy phase, (Figure 3.26).
3.2.4 The Delta Method
Using the mean parameter estimates for the fixed effects and the associated
variance-covariancematrices for those fixed effects, the delta method was applied
in order to calculate the standard errors for several PK parameters, obtained
via back-transformation from the exponential specification using the calcula-
tions outlined in section 2.8.
Using the general exponential specification given by:
C = Σni=1Ci × exp(−λi × t)
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Figure 3.25: Predicted Mean Concentration-Time Curves by Site and Pregnancy
Status: Sulfadoxine NLME Model 5
where λi is the rate parameter as before, n is the number of differentiated phases
and thus the number of exponential terms, and t is time, the calculation for the
AUC was given as:
AUC = Σni=1
Ci
λi
Thus for the bi-exponential model used in Model 4:
yˆikj = βˆ0ikj × [−exp(−βˆ1ikj × timeikj) + exp(−βˆ2ikj × timeikj)],
where:
βˆ0ikj = βˆ0 + βˆ3 × pregik. + bˆ0i + bˆ0ik,
= 70.68906+ 8.61799× pregik. + bˆ0i + bˆ0ik
βˆ1ikj = βˆ1 + bˆ1i + bˆ1ik,
= 13.36970+ bˆ1i + bˆ1ik
βˆ2ikj = βˆ2 + βˆ4 × pregik. + bˆ2ik
= 0.06037447+ 0.02777× pregik. + bˆ2ik
the AUC for the postpartum subjects may be calculated as:
AUC =
βˆ0
βˆ1
+
βˆ0
βˆ2
=
70.68906
13.36970
+
70.68906
0.06037447
= 1176.13
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Figure 3.26: Predicted Mean Concentration-Time Curves by Pregnancy Status:
Sulfadoxine NLME Model 5
The standard error for this AUC can be calculated using:
V ar(F (X)) = F ′(µ)T × V ar(X) × F ′(µ)
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where X = [70.68, 13.37, 0.06]′, and
V ar(X) =


βˆ0 βˆ1 βˆ2
βˆ0 6.088 −1.524e− 01 1.762e− 03
βˆ1 −0.152 1.135 −2.65e− 04
βˆ2 0.0018 −2.138e− 04 6.976e− 06


For the pregnant subjects, the AUC is calculated as:
AUC =
βˆ0 + βˆ3
βˆ1
+
βˆ0 + βˆ3
βˆ2 + βˆ4
=
70.68906+ 8.61799
13.36970
+
70.68906+ 8.61799
0.06037447+ 0.02777
= 905.6712
The vector of mean parameter estimates for the fixed effects is then given by
Xˆ = [70.69, 13.37, 0.06, 8.62, 0.03]′, and Cov(X) is the estimated (5×5) variance-
covariance matrix of the fixed effects X.
Table 3.13 summarizes the results from this procedure for Model 2, the initial
model excluding covariates (that displays increasing variance for the residuals),
after the removal of the subject-specific random effect for β2, and compares
them to those obtained by Nyunt et al. [5] by averaging results from individual-
specific one-compartment models.
Two sets of results are shown from Nyunt et al.: because of the skew distribu-
tions observed for most of the PK parameters, the summary statistics originally
reported were restricted to medians and inter-quartile ranges. The results ob-
tained here, however, are means and standard errors, and as such, corresponding
results were obtained from the authors for the purposes of comparison. The val-
ues for the day 7 concentrations presented in this table are the average values
of individual-specific day 7 concentrations, calculated using the predicted con-
centrations for each individual-phase grouping.
Model 2 Nyunt et al. Nyunt et al. (Reported)
Parameter Mean Std. Error Mean Std. Error Median IQR
AUC(0−inf) (ug.day/ml) 999.44 32.77 902.72 287.85 877.02 (731.93; 1069.47)
Cmax (ug/ml) 74.29 1.97 76.59 41.27 73.93 (59.85; 85.84)
Tmax (days) 0.86 0.05 0.59 0.63 0.38 (0.15; 0.88)
Vd/f (ml/kg) 314.30 7.97 338.95 116.55 305.83 (259.52; 402.48)
Cl/f (ml/kg/day) 25.01 0.86 30.32 11.13 28.20 (23.21; 34.07)
t1/2 (days) 8.71 0.22 8.26 2.82 7.92 (6.67; 9.97)
Cday7 (ug/ml) 45.61 12.10 46.40 15.41 45.75 (34.7;56.8)
Table 3.13: Comparison of PK Parameters: Sulfadoxine NLME Model 2
The same comparison is shown in Table 3.14, now for Model 4, the final preg-
nancy adjusted model, and thus for the pregnant and postpartum subjects.
The average values from the two methodologies are similar for all parameters.
91
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Model 4 Nyunt et al. Nyunt et al. (Reported)
Pregnant
Parameter Mean Std. Error Mean Std. Error Median IQR
AUC(0−inf) (ug.day/ml) 905.63 26.54 903.27 309.06 877.02 (728.53 ; 1049.69)
Cmax (ug/ml) 73.93 1.94 82.74 46.22 80.62 (67.53 ;87.90)
Tmax (days) 0.87 0.056 0.61 0.70 0.34 (0.14 ;0.97)
Vd/f (ml/kg) 308.03 7.71 307.63 112.54 284.50 (248.61 ;358.63)
Cl/f (ml/kg/day) 27.15 0.81 30.56 12.31 28.20 (22.34 ;34.24)
t1/2 (days) 7.86 0.16 7.58 2.87 7.38 (6.11 ;8.58)
Postpartum
AUC(0−inf) (ug.day/ml) 1176.13 56.31 901.25 224.70 884.38 (732.49; 1079.57)
Cmax (ug/ml) 67.11 2.44 60.01 13.23 59.69 (50.11; 70.57)
Tmax (days) 0.93 0.42 0.55 0.41 0.46 (0.28; 0.82)
Vd/f (ml/kg) 355.63 12.5 423.33 80.28 410.17 (353.12 ;490.73)
Cl/f (ml/kg/day) 21.47 1.044 29.70 7.14 27.97 (24.48; 33.87)
t1/2 (days) 11.48 0.50 10.09 1.66 9.89 (8.72; 11.11)
Table 3.14: Comparison of PK parameters during Pregnancy and after Postpar-
tum
The standard errors are much larger, however, for the values obtained from
Nyunt et al.
This is to be expected, as the authors followed the traditional two stage ap-
proach to the analysis of PK data, calculating population parameter estimates
by averaging parameters from individual-specific models, which resulted in over-
estimated values for the inter-individual errors as a consequence of the sparsely
sampled data. For the postpartum subjects, complete PK parameters could in
fact only be determined for subjects from Mali and Zambia using this approach,
as the two measurements available for postpartum subjects in Mozambique and
Sudan were not sufficient to fit the individual-specific models.
Tables B.3 and B.4 in Appendix B show the comparison between the Nyunt
et. al parameters and the results obtained from Model 5. The mean parameters
were again similar, with the exception of apparent volume of distribution and
clearance, and smaller standard errors were obtained for the results from Model
5, (the nlme model).
3.2.5 Single-Level Models: Correlated Random Effects Struc-
ture
This section serves to illustrate the alternative method for dealing with the
multiply-nested grouping structure of the data outlined in Section 2.6.
Model 4, the final pregnancy adjusted model presented earlier, was seen to have
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stage 2 equations:
β0ikj = β0 + β3 × pregik. + b0i + b0ik,
β1ikj = β1 + b1i + b1ik,
β2ikj = β2 + β4 × pregik. + b2ik
where the vector of the parameter estimates for the fixed effects was found to
be βˆ = [70.69, 13.37, 0.06, 8.62, 0.03],
bi ∼ N(0,ψ1),bik ∼ N(0,ψ2)
eikj ∼ N(0,Rik)
and the elements of Rik depend on σˆ2 = 0.077
2, and θˆ = [20.37, 1.14].
The variance-covariance matrices for the random effects were given by:
ψˆ1 =

τ
2
0 = 13.63
2 0 0
0 τ21 = 3.36
2 0
0 0 τ22 = 0

 ,
ψˆ2 =

τ
2
0k = 11.22
2 0 0
0 τ21k = 5.02
2 0
0 0 τ22k = 0.014
2


A model was fitted using a single level of grouping, maintaining the same fixed
effects structure and the same variance model for the residual errors.
Model 6:
The stage 2 equations for this model would be given by:
β0ikj = β0 + β3 × pregik. + b∗0i,
β1ikj = β1 + b∗1i,
β2ikj = β2 + β4 × pregik. + b∗2i
where, for example:
b∗0i =
[
b0i + b0i,0
b0i + b0i,1
]
and
b∗i ∼ N(0,ψ∗)
The results for the fixed effects from this model are summarized in Table 3.15.
The variance-covariance matrix for the single level of random effects is given by:
ψˆ∗ =


[
17.532 0.581
0.581 17.532
]
0 0
0
[
5.722 0.303
0.303 5.722
]
0
0 0
[
0.0142 0
0 0.0142
]


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Value Std.Error
βˆ0.(Intercept) 71.09 2.47
βˆ3.(Pregnancy) 8.60 2.47
βˆ1 12.57 0.99
βˆ2.(Intercept) 0.06 0.003
βˆ4.(Pregnancy) 0.03 0.003
Table 3.15: Bi-Exponential Model Output: Sulfadoxine NLME Model 6
The variance for the compound symmetry structure in the top-left block is given
by:
τ2b = τ
2
0 + τ
2
0k,
with correlation:
ρ =
τ20√
τ20 + τ
2
0k
Thus,
τˆ20 = 0.581× 17.532,
= 13.352,
and
τˆ20k = 17.53
2 − τ20 ,
= 17.532 − 13.352,
= 11.362.
Comparing the results from Models 6 and 4, we can then see that for both
methods, the estimates of the fixed effects and the variance-covariance matrices
for the random effects are almost identical. SAS software (Copyright, SAS
Institute Inc., Cary, NC, USA) makes use of the single-level model specification,
and in R, for this particular model, the single-level version was faster in terms
of convergence. The computational algorithms used in the nlme package in R
are, however, designed specifically for the nested model approach, and it is thus
deemed more efficient.
3.2.6 Multi-Level Models with Proportional Random Ef-
fects:
The additive random effects specification used in the previous models is unusual
for PK data: in the traditional clinical setting, the one and two compartment
models are specified in terms of logged fixed effects parameters.
This logged parameterization ensures positivity in the parameters, and also re-
sults in a different random effects structure and a proportional covariate model
specification.
Using the notation previously defined, for example:
β′0ik = log(β0) + b0i + b0ik
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when back-transformed, would be:
β0ik = β0 × exp(b0i)× exp(b0ik)
The relationship between the fixed effects parameters and the random effects is
thus no longer linear.
Model 7:
Maintaining the exponential parameterization of the structural model form, but
now using logged parameters, the model building procedure outlined for the
case in which there were additive random effects was repeated.
Parameter Value Std.Error
log(βˆ0).(Intercept) 4.25 0.037
βˆ3.(Pregnancy) 0.11 0.046
log(βˆ1) 2.62 0.05
log(βˆ2).(Intercept) -2.83 0.048
βˆ4.(Pregnancy) 0.42 0.049
Table 3.16: Bi-Exponential Model Output: Sulfadoxine NLME Model 7
The resulting final model is summarized in Table 3.16, and corresponds to the
model equation given by:
yikj = f(timeikj ,β
′
ikj) + eikj
where yikj is the jth measurement in the kth period for the ith individual, and
f(timeikj ,β
′
ikj) = exp(β
′
0ikj)[−exp(−exp(β′1ikj)×timeikj)+exp(−exp(β′2ikj)×timeikj)]
where:
β′0ikj = log(β0) + β3 × pregik. + b0ik,
β′1ikj = log(β1),
β′2ikj = log(β2) + β4 × pregik. + b2i
and hence:
β0ikj = β0 × exp(β3)× pregik. × exp(b0i),
β1ikj = β1,
β2ikj = β2 × exp(β4)× pregik. × exp(b2ik)
This model does not differ too much from our previous Model 4. Despite ob-
viously heterogeneous variance (Figure 3.27), attempts to account for this by
specifying a variance model only worsened the model fit, as did the inclusion of
additional covariates such as site.
The variance-covariance estimates for the random effects were greatly reduced,
with τˆ20k = 0.27
2 and τˆ22 = 0.19
2. This change is not unexpected, since in log-
ging the parameters we are altering the variance.
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Figure 3.27: Std Residuals vs. Fitted Values: Sulfadoxine NLME Model 7
Parameter Value Std.Error
βˆ0.(Intercept) 70.25 1.04
exp(βˆ3).(Pregnancy) 1.12 1.0047
βˆ1 13.77 1.051
βˆ2.(Intercept) 0.06 1.049
exp(βˆ4).(Pregnancy) 1.52 1.05
Table 3.17: Back-transformed Model Output for Bi-Exponential Model: Sulfa-
doxine NLME Model 7
The back-transformed results are presented in Table 3.17.
The covariate effects are interpreted as a proportional change, such that, for
example, the fixed effect estimate of parameter β0 for pregnant subjects would
be given by:
βˆ0preg = βˆ0 × exp(βˆ3),
= 70.25× 1.12,
= 78.75.
where previously, the same estimate obtained from model 4 is 79.31, which is
approximately 1.12 times the postpartum estimate.
Examination of various diagnostic plots (Appendix B figures B.27 to B.31, and
‘in-text’ Figures 3.27 and 3.28) indicates that this model does not fit as well as
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Figure 3.28: Fitted Values vs. Observed: Sulfadoxine NLME Model 7
that with additive random effects, despite much faster convergence.
This conclusion is supported by model comparison using the AIC and BIC
(AIC: 7867.059 vs. 8538.254 , BIC: 7932.586 vs. 8578.578).
3.2.7 Mechanistic Model Specification: One-Compartment
Model:
Using the specification outlined in Section 2.5 for the one-compartment model,
models were fitted with the structural form given by:
C(t) =
ka× F ×D
V/f × (ka− ke) × [e
−ke×t − e−ka×t].
where F = 1, and D = 1500, ka is the absorption rate constant, ke, the elimi-
nation rate constant, and V/f is the apparent volume of distribution.
Although the same model building procedure was followed, the development of
the covariate model was restricted, and the mechanistic models were adjusted
for pregnancy only, since this section is purely for illustrative and comparative
purposes.
Model 8:
Model 8 is the basic NLME model, ignoring covariates, and following adjustment
to the random effects specification. The model may be summarized by stage 2
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equations:
Vikj = V + b0i + b0ik,
kaikj = ka+ b1ik,
keikj = ke.
The results for the fixed effects are summarized in Table 3.18, and the variance-
covariance matrices for the random effects bi = [b0i] and bik = [b0ik, b1ik] are
given by:
ψˆ1 =
[
2.192 0
0 0
]
, ψˆ2 =
[
0.022 0
0 1.312
]
The diagonal elements of Rikj are given by σˆ
2 = 8.122.
Parameter Value Std.Error
Vˆ 10.77 0.513
kˆa 0.08 0.002
kˆe 0.15 0.007
Table 3.18: Model Output for Sulfadoxine NLME Model 8
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Figure 3.29: Std Residuals vs. Fitted Values: Sulfadoxine NLME Model 8
Examination of the diagnostic plots, (Appendix B, figures B.32 to B.36 and
Figures 3.29 and 3.30 “in-text”) indicates that the assumptions of normality for
the residuals and random effects are valid, although there does appear to be
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Figure 3.30: Fitted Values vs. Observed: Sulfadoxine NLME Model 8
non-constant variance, (Figure 3.29). The model appears to fit reasonably well,
(Figure 3.30), although comparison to Model 2 (the most similar model using
the exponential specification) indicates a better fit for the empirical parameter-
ization (AIC: 8482.187 vs. 8584.446, BIC: 8527.552 vs. 8619.730).
Model 9:
Adjusting model 8 for pregnancy, and accounting for the heteroskedasticity ob-
served by fitting a variance model of the same form as that previously specified,
we have model 9.
The results for the fixed effects are summarized in Table 3.19, and the variance-
covariance matrices for the random effects bi = [b0i] and bik = [b0ik, b1ik] are
given by:
ψˆ1 =
[
2.282 0
0 0
]
, ψˆ2 =
[
0.0142 0
0 1.112
]
The diagonal elements of Rikj are now dependent on σˆ
2 = 0.1292 and θˆ =
[12.089, 1.04].
Figures 3.31 and 3.32 show the reduction in the non-constant variance of the
residuals, and indicate a reasonably good fit.
Figures 3.33, 3.34 and 3.35 demonstrate the need for further covariate ad-
justment, in the clearly defined systematic patterns for site.
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Parameter Value Std.Error
Vˆ 9.49 0.49
kˆa.(Intercept) 0.06 0.002
kˆa.(Pregnancy) 0.03 0.003
kˆe.(Intercept) 0.15 0.007
kˆe.(Pregnancy) 0.04 0.005
Table 3.19: Model Output for Sulfadoxine NLME Model 9
Comparing Model 9 to Model 4 (the final pregnancy adjusted model for the
exponential specification), we see that the empirical parameterization again pro-
vides the better fit, (AIC: 7867.059 vs. 8015.787, BIC: 7932.586 vs. 8071.233).
Tables 3.20 and 3.21 provide a comparison of the PK parameters obtained from
the empirical and mechanistic specifications for both the basic (unadjusted)
models, and the models adjusted for pregnancy.
For the basic models, the average values for the PK parameters appear to be
reasonably similar, with comparable standard errors as well. For the models
adjusted for pregnancy however, the standard errors for the AUC and V d/f are
lower for the mechanistic model specification (Model 9).
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Figure 3.31: Std Residuals vs. Fitted Values: Sulfadoxine NLME Model 9
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Figure 3.32: Fitted Values vs. Observed: Sulfadoxine NLME Model 9
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Figure 3.33: Subject-Specific Random Effects for V vs. Covariates: Sulfadoxine
NLME Model 9
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Figure 3.34: Occasion-Specific Random Effects for V vs. Covariates: Sulfadox-
ine NLME Model 9
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Figure 3.35: Occasion-Specific Random Effects for ka vs. Covariates: Sulfadox-
ine NLME Model 9
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Model 2 Model 8
Parameter Mean Std. Error Mean Std. Error
AUC(0−inf) (ug.day/ml) 905.63 26.54 952.63 26.90
Vd/f (ml/kg) 308.03 7.71 179.52 8.58
Cl/f (ml/kg/day) 27.15 0.81 26.21 0.74
t1/2 (days) 7.86 0.16 4.74 0.22
Table 3.20: Comparison of PK Parameters: Sulfadoxine NLME Models 2 and 8
Model 4 Model 9
Pregnant
Parameter Mean Std. Error Mean Std. Error
AUC(0−inf) (ug.day/ml) 905.63 26.54 760.11 20.87
Vd/f (ml/kg) 308.03 7.71 176.58 0.79
Cl/f (ml/kg/day) 27.15 0.81 32.35 0.89
t1/2 (days) 7.86 0.16 3.78 0.18
Postpartum
AUC(0−inf) (ug.day/ml) 1176.13 56.31 957.22 33.88
Vd/f (ml/kg) 355.63 12.5 181.33 8.15
Cl/f (ml/kg/day) 21.47 1.044 26.38 0.93
t1/2 (days) 11.48 0.50 4.76 0.24
Table 3.21: Comparison of PK parameters during Pregnancy and after Postpar-
tum: Sulfadoxine NLME Models 4 and 9
3.2.8 Discussion
Results from the exponential parameterization employed indicate that both
pregnancy phase and study site have an impact on the concentration-time pro-
file of Sulfadoxine.
Subjects in Mozambique and Zambia had the highest and lowest concentra-
tions respectively, irrespective of pregnancy phase, and for Mali and Zambia,
pregnant subjects showed higher peak concentrations than postpartum subjects.
Faster rates of decline were observed for pregnant subjects in all sites, although
the rate of decline for subjects in Mozambique was lower for both the pregnant
and postpartum subjects when compared to those in other sites, (Figure 3.25
and Table 3.12).
The overall impact of this in terms of clinical parameters was a reduction in
the total drug exposure, (as measured by the area under the concentration-time
curve), for pregnant subjects in all sites except Zambia. The elimination half-
life was shorter in all sites for pregnant subjects, and longest for subjects in
Mozambique, (Appendix B, tables B.3 and B.4). Although the actual figures
for the PK parameters differed slightly from results obtained by Nyunt et al.
the overall conclusions remained the same.
The use of nlme models as opposed to the traditional two-stage approach previ-
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ously taken with this dataset (Nyunt et al. [5]) resulted in a significant reduction
in the standard errors of the estimates.
Even though the exponential parameterization is removed from the more mech-
anistic parameterization in terms of PK parameters, we were able to graph-
ically illustrate the different concentration-time curves for the various strata,
and through back-transformation, obtain sensible estimates of the PK parame-
ters. The average values of the PK parameters obtained via the empirical and
mechanistic NLME models were similar, (with the exception of Vd/f), as were
their standard errors.
Results obtained from a model specified with a single-level of grouping were
very similar to those obtained with the multiply-nested design.
Comparisons of models fit with both additive and proportional random effects
indicated that the additive structure was preferred, although this comparison
may not be entirely valid, as the heteroskedasticity in the model with propor-
tional random effects was unaccounted for. Parameter estimates and conclusions
from the two models were similar.
3.3 Pyrimethamine Models:
As in the analysis of the Sulfadoxine concentration-time data, NLS (nonlinear
least squares) models were fitted for Pyrimethamine, for both the bi-and triple-
exponential structural model forms, on the full dataset and for the pregnant
and postpartum subsets.
Results from these models and from individual-specific models are presented
here, together with the results from various nlme models fitted during the course
of model building.
The final pregnancy adjusted NLME model is detailed, together with an NLME
model adjusted for site, and predicted curves are presented for both models.
3.3.1 NLS Models
Nonlinear least squares models fitted to the Pyrimethamine data follow the
model forms specified in equations 3.2 and 3.3 for the general model specified
in equation 3.1., that is:
yj = f(xj ,β) + ej
where yj is the concentration at time j, xj = timej , and β is a p-dimensional
vector of fixed effects.
Models following the bi-exponential specification were fitted to both the full
dataset and the pregnant subset. Models for the postpartum subsets did not
converge for this specification.
Although comparisons of results with different starting values were intended,
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the starting values obtained from the analysis by Nyunt et al. for this struc-
tural model form were determined to be too inaccurate for use (estimated values
for β0 ranging from 5 to 10 for the full dataset and from 6.1 to 10.7 for the preg-
nant subset were logically inconsistent with the concentration measurements
observed).
The inaccuracy of these values is assumed to be a result of the two-stage ap-
proach taken in the analysis; despite expectations of a two-compartment model
specification for Pyrimethamine, the sparseness of the data and the use of
individual-specific models did not accommodate such a complex model form
(since at least 6 data points are required to fit a two-compartment model).
For those subjects for whom a two-compartment model was fitted, the model fit
was significantly better than that of the one-compartment model. Since the ma-
jority of subjects were unable to fit the two-compartment model, however, the
results reported by Nyunt et al. were those obtained using a one-compartment
model, and as such, the estimates of parameters such as the volume of distribu-
tion and clearance/elimination rate may be inaccurate. This in turn translates
to ill-defined starting estimates for the beta parameters in the exponential spec-
ification.
The starting values determined from the curve-stripping procedure and the anal-
ysis performed by Nyunt et al. [5] are tabulated in Table 3.22.
Parameter Data Curve Stripping Nyunt et. al
β0: Full 399.58 7.43 (5.0; 10.05)
Pregnant 497.26 8.59 (6.14; 10.72)
Postpartum N/D 5.31 (4.14; 6.67)
β1: Full 7.63 54 (17.33; 292.79)
Pregnant 4.47 53.9 (17.32; 243.86)
Postpartum N/D 102.3(18.48; 368.23)
β2: Full 0.31 0.23 (0.18; 0.3)
Pregnant 0.31 0.21 (0.17; 0.28)
Postpartum N/D 0.28(0.22; 0.35)
Table 3.22: Comparison of Starting Values for Bi-Exponential Model
Comparisons for different starting values for the triple-exponential structural
model form were also not possible, as the curve-stripping procedure was not
performed for this specification.
The values from Nyunt et al. for this specification (triple-exponential) were
still contentious, since so few individual-specific model fits were obtained for
the more complex two-compartment model in their analyses [5]. Estimates for
β2 and β4 were therefore slightly adjusted before they were used in the models.
Tables 3.23 and 3.24 are the results obtained from NLS models using the bi- and
triple-exponential structural model forms respectively, the latter for the postpar-
tum subset, which was the only subset for which the triple-exponential model
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Estimate Std. Error
βˆ0 351.9 7.73
βˆ1 14.35 1.96
βˆ2 0.14 0.0008
Table 3.23: Model Output for Pyrimethamine Bi-Exponential NLS model
Estimate Std. Error
βˆ1 18.51 5.58
βˆ2 131.96 35.88
βˆ3 1.88 0.97
βˆ4 192.01 22.10
βˆ5 0.13 0.02
Table 3.24: Model Output for Pyrimethamine Triple-Exponential NLS model
(Postpartum subset)
specification converged. Comparisons between the bi- and triple-exponential
models were therefore not possible.
Plots of the standardized residuals against the subject identification number
(Figure 3.36) for the bi-exponential model on the full dataset, indicated the
need for the subject-specific random effects.
Standardized residuals
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Figure 3.36: Residuals by Subject ID: Pyrimethamine Bi-Exponential NLS
Model
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3.3.2 Individual-Specific Models
Individual specific models were fitted for both structural model forms for the
subjects from Mali and Zambia only (since there was insufficient data for the
Mozambique and Sudan study sites).
Figure 3.37 shows the possible need for random effects on β0 and β2 for the
bi-exponential model specification. For the triple-exponential model the place-
ment of random effects was harder to determine, but β2 and β4 appeared to have
intervals which did not overlap indicating that random effects were required for
those parameters.
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Figure 3.37: Parameter Estimates and 95% Confidence Intervals for Individual
Model Fits (Please Note: label “beta3” for far right column should read“beta2”)
3.3.3 Multi-Level Models
Basic nlme models (ignoring covariates) were again fitted for both the bi- and
triple-exponential model forms, but for the full dataset only. Models with the bi-
exponential structural model form did not converge, regardless of simplification
(reductions in the number of random effects and in the number of levels of
random effects).
Model 1:
For the triple-exponential specification, stable models were achieved only once
a simplified model structure, (ignoring the occasion-specific random effects),
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was specified, and the parameter estimates from this model used as starting
estimates in the multiple-nested version.
Parameter Value Std.Error
βˆ1 36.65 11.23
βˆ2 141.34 13.43
βˆ3 0.77 0.09
βˆ4 293.45 17.45
βˆ5 0.14 0.005
Table 3.25: Triple-Exponential Model Output: Pyrimethamine NLME Model 1
The results from this model for the fixed effects are summarized in Table 3.25,
and correspond to a model of the form:
yikj = f(timeikj ,βikj) + eikj
where yikj is the jth measurement in the kth period for the ith individual, and
f(timeikj ,βikj) = β2ikj × [−exp(−β1ikj × time) + exp(−β3ikj × time)]
+β4ikj × [−exp(−β1ikj × time) + exp(−β5ikj × time)]
Such that, in the specification of the stage II equations:
βikj = Aikjβ +Bi,kjbi +Bik,jbik,
the p-dimensional vector of fixed effects β is given by
β = [β1, β2, β3, β4, β5],
the q1− and q2-dimensional vectors of the subject and occasion-specific random
effects are given by:
bi = [b1i, b2i, b3i, b4i, b5i]
bik = [b1ik, b2ik, b3ik, b4ik, b5ik]
and the design matrices Aikj, Bi,kj, and Bik,j are (5× 5) matrices of the form:
Aikj =


1 0 0 0 0
0 1 0 0 0
0 0 1 0 0
0 0 0 1 0
0 0 0 0 1

 , Bi,kj = Bik,j =


0 0 0 0 0
0 1 0 0 0
0 0 1 0 0
0 0 0 1 0
0 0 0 0 1


i.e., there are no random effects specified for β1, as indicated by the first row of
zeros in the matrix Bi,kj, (which is equivalent to matrix Bik,j).
The within group errors eikj are assumed independently and identically nor-
mally distributed, with variance-covariance matrix Rik, for every ik combina-
tion, whereRik is the positive-definite (nik×nik) matrix with diagonal elements
σˆ2 = (26.93)2.
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The subject and occasion-specific random effects are also assumed to be nor-
mally distributed:
bi ∼ N(0,ψ1),bik ∼ N(0,ψ2)
with variance-covariance matrices, (ψ1 and ψ2) given by:
ψˆ1 =


0.032 0 0 0
0 0.0042 0 0
0 0 127.642 0
0 0 0 0.0142

 ,
ψˆ2 =


103.022 0 0 0
0 0.00022 0 0
0 0 59.162 0
0 0 0 0.0122


Based on the paper by Liang and Derendorf [56], the above model is misspecified
(|β4| = 293.45 > |β2| = 141.34).
However, since we were unable to fit a reasonable bi-exponential model, and
since the semi-log profile clearly indicates a bi-phasic elimination phase for
Pyrimethamine, (Figure 3.38), and the use of a two compartment model (anal-
ogous to the empirical triple-exponential specification used here) is not unusual
for Pyrimethamine, [23], model building was continued using this structural
model form.
The diagnostic plots for this model (Appendix C, figures C.1 to C.5) indicated
that the normality assumptions for the residual effects and occasion-specific
random effects were reasonable, although the QQplots of the subject-specific
grouping level random effects indicated slightly skewed distributions for bˆ4i and
bˆ5i.
No distinct correlation patterns were observed, (Appendix C, figures C.6 and C.7),
and the assumption of constant variance for the residuals did not appear to be
violated to any great extent, (Figure 3.39).
The overall fit of the model was examined using plots of the fitted values vs. the
observed (Figure 3.40), and plots of the predicted concentration-time curves for
the population, individual-specific and occasion-specific levels vs. the observed
values for each individual-occasion grouping, (Figure 3.41).
As before, the blue lines represent the population curve obtained using the mean
parameter estimates of the fixed effects, and the pink and green lines are the
predicted curves for the subject and occasion-specific grouping levels respec-
tively.
The overlapping of the blue, pink and green lines for the absorption phase of
the curves demonstrates the lack of any subject or occasion-specific variability
for the parameter representing the slope of this line (no random effects were
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Figure 3.38: Semi-log Plot of Observed Concentration vs. Time
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Figure 3.39: Standardized Residuals vs. Fitted Values: Pyrimethamine NLME
Model 1
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Figure 3.40: Fitted values vs. Observed: Pyrimethamine NLME Model 1
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Figure 3.41: Population, Subject and Occasion-Specific Predicted Curves (Sub-
set: Mozambique): Pyrimethamine NLME Model 1
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included for this parameter). The model appears to fit reasonably well.
As previously shown, plots of the random effects vs. covariates were used to
inform the placement of covariates.
Plots of the both the subject and occasion-specific random effects vs. trimester,
weight, site and anaemia indicated clear systematic patterns for β4 only, al-
though potential systematic differences in variation were observed for site on
β2, (Appendix C, figure C.8) and again on β3, (Appendix C, figure C.10), for
the subject-specific level of random effects.
Figures 3.42, and 3.43 are plots of the subject and occasion-specific random
effects versus covariates for β4. The plots for the parameters and grouping lev-
els not shown here may be found in Appendix C, figures C.8 to C.13.
Using study site Mali as a reference category, subjects in study sites Sudan
and Mozambique appear to have increasingly higher median β4 values. Sub-
jects in Zambia appear to have lower median β4 values.
Subjects in their 2nd or 3rd trimester appear to have higher median β4 val-
ues (when compared to postpartum subjects). There does not appear to be any
effect for weight or anaemia (overlapping IQR’s).
For the occasion-specific grouping level the site effect is no longer in evidence.
The trimester effect is still there however, albeit less pronounced.
The model building procedure followed for pregnancy and its proxy measure-
ments was the same as that for the Sulfadoxine case; an iterative stepwise pro-
cedure, adding pregnancy to each parameter in turn and then in various com-
binations in increasing levels of complexity, with continuous assessment of the
random effects and residual diagnostics.
For the models including random effects on all parameters except β1 for both
levels of grouping (as for the basic Model 1), pregnancy could only reasonably
be included on β3, (Model 2), since adding it to any other parameters resulted
in multi-collinearity.
High correlations were however observed between the intercept and slope pa-
rameters for the linear relationship between β3 and pregnancy, (pˆ = 0.9).
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Figure 3.42: Subject-Specific Random Effects for β4 vs. Covariates:
Pyrimethamine NLME Model
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Figure 3.43: Occasion-Specific Random Effects for β4 vs. Covariates:
Pyrimethamine NLME Model
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Model 3:
Iterative reassessment of the random effects and fixed effects in turn resulted in
a model with stage 2 equations given by:
β1ikj = β1,
β2ikj = β2 + b2ik,
β3ikj = β3
β4ikj = β4 + β6 × pregik. + b4i,
β5ikj = β5 + b5i + b5ik,
The distributional assumptions for the eikj and the subject and occasion-specific
random effects remained unchanged. No models including a variance function
of any form would converge and the results for the fixed effects are summarized
in Table 3.26.
Parameter Value Std.Error
βˆ1 44.15 29.06
βˆ2 134.7 13.14
βˆ3 0.71 0.08
βˆ4.(Intercept) 253.72 18.56
βˆ6.(Pregnancy) 57.55 7.88
βˆ5 0.14 0.005
Table 3.26: Triple-Exponential Model Output: Pyrimethamine NLME Model 3
The variance-covariance matrices for the random effects for each grouping level,
(bˆi = [bˆ4i, bˆ5i]
′ and bˆik = [bˆ2ik, bˆ5ik]
′), are given by:
ψˆ1 =
[
132.642 0
0 0.0052
]
, ψˆ2 =
[
85.452 0
0 0.0232
]
and the diagonal elements of Rik are given by σˆ2 = (27.75)
2.
This model was determined to be significantly better than model 2 (AIC: 11540.66
vs. 11564.72, BIC: 11596.11 vs. 11640.33 and lrtest p-value: 0.0029).
Examination of the diagnostic plots for this model (Appendix C, figures C.14
to C.16) indicate no departure from the normality assumptions, for both the
residual errors and both levels of random effects.
With the exception of one or two outliers, QQplots for the random effects were
roughly centered around zero, (Figures 3.44 and 3.45), and no correlation pat-
terns were observed for the random effects using pairs plots, (Appendix C, fig-
ures C.17 and C.18).
Examination of the plot of the random effects vs. covariates for β4, (Figure 3.46)
shows that the inclusion of pregnancy as a covariate on β4 has not lessened the
systematic patterns of variation, i.e. that the model is not accurately capturing
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Figure 3.44: QQplots for Subject-Specific Random Effects: Pyrimethamine
NLME Model 3
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Figure 3.45: QQplots for Occasion-Specific Random Effects: Pyrimethamine
NLME Model 3
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the effects observed.
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Figure 3.46: Subject-Specific Random Effects for β4 vs. Covariates:
Pyrimethamine NLME Model 3
Further changes to the random effects and placement of the pregnancy covariate
did not improve the model fit. Model 3 was therefore determined to be the“best”
pregnancy adjusted model, not accounting for other covariates. Figure 3.47 is a
plot of the mean predicted concentration-time curves by pregnancy phase.
The remaining model building followed an hypothesis driven approach, taking
into account the degrees of freedom and the lack of physiological information
regarding the placement of covariates together with the computational intensity
involved in fitting all combinations of parameters and covariates.
Model 4:
The “final” pregnancy model (model 3) described above appears to be inade-
quate in terms of the quantification of the impact of covariates. Neither the
pregnancy nor the site effect seen in Figure 3.46 have been reduced. Model
building was therefore continued.
Despite the expected impact of site on β4, models incorporating the categori-
cal covariate on this parameter would not converge. Attempts were then made
to capture this effect via the impact of site on the remaining parameters, in
an approach similar to that undertaken during the Sulfadoxine model building
procedure.
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Figure 3.47: Predicted Mean Concentration-Time Curves by Pregnancy Phase:
Pyrimethamine NLME Model 3
The final model for Pyrimethamine included site as a covariate on β4, together
with an interaction between site and pregnancy, such that:
β1ikj = β1,
β2ikj = β2 + b2ik,
β3ikj = β3
β4ikj = β4 + β6 × pregik. + β7 ×mozambiquei.. + β8 × sudani..
+ β9 × zambiai.. + β10 × pregik. ×mozambiquei..
+ β11 × pregik. × sudani.. + β12 × pregik. × zambiai.. + b4i
β5ikj = β5 + b5ik.
The results for the fixed effects from this model are summarized in Table 3.27.
The variance-covariance matrices for the random effects, (bˆi = [bˆ4i, bˆ5i]
′ and
bˆik = [bˆ2ik, bˆ5ik]
′), are given by:
ψˆ1 =
[
48.932 0
0 0.0122
]
, ψˆ2 =
[
71.292 0
0 0.0212
]
,
and the diagonal elements of Rik are given by σˆ2 = (28.06)
2.
Both pregnancy and site appear to directly impact the range of concentrations
only, in their effect on β4. Close examination of the summarized results in Ta-
ble 3.27 shows that βˆ2 = 129.94 < βˆ4 = 175.9.
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Parameter Value Std.Error
βˆ1 55.22 116.56
βˆ2 129.94 12.96
βˆ3 0.68 0.08
βˆ4.(Intercept) 175.94 18.69
βˆ6.(Pregnancy) 84.99 12.51
βˆ7.(Mozambique) 233.16 29.11
βˆ8.(Sudan) 141.71 37.32
βˆ9.(Zambia) -60.58 19.99
βˆ10.(Pregnancy ×Mozambique) -31.00 27.35
βˆ11.(Pregnancy × Sudan) -64.84 36.03
βˆ12.(Pregnancy × Zambia) -58.46 16.92
βˆ5 0.14 0.01
Table 3.27: Triple-Exponential Model Output: Pyrimethamine NLME Model 4
As previously demonstrated, this is indicative of a potential misspecification
(as shown by Liang and Derendorf [56]). However, for the reasons previously
cited in the case of Pyrimethamine, Model 4 is deemed satisfactory.
Figures 3.48 and 3.49 show the concentration-time curve for this model for
the baseline site and pregnancy status (Mali, Postpartum), together with their
constituent components.
0 10 20 30 40
0
50
10
0
15
0
20
0
25
0
30
0
Time
C(t
)
0
50
10
0
15
0
20
0
25
0
30
0
0
50
10
0
15
0
20
0
25
0
30
0
beta2(− exp(− beta1day) + exp(− beta3day))
beta4(− exp(− beta1day) + exp(− beta5day))
Combined Curve
β2 = 129.94
β4 = 175.94
Figure 3.48: Concentration-Time Curve and Components: Pyrimethamine
NLME Model 4
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Figure 3.49: Concentration-Time Curve and Components: Original Triple-
Exponential Form
Examination of Figures 3.48 and 3.49 demonstrate the different constituent
curves for different structural parameterizations, that of
C(t) = β2 × [−exp(−β1 × time) + exp(−β3 × time)]
+ β4 × [−exp(−β1 × time) + exp(−β5 × time)]
shown in Figure 3.48, and that of
C(t) = β0 × exp(−β1 × time) + β2 × exp(−β3 × time)
+ β4 × exp(−β5 × time)
which is the original exponential form, prior to any simplification, shown in
Figure 3.49.
The constituent curves for the simplified model form are easily seen to be bi-
exponential curves. For the original specification, the constituent parts of the
combined curve are various single exponential curves.
It should be noted that the curves in Figure 3.49 were created using the param-
eter values for the simplified model structure: had the original (unsimplified)
structural form been fitted, the parameter values would be slightly different,
and the slope of the absorption phase in Figure 3.49 would be seen to be less
steep.
The graphs here serve merely as an illustration of the break down of the com-
bined exponential curve, and illustrate that in spite of the apparent misspeci-
fication, (due to βˆ2 = 129.94 < βˆ4 = 175.9), the sum of the constituent parts
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results in a combined curve that is biphasic in its decline.
Model 4 was determined to be significantly better than model 3 (AIC: 11382.50
vs. 11540.66, BIC: 11468.19 vs. 11596.11), despite the multi-collinearity noted
for the β1 parameter.
The effects previously seen in Figure 3.46 are no longer in evidence, (Fig-
ure 3.50).
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Figure 3.50: Subject-Specific Random Effects for β4 vs. Covariates:
Pyrimethamine NLME Model 4
Examination of the diagnostic plots for this model, (Appendix C, figures C.19
to C.26), showed no departure from the normality assumptions for either the
residuals or the random effects.
The model fit, as determined by the plot of the fitted values versus the ob-
served, (Figure 3.51), was also reasonably good.
Figures 3.52 and 3.53 show the mean predicted concentration-time profiles by
site and pregnancy phase.
Irrespective of pregnancy phase, the predicted mean concentrations are high-
est in Mozambique and Sudan, and lowest in Zambia. Pregnant subjects are
seen to have a consistently higher mean range of concentrations in all sites except
for Sudan, where no pregnancy effect is observed.
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Figure 3.51: Fitted Values vs. Observed: Pyrimethamine NLME Model 4
3.3.4 The Delta Method
For the most part, the equations outlined in section 2.8.2 for the calculation of
PK parameters via back-transformation apply only in the bi-exponential case.
The calculations for the area under the concentration-time curve, (AUC), ap-
parent volume of distribution (Vd/f), and apparent clearance (Cl/f) may still
be used however for the triple-exponential specification.
Recalling the original exponential specification for the triple exponential model:
C(t) = β2 × [−exp(−β1 × time) + exp(−β3 × time)]
+ β4 × [−exp(−β1 × time) + exp(−β5 × time)]
using the general form for the calculation of the AUC given by:
AUC = Σni=1
Ci
λi
we would specify:
AUC = Σ3i=1
Ci
λi
=
βˆ0
βˆ1
+
βˆ2
βˆ3
+
βˆ4
βˆ5
.
Since β0 = −(β2 + β4), however, we may express the above as:
AUC = Σ3i=1
Ci
λi
=
βˆ2
βˆ1
+
βˆ2
βˆ3
+
βˆ4
βˆ1
+
βˆ4
βˆ5
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Figure 3.52: Predicted Mean Concentration-Time Curves by Site:
Pyrimethamine NLME Model 4
Then, assuming F = 1, and defining:
ke =
βˆ3 × βˆ5
k21
where
k21 =
(βˆ2 × βˆ5 × βˆ1 + βˆ4 × βˆ3 × βˆ1 − (βˆ2 + βˆ4)× βˆ3 × βˆ5)
(βˆ2 × (βˆ1 − βˆ3) + βˆ4 × (βˆ1 − βˆ5))
.
we were able to calculate the Cl/f using the general form given by:
Cl/f =
F ×D
Σni=1
Ci
λi
=
F ×D
AUC
Individual-specific values for Cmax were calculated using the predicted concen-
trations for each individual-phase grouping. These values were then averaged
by site and pregnancy. The mean PK parameters and their standard errors
resulting from this procedure and that using back transformation and the delta
method are summarized in Table 3.28 for the various sites and pregnancy phases.
The clinical values obtained using nlme model 4 may not be explicitly com-
pared with those from the analysis performed by Nyunt et al., since the struc-
tural model forms used in the different analyses are not compatible. The V d/f
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was not calculated for this same reason.
However, as illustrated in Table 3.28, the overall conclusions are similar: Nyunt
et al. [5] report the highest and lowest mean Cmax and AUC values for Mozam-
bique and Zambia respectively, and for those sites in which postpartum PK
parameters could be obtained (Mali and Zambia), the mean Cmax and AUC
values corresponding to the pregnant subjects were consistently higher. The
conclusions for apparent clearance and volume of distribution are also similar
to those obtained by Nyunt et. al, with postpartum subjects in both Mali
and Zambia having higher mean values for these parameters. The medians and
inter-quartile ranges actually reported for the analysis from Nyunt et al. may
be found in Appendix C, Table C.1.
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Model 4 Nyunt et al. [5]
Pregnant Postpartum Pregnant Postpartum
Country Parameter Mean Std. Error Mean Std. Error Mean Std. Error Mean Std. Error
Mali AUC(0−inf) (ng.day/ml) 2040.28 110.90 1439.23 107.13 1730.79 271.32 1135.15 466.35
Cl/f (ml/kg/day) 602.62 32.75 877.30 65.30 738.2423 143.6674 1288.19 453.98
Cmax (ng/ml) 304.07 40.70 250.90 35.96 373.7846 61.88207 325.66 49.71
Mozambique AUC(0−inf) (ng.day/ml) 3469.98 120.95 3088.15 186.00 3599.25 1280.14 N/D N/D
Cl/f (ml/kg/day) 354.33 12.35 408.86 24.63 377.33 120.99 N/D N/D
Cmax (ng/ml) 489.77 73.18 431.75 51.23 561.487 274.93 N/D N/D
Sudan AUC(0−inf) (ng.day/ml) 2583.93 109.62 2441.41 243.73 2112.09 479.46 N/D N/D
Cl/f (ml/kg/day) 475.83 20.19 517.17 51.63 580.01 170.98 N/D N/D
Cmax (ng/ml) 372.92 50.75 359.52 30.66 405.50 106.02 N/D N/D
Zambia AUC(0−inf) (ng.day/ml) 1198.46 83.69 1010.82 NaN** 1039.53 323.96 832.38 249.46
Cl/f (ml/kg/day) 1025.9 71.64 1249.11 NaN 1332.31 507.61 1613.75 430.43
Cmax (ng/ml) 192.54 43.65 161.26 32.40 242.03 66.22 205.99 44.46
Table 3.28: Comparison of PK parameters by Site and Pregnancy Phase: Pyrimethamine NLME Model 4
N/D*= Not determined, NaN**= Computation not possible
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3.3.5 Discussion
Both pregnancy status and study site appear to play a role in the determination
of the Pyrimethamine concentration-time profiles, where the pregnancy effect is
dependent on the study site.
For the exponential parameterization and the predicted curves, pregnant sub-
jects appear to have a consistently higher range of concentrations in all sites ex-
cept for Sudan, where no pregnancy effect is observed. Subjects in Mozambique
and Zambia have the highest and lowest concentrations respectively, regardless
of pregnancy phase. No direct impact of pregnancy or site could be determined
for any of the rate parameters.
Calculation of the PK parameters using back-transformation of the parameters
from the exponential specification is more complicated for the triple-exponential
case, with only some of the relevant equations actually applicable. Although
comparisons between the Nyunt et al. results and the results from the final
model are not ideal, (since the Nyunt et al. analysis makes use of individual-
specific one-compartment models, which are analogous to the bi-exponential
model form and not the the triple exponential), the conclusions reached in both
analyses are the same.
The final adjusted model for Pyrimethamine, determined via an hypothesis-
driven model-building procedure appears to induce multi-collinearity for the β1
parameter, as illustrated by the large standard error. Simpler models with fewer
covariates did not converge however, and the previous “best” model, adjusted
only for pregnancy, did not appear to capture any of the covariate effects. In
general, estimation of the Pyrimethamine models was more difficult than that of
the Sulfadoxine models, most likely due to more complicated structural model
form.
3.4 Sequential Models
The results presented in this section are those for the sequential model. NLME
Models were run for both Sulfadoxine and Pyrimethamine, with the predicted
concentrations of the drug not being modeled included as a time-varying covari-
ate in the model of the partner drug.
3.4.1 Impact of Predicted Pyrimethamine Concentrations
on Sulfadoxine
The models presented here illustrate the impact of the predicted Pyrimethamine
concentrations on the concentration-time profile of Sulfadoxine. Model 1 is
that previously presented in the section pertaining to the separate Sulfadox-
ine models (section 3.2), with results summarized by Table 3.9. The predicted
Pyrimethamine concentrations were generated using the basic Pyrimethamine
model (Model 1, section 3.3), which ignores the impact of covariates.
Figures 3.54 and 3.55 are plots of the subject-specific random effects vs. covari-
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Figure 3.54: Subject-Specific Random Effects for β0 vs. Covariates: Sequential
NLME Model 1
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Figure 3.55: Subject-Specific Random Effects for β1 vs. Covariates: Sequential
NLME Model 1
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Figure 3.56: Occasion-Specific Random Effects for β2 vs. Covariates: Sequential
NLME Model 1
ates for parameters β0 and β1, and Figure 3.56 is the plot of the occasion-specific
random effects vs. covariates for β2. The plots for the random effects and group-
ing levels not presented here may be found in Appendix D, figures D.1 to D.3.
The site and pregnancy effects previously noted for this model are unchanged.
A systematic pattern may be observed in the plot of the random effects versus
the predicted Pyrimethamine concentrations for parameter β0, (Figure 3.54).
Model 2
The covariate plots were used as a guideline only, and the impact of the predicted
Pyrimethamine concentrations on the fixed effects was determined through an
iterative stepwise model building procedure.
The time-varying covariate was added to each parameter in turn, and then
to various combinations of parameters in increasing levels of complexity, with
the random effects and model diagnostics assessed at every turn.
The resulting “unadjusted”model is described by stage 2 equations:
β0ikj = β0 + β3 × pyrimethamineikj + b0i + b0ik,
β1ikj = β1 + b1i + b1ik,
β2ikj = β2 + b2ik.
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The subject and occasion-specific random effects are still assumed to be normally
distributed:
bi ∼ N(0,ψ1),bik ∼ N(0,ψ2)
with variance-covariance matrices, (ψ1 and ψ2) given by:
ψˆ1 =

6.72
2 0 0
0 1.842 0
0 0 0

 ,
ψˆ2 =

11.82
2 0 0
0 4.292 0
0 0 0.0142


and the diagonal elements of Rik are given by σˆ2 = (7.54)
2.
The results for the fixed effects are summarized in Table 3.29.
Parameter Value Std.Error
βˆ0.(Intercept) 52.81 2.29
βˆ3.(Pyrimethamine) 0.09 0.006
βˆ1 10.91 0.72
βˆ2 0.054 0.003
Table 3.29: Model Output for Sequential NLME Model 2
The plot of the subject-specific random effects versus covariates for parameter
β0 for model 2, indicates a reduction in the systematic patterns previously ob-
served for trimester and the predicted Pyrimethamine concentration.
The pattern observed for site remains, although it is much reduced, (Figure 3.57),
with the only difference indicated for Zambia.
The same plot for parameter β2 indicates the possible impact of pregnancy
(trimester), (Figure 3.58).
The diagnostics plots for this model, (Appendix D, figures D.4 to D.11) in-
dicated roughly normal residuals and random effects for both grouping levels,
but showed increasing residual variance, (Figure 3.59).
Following the incorporation of a variance model of the same form as previously
shown, model building was continued using an hypothesis based approach, and
the effects of pregnancy and site were examined.
The distributions and variance-covariance matrices for the random effects were
iteratively examined for each prospective model.
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Figure 3.57: Subject-Specific Random Effects for β0 vs. Covariates: Sequential
NLME Model 2
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Figure 3.58: Occasion-Specific Random Effects for β2 vs. Covariates: Sequential
NLME Model 2
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Figure 3.59: Standardized Residuals vs. Fitted Values: Sequential Model 2
Model 3
The final adjusted sequential model is given by stage 2 equations:
β0ikj = β0 + β3 × pyrimethamineikj + β5 × zambiai.. + b0ik,
β1ikj = β1 + b1ik,
β2ikj = β2 + β4 × pregik. + b2i.
The results for the fixed effects are summarized in Table 3.30.
Parameter Value Std.Error
βˆ0.(Intercept) 61.07 2.38
βˆ3.(Pyrimethamine) 0.08 0.007
βˆ5.(Zambia) -15.96 2.33
βˆ1 10.09 0.65
βˆ2 0.05 0.003
βˆ4.(Pregnancy) 0.02 0.002
Table 3.30: Model Output for Sequential NLME Model 3
The random effects, bˆi = [bˆ2i]
′ and bˆik = [bˆ0ik, bˆ1ik]
′, have variance τˆ22 = 0.012
2
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and variance-covariance matrix:
ψˆ2 =
[
10.432 0
0 4.032
]
respectively, and the diagonal elements of Rik are dependent on σˆ2 = (0.097)
2
and θˆ = [15.74, 1.09].
This model was determined to be significantly better than both Model 1 and
Model 2, as illustrated in Table 3.31, which details the Aikaike and Bayesian
Information Criteria for each of the models.
Model df AIC BIC
Model l 9 8482.187 8527.552
Model 2 11 7881.795 7937.241
Model 3 12 7767.627 7828.114
Table 3.31: AIC and BIC for Sequential Models 1, 2 and 3
The assumptions of normality for both the residuals and random effects did
not appear to be violated (Appendix D, figures D.12 toD.17), and Figure 3.60
illustrates the impact of the variance model on the heteroskedasticity of the
residuals.
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Figure 3.60: Standardized Residuals vs. Fitted Values: Sequential Model 3
Figures 3.62 and 3.63 demonstrate the lack of systematic patterns in the ran-
dom variability about parameters β0 and β2, indicating that Model 3 adequately
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accounts for those covariate effects considered, and Figure 3.61, the plot of the
fitted values versus the observed, indicates a relatively good fit, although the
outward fanning towards the top right-hand side of the graph does suggest that
the peak concentration values are being under- or over-estimated.
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Figure 3.61: Fitted Values vs. Observed: Sequential NLME Model 3
This is further emphasized by Figure 3.64, which looks at the population, in-
dividual and phase-specific predicted concentration-time curves versus the ob-
served values (for a subset of the data).
As shown by (for example) subject “ZAMB 004/1”, whilst the phase-specific
predicted concentration-time curve captures most of the observed information
quite accurately, the peak concentration is under-estimated.
The mean predicted concentration-time profiles by site and pregnancy status,
shown in Figures 3.65 and 3.66, illustrate the effects of pregnancy and site for
the Model 3, for the case in which the predicted Pyrimethamine concentration
is 0ng/ml, and the case in which the predicted Pyrimethamine concentration is
400ng/ml.
Pregnant subjects appear to have a faster rate of decline than those postpartum,
regardless of study site, and higher peak concentrations in all sites except for
Sudan.
Subjects in Zambia have the lowest range of concentrations compared to the
other sites, irrespective of pregnancy phase.
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Figure 3.62: Subject-Specific Random Effects for β2 vs. Covariates: Sequential
NLME Model 3
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Figure 3.63: Occasion-Specific Random Effects for β0 vs. Covariates: Sequential
NLME Model 3
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Figure 3.64: Population, Individual and Phase-Specific Predicted
Concentration-Time Curves (Subset: Zambia): Sequential NLME Model
3
The curves in Figure 3.65 differ slightly from those in Figure 3.25: the over-
all range of concentrations reached is lower than that found with the separate
Sulfadoxine Model, irrespective of study site or pregnancy phase, and the higher
peak concentrations previously seen in pregnant subjects in Mali and Zambia
are no longer observed.
As a result of the latter, in all sites, the slope of decline for pregnant subjects is
consistently lower than that for postpartum subjects for the entire time period
observed, where before it was lower for only the later portion of the curves in
Mali and Zambia.
The approximate magnitude of the difference between the pregnant and postpar-
tum slopes of decline is, however, roughly the same as that previously observed.
The curves in Figure 3.66, which account for an increase in Pyrimethamine
predicted concentrations from 0 to 400ng/ml (amount arbitrarily chosen for
illustrative purposes), show a much higher range of concentrations for all sub-
jects in all sites, with the same basic relationship maintained between postpar-
tum and pregnant subjects in Mali, Zambia and Sudan, albeit with a slightly
greater magnitude of difference. For Mozambique, greater changes are observed.
135
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn 0
10
20
30
40
0 20 40 60 80
M
ali
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
0
10
20
30
40
0 20 40 60 80
S
udan
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
0
10
20
30
40
0 20 40 60 80
M
ozam
bique
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
0
10
20
30
40
0 20 40 60 80
Zam
bia
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
P
regnant
P
o
stpartum
F
ig
u
re
3
.6
5
:
M
ea
n
P
red
icted
C
o
n
cen
tra
tio
n
-T
im
e
C
u
rv
es
b
y
S
ite
a
n
d
P
reg
n
a
n
cy
P
h
a
se:
S
eq
u
en
tia
l
N
L
M
E
M
o
d
el
3
0
10
20
30
40
0 20 40 60 80
M
ali
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
0
10
20
30
40
0 20 40 60 80
S
udan
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
0
10
20
30
40
0 20 40 60 80
M
ozam
bique
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
0
10
20
30
40
0 20 40 60 80
Zam
bia
Tim
e(Days)
Mean Sulfadoxine Concentration (ug/ml)
0
10
20
30
40
Tim
e(Days)
P
regnant+P
yrim
etham
ine (400ng/m
l)
P
o
stpartum
+P
yrim
etham
ine (400ng/m
l)
F
ig
u
re
3
.6
6
:
M
ea
n
P
red
icted
C
o
n
cen
tra
tio
n
-T
im
e
C
u
rv
es
b
y
S
ite
a
n
d
P
reg
n
a
n
cy
P
h
a
se
II:
S
eq
u
en
tia
l
N
L
M
E
M
o
d
el
3
1
3
6
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
3.4.2 Impact of Predicted Sulfadoxine Concentrations on
Pyrimeth-amine
Predicted Sulfadoxine concentrations were generated using the basic Sulfadox-
ine model ignoring covariates, given by Model 1 in section 3.2. the basic triple-
exponential model previously used as a starting point for the Pyrimethamine
concentration-time models (Model 1, section 3.3) was then re-fitted, with the
predicted Sulfadoxine concentrations included in the covariate model. Despite
the attempted inclusion of Sulfadoxine on each of the parameters in turn and
in various combinations, none of the models reached convergence.
This was not entirely unexpected, as the original hypothesis was that the Pyrimethamine
concentrations would impact on Sulfadoxine, rather than vise versa, due to the
more rapid absorption and elimination of Pyrimethamine.
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Figure 3.67: Subject-Specific Random Effects for β4 vs. Covariates: Sequential
Pyrimethamine NLME Model 1
This hypothesis was further supported by the plots of the random effects ver-
sus the covariates for the basic Pyrimethamine model, (Figures 3.67 and 3.68),
which showed no clear relationship for Sulfadoxine.
3.4.3 Discussion
In the sequential modeling, as hypothesized, the Pyrimethamine concentration
appears to impact the concentration range of Sulfadoxine.
Including Pyrimethamine as a time-varying covariate also appears to influence
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Figure 3.68: Occasion-Specific Random Effects for β4 vs. Covariates: Sequential
Pyrimethamine NLME Model 1
the effects of pregnancy and site, removing pregnancy as a covariate on param-
eter β0, and reducing the impact of site-based differences.
The Pyrimethamine concentrations may not necessarily influence those of Sul-
fadoxine directly. Since Pyrimethamine is more rapidly absorbed, it may act as
a surrogate indicator of the individual/groups’ ability to absorb drugs, rather
than increasing or altering the Sulfadoxine absorption.
As such, the sequential model formulation appears to be of limited use in the
PK-PK setting in which multiple drug concentrations are modelled. It would
be more useful in the PK-PD setting, where the mechanism of interaction is
more widely understood, and there is a direct impact of the predicted drug
concentration on the PD response.
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3.5 Simultaneous Models
This section details the results from the simultaneous models for both model
specifications:
1. Response type fitted as a covariate to a single structural model form, and
2. Response type included as part of the original structural form, indicating
which form is applicable for which response
In order for either model specification to be used, the data itself required re-
structuring.
Table 3.32 is an excerpt of the data demonstrating the “stacked” vector of re-
sponses.
Participant Day Concentration δl... Response Pregnant
(ug/ml)/(ng/ml) (0/1)
MALI 001 0 0 0 Pyrimethamine 0
MALI 001 0.125 343 0 Pyrimethamine 0
MALI 001 0.25 444 0 Pyrimethamine 0
MALI 001 0.5 328 0 Pyrimethamine 0
MALI 001 1 286 0 Pyrimethamine 0
MALI 001 3 260 0 Pyrimethamine 0
MALI 001 7 148 0 Pyrimethamine 0
MALI 001 14 48 0 Pyrimethamine 0
MALI 001 21 18.7 0 Pyrimethamine 0
MALI 001 0 0 0 Sulfadoxine 0
MALI 001 0.125 66.4 1 Sulfadoxine 0
MALI 001 0.25 86.3 1 Sulfadoxine 0
MALI 001 0.5 66.2 1 Sulfadoxine 0
MALI 001 1 65.3 1 Sulfadoxine 0
MALI 001 3 64.5 1 Sulfadoxine 0
MALI 001 7 45.8 1 Sulfadoxine 0
MALI 001 14 23.6 1 Sulfadoxine 0
MALI 001 21 15.4 1 Sulfadoxine 0
MALI 001 28 9.9 1 Sulfadoxine 0
Table 3.32: Subset of Restructured Data: Example
The results from model specification 1 are presented first, including a detailed
description of the model building procedure, the results from the final model
and the predicted curves resulting from this model.
3.5.1 Model Specification 1: Covariate Specification
Since the same structural model form is fitted for both response types in this
model specification, the triple-exponential model was selected in order to ac-
count for the more complex Pyrimethamine concentration-time curves.
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Model 1
Fitting the response type as a binary indicator variable on all parameters, the
stage 2 equations for Model 1 (the basic model, ignoring the impact of other
covariates), may be given by:
β1likj = β1 + β6 × δl...
β2likj = β2 + β7 × δl... + b2i + b2ik
β3likj = β3 + β8 × δl... + b3i + b3ik
β4likj = β4 + β9 × δl... + b4i + b4ik
β5likj = β5 + β10 × δl... + b5i + b5ik
for a model of the form:
ylikj = f(xlikj,βlikj) + elikj
= β2likj × [−exp(−β1likj × timelikj) + exp(−β3likj × timelikj)]
+β4likj × [−exp(−β1likj × timelikj) + exp(−β5likj × timelikj)]
+elikj
where the random effects and residual errors eikj are defined as before, and
where δl... is a binary variable indicating the response type as Pyrimethamine
(δl... = 0) or Sulfadoxine (δl... = 1).
The results for the fixed effects are summarized in Table 3.33.
Parameter Value Std.Error
βˆ1.(Baseline) 37.47 10.90
βˆ6.(Sulfadoxine) -37.29 10.90
βˆ2.(Baseline) 298.04 19.25
βˆ7.(Sulfadoxine) 80.30 53.81
βˆ3.(Baseline) 0.14 0.004
βˆ8.(Sulfadoxine) 0.005 0.01
βˆ4.(Baseline) 124.88 9.67
βˆ9.(Sulfadoxine) -191.99 9.91
βˆ5.(Baseline) 0.65 0.09
βˆ10.(Sulfadoxine) 12.35 1.96
Table 3.33: Triple-Exponential Model Output: Simultaneous NLME Model 1
The variance-covariance matrices for the random effects for each grouping level
are given by:
ψˆ1 =


139.912 0 0 0
0 0.0082 0 0
0 0 0.022 0
0 0 0 0.00022

 ,
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ψˆ2 =


61.072 0 0 0
0 7.49e− 072 0 0
0 0 0.0012 0
0 0 0 1.88e− 052


and the diagonal elements of Rik are given by σˆ2 = (23.41)
2.
The diagnostic plots for this model indicated roughly normal residuals and ran-
dom effects for both levels, although some skewness was observed in the QQplots
of the random effects (Appendix E, figures E.1 to E.7).
Heteroskedasticity is however indicated for Sulfadoxine (Figure 3.69).
Although the fit for Pyrimethamine appears to be reasonable, for Sulfadox-
ine, the plot of the fitted values versus the observed shows an outward fanning
towards to the top right-hand side of the graph, indicating a lack of fit for the
higher concentrations, (Figure 3.70).
The incorporation of a variance function at this stage of the model building
procedure was not possible, and the focus therefore turned to the number of
random effects included in the basic model, and their specification.
Model 2
The distributions of the random effects were restructured in order to take into
account potential differences in the subject and occasion-specific variability due
to different response types.
The resulting model had stage 2 equations:
β1likj = β1 + β6 × δl...,
β2likj = β2 + β7 × δl... + b2i + b2ik + b7i + b7ik,
β3likj = β3 + β8 × δl... + b3i,
β4likj = β4 + β9 × δl... + b4i + b∗4i,
β5likj = β5 + β10 × δl...,
such that, in the linear relationship between (for example) parameter β2likj and
the response type indicator variable δl..., random effects were specified for both
β2 and β7 for both grouping levels.
The random effects for this model have been specified in two different ways.
The first method specifies random effects for the “intercept” term, and the term
for the “slope” or effect modifier, i.e. in the linear relationship between pa-
rameter β2likj and the indicator variable δl..., we have random effects for the
“intercept” parameter β2, given by b2i and b2ik, and we have random effects for
the “slope” parameter β7, given by b7i and b7ik.
The second method specified random effects for the two different intercepts
given by, a.) the original “intercept” parameter, and b.) the original “intercept”
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Sulfadoxine: Fitted Values
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Pyrimethamine: Fitted Values
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Figure 3.69: Standardized Residuals vs. Fitted Values: Simultaneous NLME
Model 1
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Sulfadoxine: Fitted Values
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Figure 3.70: Fitted Values vs. Observed: Simultaneous NLME Model 1
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parameter plus the parameter for the “slope”.
Thus, in the linear relationship between parameter β4likj and the indicator vari-
able δl..., we have random effects for the original “intercept” parameter β4, (the
Pyrimethamine value) given by b4i, and we have random effects for the second
“intercept” parameter β4 + β9, (corresponding to the Sulfadoxine value),given
by b∗4i.
The different specifications came about during the model building procedure,
with this particular combination providing the best fit.
The random effects for β2likj were further constrained at this point so that
b2i = b7i and b2ik = b7ik.
The results for the fixed effects from this model are summarized in Table 3.34.
Parameter Value Std.Error
βˆ1.(Baseline) 26.32 2.30
βˆ6.(Sulfadoxine) -12.04 3.02
βˆ2.(Baseline) 326.68 13.77
βˆ7.(Sulfadoxine) -227.93 27.37
βˆ3.(Baseline) 0.15 0.004
βˆ8.(Sulfadoxine) -0.05 0.01
βˆ4.(Baseline) 156.66 30.36
βˆ9.(Sulfadoxine) -178.74 38.28
βˆ5.(Baseline) 1.30 0.09
βˆ10.(Sulfadoxine) -1.04 0.19
Table 3.34: Triple-Exponential Model Output: Simultaneous NLME Model 2
The variance-covariancematrices for the random effects bˆi = [bˆ2i, bˆ3i, bˆ4i, bˆ7i, bˆ4i∗]
′
and bˆk = [bˆ2ik, bˆ7ik]
′ are now given by:
ψˆ1 =


119.82982 0 0 0 0
0 119.82982 0 0 0
0 0 0.032 0 0
0 0 0 270.292 0
0 0 0 0 1.90e− 102

 ,
ψˆ2 =
[
53.122 0
0 53.12
]
and the diagonal elements of Rik are given by σˆ2 = (18.95)
2.
The diagnostic plots for Model 2 indicate a much better model fit, (Figures 3.71
and 3.72), and a reduction in the heteroskedasticity previously seen for the resid-
uals related to the Sulfadoxine response, (Figure 3.73).
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Figure 3.71: Sulfadoxine Fitted Values vs. Observed: Simultaneous NLME
Model 2
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Figure 3.72: Pyrimethamine Fitted Values vs. Observed: Simultaneous NLME
Model 2
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Figure 3.73: Standardized Residuals vs. Fitted Values: Simultaneous NLME
Model 2
For parameter β2, for the random effects b2i and b2ik, (labeled“beta2.(Intercept)”),
the effects of pregnancy and site are indicated for both the subject and occasion-
specific random effects.
For the random effects b7i and b7ik however, (labeled “beta2.pk factsulf”), the
site and pregnancy effects for both the subject and occasion-specific random ef-
fects appear to be in the opposite direction to what they should be, (Figure 3.74
and Figure 3.75).
This is in part explained by the perfect negative correlation between the β2
and β7 random effects noted for both grouping levels, shown here for the phase
within subject level (Figure 3.76).
The same phenomenon is not noted for the random effects b4i and b∗4i, (labeled
“beta4.pk factpyr”and“beta4.pk factsulf” respectively), which had the alterna-
tive specification previously described, (Figure 3.77).
A potential site effect is also noted for β3 in the plot of the subject-specific
random effects versus covariates for this parameter, (Appendix E, figure E.8).
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Figure 3.74: Subject-Specific Random Effects for β2 and β7 vs. Covariates:
Simultaneous NLME Model 2
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Figure 3.75: Occasion-Specific Random Effects for β2 and β7 vs. Covariates:
Simultaneous NLME Model 2
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Figure 3.76: Pairs plots of Occasion-Specific Random Effects: Simultaneous
NLME Model 2
Model 3
This model adjusts for the impact of pregnancy and site, and corresponds to
stage 2 equations:
β1likj = β1 + β6 × δl...,
β2likj = β2 + β7 × δl... + β11 × pregnancylik. + β12 ×mozambiqueli..
+ β13 × sudanli.. + β14 × zambiali.. + b2i + b2ik + b7i + b7ik,
β3likj = β3 + β8 × δl... + b3i,
β4likj = β4 + β9 × δl... + b4i + b4i∗,
β5likj = β5 + β10 × δl...,
The constraint previously applied to the random effects for β2likj , such that
b2i = b7i and b2ik = b7ik has been removed, and the variance-covariance matrices
for the random effects are thus given by:
ψˆ1 =


53.532 0 0 0 0
0 113.362 0 0 0
0 0 0.022 0 0
0 0 0 238.632 0
0 0 0 0 3.84e− 52

 ,
ψˆ2 =
[
46.262 0
0 45.70
]
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Figure 3.77: Subject-Specific Random Effects b4i and b4i∗ vs. Covariates: Si-
multaneous NLME Model 2
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and the diagonal elements of Rik are given by σˆ2 = (19.23)
2.
The results for the fixed effects from Model 3 are summarized in Table 3.35.
Parameter Value Std.Error
βˆ1.(Baseline) 25.55 2.12
βˆ6.(Sulfadoxine) -11.06 2.91
βˆ2.(Baseline) 231.72 16.63
βˆ7.(Sulfadoxine) -220.33 33.71
βˆ11.(Pregnancy) 45.78 8.73
βˆ12.(Mozambique) 191.16 20.60
βˆ13.(Sudan) 106.28 22.59
βˆ14.(Zambia) -86.63 20.70
βˆ3.(Baseline) 0.15 0.004
βˆ8.(Sulfadoxine) -0.05 0.01
βˆ4.(Baseline) 150.95 27.16
βˆ9.(Sulfadoxine) -179.06 41.10
βˆ5.(Baseline) 1.26 0.08
βˆ10.(Sulfadoxine) -1.05 0.14
Table 3.35: Triple-Exponential Model Output: Simultaneous NLME Model 3
The plots of the subject-specific random effects for parameters β2 and β7,
(b2i and b7i respectively), shown in Figure 3.78, demonstrate that this model
has captured the impact of pregnancy and site for Pyrimethamine only (plot
labeled “beta2.(Intercept)”), since the patterns remain for β7, (plot labeled
“beta2.pk factsulf”).
A similar phenomenon is seen in Figure 3.79, for the occasion-specific random
effects.
Model 4
Model 4, (output not shown) incorporates interaction terms between the δl...
variable and the variables for pregnancy and site.
The plots of the subject- and occasion-specific random effects versus the co-
variates for parameters β2 and β7, (Figures 3.80, and 3.81), show the reduction
in the patterns previously observed for β7, (labeled “pk factsulf”).
Model 5
The final simultaneous model for the covariate specification is Model 5, which in-
corporates the interaction terms described, and no longer has the response type
indicator variable for parameter β5 (since its inclusion induces multi-collinearity
in this model). The results for this model are summarized in Table 3.36, corre-
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Figure 3.78: Subject-Specific Random Effects for β2 and β7 vs. Covariates:
Simultaneous NLME Model 3
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Figure 3.79: Occasion-Specific Random Effects for β2 and β7 vs. Covariates:
Simultaneous NLME Model 3
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Figure 3.80: Subject-Specific Random Effects for β2 and β7 vs. Covariates:
Simultaneous NLME Model 4
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Figure 3.81: Occasion-Specific Random Effects for β2 and β7 vs. Covariates:
Simultaneous NLME Model 4
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sponding to stage 2 equations given by:
β1likj = β1 + β6 × δl...,
β2likj = β2 + β7 × δl... + β10 × pregnancylik. + β11 ×mozambiqueli..
+ β12 × sudanli.. + β13 × zambiali..
+ β14 × δl... × pregnancylik. + β15 × δl... ×mozambiqueli..
+ β16 × δl... × sudanli.. + β17 × δl... × zambiali.. + b2i + b2ik + b7i + b7ik,
β3likj = β3 + β8 × δl... + b3i,
β4likj = β4 + β9 × δl... + b4i + b4i∗,
β5likj = β5,
Parameter Value Std.Error
βˆ1.(Baseline) 41.78 16.36
βˆ6.(Sulfadoxine) -27.74 16.52
βˆ2.(Baseline) 172.62 13.23
βˆ7.(Sulfadoxine) -88.62 13.43
βˆ10.(Pregnancy) 43.74 4.90
βˆ11.(Mozambique) 234.65 12.33
βˆ12.(Sudan) 119.52 13.41
βˆ13.(Zambia) -71.71 10.99
βˆ14.(Sulfadoxine× Pregnancy) -42.23 4.30
βˆ15.(Sulfadoxine×Mozambique) -223.19 11.46
βˆ16.(Sulfadoxine× Sudan) -111.58 12.39
βˆ17.(Sulfadoxine× Zambia) 50.29 10.20
βˆ3.(Baseline) 0.14 0.005
βˆ8.(Sulfadoxine) -0.05 0.0071
βˆ4.(Baseline) 130.86 14.70
βˆ9.(Sulfadoxine) -138.79 15.79
βˆ5 0.54 0.04
Table 3.36: Triple-Exponential Model Output: Simultaneous NLME Model 5
The variance-covariance matrices for the random effects for this model are given
by:
ψˆ1 =


0.062 0 0 0 0
0 0.022 0 0 0
0 0 0.032 0 0
0 0 0 86.972 0
0 0 0 0 0.00012

 ,
ψˆ2 =
[
21.202 0
0 12.02
]
and the diagonal elements of Rik are given by σˆ2 = (22.1)
2.
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Sulfadoxine: Fitted Values
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Pyrimethamine: Fitted Values
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Figure 3.82: Standardized Residuals vs. Fitted Values: Simultaneous NLME
Model 5
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Sulfadoxine: Fitted Values
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Figure 3.83: Fitted Values vs. Observed: Simultaneous NLME Model 5
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Despite the slight heteroskedasticity still observed, (Figure 3.82), no variance
models could be fitted. The diagnostic plots for this model (Appendix E, fig-
ures E.9 to E.14) indicate that the assumptions of normality are not violated
for either the residuals or random effects, although the QQplots of the random
effects do indicate slightly skewed distributions, led mainly by outliers, (Ap-
pendix E, figures E.11 and E.12).
The perfect correlation previously observed for some of the random effects is
no longer apparent, (Appendix E, figures E.13 and E.14), and the model ap-
pears to give a reasonably good fit for both the Sulfadoxine and Pyrimethamine
responses, (Figure 3.83).
Although the values of the variances for the random effects b2i and b7i are
relatively small, models without these random effects could not be obtained.
This then is the “best”model that could be obtained for this specification, deter-
mined by an hypothesis-based model building procedure. Table 3.37 summarizes
the fixed effects for each response and for the various categories of pregnancy
and site, after taking the effect modification parameters and interaction terms
into account.
Pyrimethamine
Parameter Postpartum Pregnant
Mali Mozambique Sudan Zambia Mali Mozambique Sudan Zambia
βˆ1 41.77 41.77 41.77 41.77 41.77 41.77 41.77 41.77
βˆ2 172.62 407.27 292.14 100.91 216.36 451.01 335.88 144.65
βˆ3 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14
βˆ4 130.86 130.86 130.86 130.86 130.86 130.86 130.86 130.86
βˆ5 0.54 0.54 0.54 0.54 0.54 0.54 0.54 0.54
Sulfadoxine
Parameter Postpartum Pregnant
Mali Mozambique Sudan Zambia Mali Mozambique Sudan Zambia
βˆ1 14.03 14.03 14.03 14.03 14.03 14.03 14.03 14.03
βˆ2 84.00 95.45 91.94 62.57 85.51 96.97 93.45 64.09
βˆ3 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
βˆ4 -7.93 -7.93 -7.93 -7.93 -7.93 -7.93 -7.93 -7.93
βˆ5 0.54 0.54 0.54 0.54 0.54 0.54 0.54 0.54
Table 3.37: Fixed Effects by Response Type, Pregnancy Phase and Site: Simul-
taneous NLME Model 5
This table, together with Figure 3.84, which shows the mean predicted concentration-
time curves by response type, pregnancy phase and site (for Mali and Zambia
only), illustrate the results from Model 5 more clearly.
Once again, the highest and lowest concentrations occur for subjects in Mozam-
bique and Zambia respectively, irrespective of pregnancy phase, for both re-
sponses.
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Pregnant subjects have higher concentrations in all sites, for both response
types, although the difference in concentrations between postpartum and preg-
nant subjects is not as pronounced for Sulfadoxine. Although this model does
not quite capture all the effects previously seen, the conclusions reached are
similar to those found with the separate models.
It is worth noting that the greatest impact of the indicator variable are on pa-
rameters β2 and β4, which indicate the overall range of concentrations reached,
and would thus necessarily differ greatly for the two response types because of
the different units used for the concentration measurements.
Pyrimethamine appears to have a much faster absorption rate, (shown by the
larger β1 parameter value, which corresponds to the slope of the absorption
phase), and a slightly faster initial rate of decline, (given by β3). The terminal
rate of decline is unchanged.
The main benefit of this model lies in the comparison of the different struc-
tural forms for the different response types. Were the calculation of the degrees
of freedom for the NLME models correct, the interpretation of the resultant
p-values for the conditional t-tests for these parameters would provide a statis-
tically appropriate test of the “correct”model form. Approximate p-values may,
however, be obtained using Wald tests, since the diagnostic plots for this model
(Appendix E, figures E.8) indicate that the assumptions of normality are not
violated.
Table 3.38 summarizes the results for the fixed effects parameters as before,
together with the values of the Wald test for each parameter, given by βˆi/ ˆseβi
for i = 1, . . . , p, and the corresponding p-value.
Then testing the null hypothesis that the β4 parameter for Sulfadoxine, resulting
from adding βˆ9.(Sulfadoxine) to βˆ4.(Baseline), is actually zero, i.e. testing:
H0 :βˆ4.(Sulfadoxine) = 0
vs.
HA :βˆ4.(Sulfadoxine) 6= 0
using V ar(A + B) = V ar(A) + V ar(B) + 2 × Cov(A,B) for random variables
A and B, the wald test would be given by:
−7.93111√
14.7049172+ 15.7942862+ 2×−0.915
and the corresponding p-value would be p = 0.713, indicating that the null
hypothesis that the β4 parameter for Sulfadoxine is equal to zero may not be
rejected.
Hence, we may conclude that the structural form for Sulfadoxine is that of
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Parameter Value Std.Error |Z| P-value
βˆ1.(Baseline) 41.78 16.36 2.55 0.011
βˆ6.(Sulfadoxine) -27.74 16.52 1.68 0.093
βˆ2.(Baseline) 172.62 13.23 13.05 <.0001
βˆ7.(Sulfadoxine) -88.62 13.43 6.60 <.0001
βˆ10.(Pregnancy) 43.74 4.90 8.93 <.0001
βˆ11.(Mozambique) 234.65 12.33 19.03 <.0001
βˆ12.(Sudan) 119.52 13.41 8.91 <.0001
βˆ13.(Zambia) -71.71 10.99 6.52 <.0001
βˆ14.(Sulfadoxine× Pregnancy) -42.23 4.30 9.83 <.0001
βˆ15.(Sulfadoxine×Mozambique) -223.19 11.46 19.47 <.0001
βˆ16.(Sulfadoxine× Sudan) -111.58 12.39 9.01 <.0001
βˆ17.(Sulfadoxine× Zambia) 50.29 10.20 4.93 <.0001
βˆ3.(Baseline) 0.14 0.005 27.43 <.0001
βˆ8.(Sulfadoxine) -0.05 0.0071 6.42 <.0001
βˆ4.(Baseline) 130.86 14.70 8.90 <.0001
βˆ9.(Sulfadoxine) -138.79 15.79 8.79 <.0001
βˆ5 0.54 0.04 13.27 <.0001
Table 3.38: Triple-Exponential Model Output (Wald Test): Simultaneous
NLME Model 5
a bi-exponential model, since in the equation given by:
C(t) = β2 × [−exp(−β1 × time) + exp(−β3 × time)]
+ β4 × [−exp(−β1 × time) + exp(−β5 × time)]
the second bi-exponential function no longer applies.
This conclusion is further supported by an examination of Figure 3.85, which
shows the combined curves (for the baseline study site and pregnancy status)
and their constituent parts for Pyrimethamine and Sulfadoxine respectively.
In Figure 3.85, it is easily seen that the combined curve does not indicate a bipha-
sic rate of decline, and that the constituent curve given by β4 × (−exp(−β1 ×
time) + exp(−β5 × time)) serves merely to lower the Cmax value.
3.5.2 Model Specification 2: Different Functional Forms
The model specification in which different structural forms are accommodated
is that directly adapted from the traditional simultaneous model in which the
PK-PD relationship is investigated.
In this (adapted) model specification, as previously outlined, both a bi- and
triple-exponential model are simultaneously fit to the full dataset, restructured
so as to accommodate the multiple responses. The appropriate parameteriza-
tion for the different responses is then indicated in the structural model, with
the use of a binary indicator variable.
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Figure 3.85: Mean Predicted Pyrimethamine and Sulfadoxine Concentration-
time Curves by Response type, Pregnancy Phase and Site (Mali and Zambia):
Simultaneous NLME Model 5
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The model building procedure applied in all other instances in this thesis has
not been used for the models presented here, owing to the computational inten-
sity of such a procedure for a model of such complexity.
A single model is presented here, with the covariate and random effects structure
most closely approximating those seen for the respective individual (separate)
Sulfadoxine and Pyrimethamine models.
Model 1
This model follows the basic structural form given by:
f(xlikj,βlikj) =
[
β0likj(−e−β1likj×timelikj + e−β2likj×timelikj )
]
︸ ︷︷ ︸
×δl...
Bi-Exponential Model Form: Sulfadoxine
+
[
β3likj × [−exp(−β5likj × timelikj) + exp(−β6likj × timelikj)]
+ β4likj × [−exp(−β5likj × timelikj) + exp(−β7likj × timelikj)]
]
︸ ︷︷ ︸
Triple-Exponential Model Form: Pyrimethamine
× (1 − δl...)
where δl... is a binary variable indicating the response type as Pyrimethamine
(δl... = 0) or Sulfadoxine (δl... = 1).
The stage 2 equations, and hence the covariate model, are given by:
β0likj = β0 + β8 × pregnancylik. + β11 ×mozambiqueli.. + β12 × zambiali.. + b0i + b0ik
β1likj = β1
β2likj = β2 + β9 × pregnancylik.
β3likj = β3 + b3i + b3ik
β4likj = β4 + β10 × pregnancylik.
+ β13 ×mozambiqueli.. + β14 × sudanli.. + β15 × zambiali.. + b4i + b4ik
β5likj = β5
β6likj = β6
β7likj = β7
The results for the fixed effect parameters are summarized in Table 3.39.
Although the interaction effect previously seen between pregnancy and site for
the Pyrimethamine model (Model 4) is not included here, together with the
effect of Zambia on the β2 parameter in the previous Sulfadoxine model (Model
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Parameter Value Std.Error
βˆ0.(Intercept) 70.96 2.53
βˆ8.(Pregnancy) 11.13 2.67
βˆ11.(Mozambique) 10.35 3.09
βˆ12.(Zambia) -21.47 2.47
βˆ1 14.96 1.98
βˆ2.(Intercept) 0.06 0.005
βˆ9.(Pregnancy) 0.03 0.006
βˆ3 141.81 21.50
βˆ4.(Intercept) 199.69 18.11
βˆ10.(Pregnancy) 55.56 10.49
βˆ13.(Mozambique) 228.78 22.10
βˆ14.(Sudan) 94.06 23.92
βˆ15.(Zambia) -80.42 22.39
βˆ5 25.85 2.19
βˆ6 0.99 0.07
βˆ7 0.14 0.003
Table 3.39: Triple-Exponential Model Output: Simultaneous NLME Model 1
(Indicator Specification)
5), the values of the parameters that are included here are very similar to those
obtained from the separate models (Tables 3.12 and 3.27), and the relationships
indicated for pregnancy and site are of the same approximate magnitude and in
the same directions.
The random effects for this model are restricted to subject and occasion-specific
random effects on parameters β2, β3 and β4 only.
The variance-covariance matrices for these random effects are block-diagonal
matrices, which do not yet take into account potential correlations between the
random effects for the different model specifications.
The variance-covariance matrices for these random effects are given by:
ψˆ1 =


[
0.006
]
0
0
[
184.23 0
0.006 56.96
]
ψˆ2 =


[
7.48
]
0
0
[
36.26 0
0.006 54.42
]
This is an obvious limitation to the use and interpretation of the model, since
for this specification, the joint distribution of the random effects and the ac-
commodation of these potential correlations is the driver behind accounting for
the possible interdependence and relationship between the responses.
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Since the complexity of the indicator model specification forces the most simple
approach, in this case, there is no obvious benefit to be had from using this
version of the simultaneous model. Additionally, the “nested” structure of the
two constituent structural model forms (the bi- and triple-exponential specifi-
cations) lends itself to the covariate version of the simultaneous model, which
allows us to formally test which structural form is most appropriate for each
response.
We were also unable to fit a variance function to this model, although the
initial function specified was structured so as to allow for different θ values for
the different response types.
The diagonal elements of the matrix Rik(nik×nik) were thus given by σˆ
2 =
(19.76)2.
Examination of the diagnostic plots for this model indicate a relatively good
fit for Pyrimethamine, (Figures 3.86 and 3.87), with less heter skedasticity ob-
served for the residual variance, (Figure 3.86 ).
Figures 3.88 and 3.89 show the plot of the standardized residuals versus the
fitted values, and the plot of the fitted values versus observed for Sulfadoxine
respectively, which does not appear to have as accurate a fit.
The remaining diagnostic plots (Appendix F, figures F.1 to F.6) do not indicate
any further departures from the assumptions of normality, although potential
correlations are indicated between the subject-specific random effects for β3 and
β4, and between the occasion-specific random effects for β0 and β4.
3.5.3 Discussion and Conclusions
The original undertaking theorized for this master’s thesis was to explore and
in effect “master” the basic theoretical and computational constructs involved
in the use of nonlinear mixed effect models.
The use of concentration-time data for the antimalarial compounds Sulfadoxine
and Pyrimethamine further allowed for the extension of these NLME models to
a “multivariate framework”.
Owing to the complexity of the available data, in particular, the self-matched
study design, these single level NLME models (multivariate or otherwise) were
no longer adequate, and hence, multilevel NLME models were required.
Ordinarily, the modeling of concentration-time data is achieved through the
use of mechanistic pharmacokinetic models. In this thesis however, a more em-
pirical approach was taken, and the structural model forms were specified as
poly-exponential expressions, with the parameters having little direct mecha-
nistic interpretation.
The use of the exponential parameterization was initially decided on as a means
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Figure 3.86: Standardized Residuals vs. Fitted Values: Simultaneous NLME
Model 1 (Indicator)
of smoothing and interpolating the observed concentration-time curves, whilst
simultaneously distancing the development of the methodology from a PK anal-
ysis.
The PK parameters obtained from the back transformation of these exponential
parameters appeared to be consistent with those found using the mechanistic
NLME models, and indeed with those found using the more traditional two-stage
approach to the analysis of PK data, and despite the various complications aris-
ing from the use of the exponential specification (such as the loss of clinical
information regarding the placement of covariates, and the issue of starting val-
ues), this parameterization allowed for the break down of the curves into their
constituent components.
This thesis demonstrates that, in general, the use of NLME techniques pro-
vides a flexible and powerful tool for the analysis of longitudinal data, and in
this particular case, for the estimation of separate, sequential and simultaneous
models of drug-concentrations over time. The resulting models have enabled
us to draw conclusions regarding the impact of covariates on the concentration-
time profiles of the individual compounds, as well as examine the structural
forms most appropriate to the different response types.
The sequential and simultaneous approaches used here are based on methods
applicable in the traditional PK-PD context, and although clinically, the mo-
tivation behind the modeling of the drug-drug relationship was to develop a
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Figure 3.87: Fitted Values vs. Observed: Simultaneous NLME Model 1 (Indi-
cator)
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Figure 3.88: Standardized Residuals vs. Fitted Values: Simultaneous NLME
Model 1 (Indicator)
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Figure 3.89: Fitted Values vs. Observed: Simultaneous NLME Model 1 (Indi-
cator)
further understanding of the interaction between the two compounds and hence
to understand the underlying synergistic mechanism of action on the malaria
parasite, the models developed here do not appear to answer that question.
Further work, undertaken for subjects in Mozambique for whom we have PD
data, (not used in this analysis), might see the development of a PK-PD model
in which the PD model accounts for the two predicted drug concentrations si-
multaneously.
From a mathematical perspective, the sequential and simultaneous models pre-
sented in this thesis provide an interesting approach to the determination of the
correct underlying structural form (despite the use of approximate significance
calculations necessitated by the incorrect calculation of degrees of freedom).
The flexibility of the NLME model is impressive: results from the multilevel
specification may be effectively replicated using a single level model with a
variance-covariance structure for the random effects that mimics the correlation
induced by the nesting structure of the data, and the random effects may be
specified in multiple ways (as demonstrated in the covariate specification of the
simultaneous model). The use of explicit variance models appears to effectively
handle the heterogeneous variance so often observed in models for data of this
type, although the correct specification of this variance structure is not always
straightforward.
The specification of accurate starting estimates appeared to play a significant
role in the convergence of the models, and in the development of robust, stable
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models. The multilevel nesting structure for the random effects exacerbated
this problem, and in some instances (such as with the separate Pyrimethamine
models), a simpler single-level model (which ignored the data structure) was
required in order to obtain useable starting values. Curve-stripping procedures
helped somewhat for the bi-exponential model specification, but were not ap-
plied for the more complicated triple-exponential model form. The exponential
specification also contributed to the difficulty in the determination of robust
model estimates, since with this specification, different parameter estimates of-
ten result in almost identical predicted curves.
The calculation of the degrees of freedom was a major obstacle, which has yet
to be overcome, and will hopefully form part of further work on these models.
There does not appear to be any common consensus on the correct approxima-
tion to use, which will only be further aggravated by the nested random effects
structure. For the models presented here, with the exception of the simultane-
ous model in which the Wald test was used, the degrees of freedom, and hence
the associated p-value and significance of the model parameters could not be
determined, which made it difficult to interpret the impact of covariates, and
also made model building more complicated.
As previously mentioned, the exponential parameterization further complicated
the covariate model building procedure, in that clinical information on the place-
ment of covariates was not as clearly applicable. Convergence and stability issues
also resulted in fewer covariates being considered for inclusion, despite indica-
tions that covariates not included, such as anaemia, might still play a role in
determining the relationship between the two drug concentrations and the im-
pact of pregnancy induced changes. It should be noted that there are alternative
methods available for the estimation of parameters of non-linear mixed effect
models, whicih may not have the same convergence issues of the ‘nlme’package
in R. Markov Chain Monte Carlo (MCMC) methods are one such example, and
are available in both WinBugs and Monolix.
The predicted population, individual- and occasion-specific curves generated
by the models did, however, appear to capture the observed concentration-time
relationships, and the determined site and pregnancy effects were consistent
with previous results. The results obtained through the use of the delta method
in the calculation of the standard errors for back transformed PK parameters
appeared adequate, and the comparison of NLME results with those obtained
from the two-stage approach used by Nyunt et al. [5] showed the reduction in
the standard errors for the NLME model.
Results from the separate Sulfadoxine and Pyrimethamine models indicated that
both pregnancy and site played a role in the determination of the concentration-
time profiles for the different compounds. The overall range of concentrations
was higher in pregnant subjects for both Sulfadoxine and Pyrimethamine, but
the additional impact of pregnancy on the elimination rate and hence the clear-
ance of Sulfadoxine resulted in a reduction in the overall drug exposure, as
measured by the AUC, where the opposite was seen for Pyrimethamine. Study
sites varied widely, and for Pyrimethamine, the pregnancy effect was dependent
on the study site of the individual. The dosing implications of these results are
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not clear, particularly as these models were developed from a purely empirical
perspective.
The use of NLME modeling techniques is evidently of enormous potential bene-
fit. This thesis manages an introduction to the large scope of possible uses and
applications of these techniques, and provides a glimpse into the power, flexi-
bility and elegance of NLME models, whilst demonstrating the computational
and theoretical complexity involved in their development.
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Appendix A
Data Exploration
--------------------------------------------------------------------
Example Code for Pairs plot (Figure 3.5 in text) (58):
--------------------------------------------------------------------
panel.cor <- function(x, y, digits=2, prefix=""){
usr <- par("usr"); on.exit(par(usr))
par(usr = c(0, 1, 0, 1))
r <- abs(cor(x, y))
txt <- format(c(r, 0.123456789), digits=digits)[1]
txt <- paste(prefix, txt, sep="")
#if(missing(cex.cor)) cex.cor <- 0.8/strwidth(txt)
#text(0.5, 0.5, txt, cex = cex.cor * r)
text(0.5, 0.5, txt, col=ifelse(as.numeric(txt)>0.3,"brown","blue"))
}
panel.hist <- function(x, ...){
usr <- par("usr"); on.exit(par(usr))
par(usr = c(usr[1:2], 0, 1.5) )
h <- hist(x, plot = FALSE)
breaks <- h$breaks; nB <- length(breaks)
y <- h$counts; y <- y/max(y)
rect(breaks[-nB], 0, breaks[-1], y, col="cyan", ...)
}
pairs(iptsub[,-match(c("preg","trimester","site","anaem10"),
names(iptsub))],lower.panel=panel.smooth,diag.panel=panel.hist,
upper.panel=panel.cor,cex.labels=1)
--------------------------------------------------------------------
Example Code for Figures A.1 to A.4 and Figures 3.1 to 3.4 in text: (Identifi-
cation of Biologically Implausible Concentrations)
--------------------------------------------------------------------
xyplot(sulfadoxine ~ day, initialsulf, groups = pid, type = 'b',
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subset = (site=="Mali" & preg==1),
,sub="Pregnant Subjects: Mali",
xlab="Time (days)",ylab="Sulfadoxine Concentration (ug/ml)",
panel = function( x, y, subscripts, ...) {
panel.superpose( x,y,subscripts,...)
panel.identify( x,y, subscripts = subscripts,
labels = initialsulf$pid[subscripts],...)
panel.identify( x,y, subscripts = subscripts,
labels=initialsulf$day[subscripts],offset=1.25, ...)
})
--------------------------------------------------------------------
Identification of Biologically Implausible Concentrations, Mali and Zambia:
--------------------------------------------------------------------
Pregnant Subjects: Mali
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Figure A.1: Identification of Biologically Implausible Sulfadoxine Concentra-
tions: Mali
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Pregnant Subjects: Zambia
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Figure A.2: Identification of Biologically Implausible Sulfadoxine Concentra-
tions: Zambia
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Figure A.3: Identification of Biologically Implausible Pyrimethamine Concen-
trations: Mali
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Pregnant Subjects: Zambia
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Figure A.4: Identification of Biologically Implausible Pyrimethamine Concen-
trations: Zambia
--------------------------------------------------------------------
Further Data Exploration: Boxplots of Continuous Covariates by Pregnancy
Status and Site
--------------------------------------------------------------------
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Figure A.5: Boxplots of Continuous Covariates vs. Pregnancy
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Figure A.6: Boxplots of Continuous Covariates vs. Site
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Figure A.7: Boxplots of Day 7 Concentrations by Pregnancy Phase
--------------------------------------------------------------------
Data Exploration for Subset of Data
--------------------------------------------------------------------
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Figure A.8: Sulfadoxine Concentration vs. Time by Grouping (Multiple Levels)
Figure A.9: Sulfadoxine Concentration vs. Time by Site and Pregnancy Status
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Figure A.10: Sulfadoxine Concentration vs. Time by Grouping (Subject Level)
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Figure A.11: Sulfadoxine Concentration vs. Time (Collapsed)
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Figure A.12: Pyrimethamine Concentration vs. Time by Grouping (Multiple
Levels)
Figure A.13: Pyrimethamine Concentration vs. Time by Site and Pregnancy
Status
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Figure A.14: Pyrimethamine Concentration vs. Time by Grouping (Subject
Level)
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Figure A.15: Pyrimethamine Concentration vs. Time (Collapsed)
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Appendix B
Sulfadoxine Models
--------------------------------------------------------------------
Example Code for NLS Models:
--------------------------------------------------------------------
sulf1comp_preg.nls=nls(sulfadoxine~fm1comp(beta0,beta1,beta2,day),
data=sulf,
start=c(beta0=91.2964786,beta1=6.5815878,
beta2=0.1476355),
control=controlS,,subset=preg==1)
summary(sulf1comp_preg.nls)
--------------------------------------------------------------------
Model Output: Sulfadoxine NLS Models (Pregnant and Postpartum Subsets)
--------------------------------------------------------------------
Estimate Std. Error t value Pr(>|t|)
beta0 78.39 1.19 65.63 0.00
beta1 10.36 0.86 12.11 0.00
beta2 0.08 0.00 25.01 0.00
Table B.1: Model Output for Sulfadoxine Bi-Exponential NLS model: Pregnant
Subset
Estimate Std. Error t value Pr(>|t|)
beta0 61.47 1.39 44.38 0.00
beta1 12.26 1.48 8.28 0.00
beta2 0.05 0.00 14.94 0.00
Table B.2: Model Output for Sulfadoxine Bi-Exponential NLS model: PostPar-
tum Subset
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--------------------------------------------------------------------
Example Code for NLSLIST Models (Individual-Specific):
--------------------------------------------------------------------
#NLSLIST MODELS: BI-EXPONENTIAL MODELS
#FULL DATASET
sulf1comp.lis=nlsList(sulfadoxine~fm1comp(beta0,beta1,beta2,day),
data=sulf,
start=c(beta0=86.7155320,beta1=5.9219280,
beta2=0.1476355),
control=controlS,,subset=!(site=="Mozambique")
&!(site=="Sudan"))
#INTERVALS PLOT: FIGURE 3.11 IN TEXT
plot(intervals(sulf1comp.lis),layout=c(3,1,1),devAskNewPage(ask=T))
#BETA ESTIMATES AVERAGED OVER INDIVIDUALS
summary(sulf1comp.lis)
coef_sulf1comp.lis=as.data.frame(coefficients(sulf1comp.lis))
avecoef=c(mean(as.numeric(coef_sulf1comp.lis[1:79,1]),na.rm=T),
mean(as.numeric(coef_sulf1comp.lis[1:79,2]),na.rm=T),
mean(as.numeric(coef_sulf1comp.lis[1:79,3]),na.rm=T))
#EXAMINING OUTLIERS
sulflis=coef(sulf1comp.lis)
subset(sulflis,sulflis$beta1==max(sulflis$beta1,na.rm=T))#ZAMB_009/0
subset(sulflis,sulflis$beta2==max(sulflis$beta2,na.rm=T))#ZAMB_008/1
sulf1comp2.lis=nlsList(sulfadoxine~fm1comp(beta0,beta1,beta2,day),
data=sulf,
start=c(beta0=86.7155320,beta1=5.9219280,
beta2=0.1476355),
control=controlS,,subset=!(site=="Mozambique")
&! (site=="Sudan")
&! (pid=="ZAMB_009" & preg==0)
&! (pid=="ZAMB_008"&preg==1))
#INTERVALS PLOT: FIGURE 3.12 IN TEXT
plot(intervals(sulf1comp2.lis),layout=c(3,1,1),devAskNewPage(ask=T))
--------------------------------------------------------------------
Diagnostic plots: Sulfadoxine NLME Model 1
--------------------------------------------------------------------
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Figure B.1: Histogram of Residuals: Sulfadoxine NLME Model 1
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Figure B.2: Residuals by Subject ID: Sulfadoxine NLME Model 1
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Figure B.3: QQplot of Residuals: Sulfadoxine NLME Model 1
Random effects
Qu
an
tile
s o
f s
ta
nd
ar
d 
no
rm
a
l
−2
−1
0
1
2
−20 −10 0 10 20 30
beta0
−3 −2 −1 0 1 2
beta1
−5e−09 0e+00 5e−09
beta3
Figure B.4: QQplot of Random Effects (Subject Level): Sulfadoxine NLME
Model 1
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Figure B.5: QQplot of Random Effects (Phase-within-Subject Level) : Sulfa-
doxine NLME Model 1
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Figure B.6: Pairs Plot of Random Effects (Phase-within-Subject Level) : Sulfa-
doxine NLME Model 1
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Figure B.7: Pairs Plot of Random Effects (Phase-within-Subject Level) : Sulfa-
doxine NLME Model 1
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Figure B.8: Fitted Values vs. Observed: Sulfadoxine NLME Model 1
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--------------------------------------------------------------------
Random Effects versus Covariates: Sulfadoxine NLME Model 1
--------------------------------------------------------------------
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Figure B.9: Subject-Specific Random Effects for β2 vs. Covariates: Sulfadoxine
NLME Model 1
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Figure B.10: Occasion-Specific Random Effects for β0 vs. Covariates: Sulfadox-
ine NLME Model 1
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Figure B.11: Occasion-Specific Random Effects for β1 vs. Covariates: Sulfadox-
ine NLME Model 1
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--------------------------------------------------------------------
Example Code: Sulfadoxine NLME Model 3:
--------------------------------------------------------------------
#MODEL
sulf1comp.13=update(sulf1comp.8,fixed=list(beta0~preg,beta1~1,
beta2~preg),
random=list(pid=pdDiag(beta0+beta1~1),
preg=pdDiag(beta0+beta1+beta2~1)),
start=list(fixed=c(80,0,14,0.06,0)))
summary(sulf1comp.13)
#MODEL DIAGNOSTICS FOR MODEL 13
#RESIDUALS VS. FITTED
par(oma=c(0,0,0,0))
plot(sulf1comp.13,resid(.,type="p")~fitted(.),id=0.10,adj=-0.1,
idLabels=~as.numeric(site))
#HISTOGRAM, QQPLOT OF RESIDUALS, RESIDUALS BY SUBJECT ID
hist(resid(sulf1comp.13,type="p"),col="blue",main="")
plot(sulf1comp.13,pid~resid(.,type="p"),abline=0)
qqnorm(sulf1comp.13,~resid(.,type="p") )
#QQPLOTS OF RANDOM EFFECTS (BOTH LEVELS)
qqnorm(sulf1comp.13,~ranef(.,level=1),layout=c(2,1,1),
devAskNewPage(ask=T),id=0.05)
qqnorm(sulf1comp.13,~ranef(.,level=2),layout=c(3,1,1),
devAskNewPage(ask=T),id=0.05,adj=0.5,idLabel=~as.numeric(site))
#PAIRS PLOTS OF RANDOM EFFECTS
pairs(sulf1comp.13,~ranef(.,level=1),control=list(cex.axis=0.7),id=0.05)
pairs(sulf1comp.13,~ranef(.,level=2),control=list(cex.axis=0.7),id=0.05)
#PLOT OF PREDICTED CONCENTRATION-TIME CURVES BY INDIVIDUAL (MULTIPLE-LEVELS)
devAskNewPage(ask=TRUE)
plot(augPred(sulf1comp.13,level=0:2),layout=c(6,5,6),
strip=strip.custom(par.strip.text =list(cex=0.65)))
#FITTED VALUES VS. OBSERVED
plot(sulf1comp.13,sulfadoxine~fitted(.),id=0.05,adj=-0.1,
idLabel=~as.numeric(site))
--------------------------------------------------------------------
Diagnostic Plots: Sulfadoxine NLME Model 3
--------------------------------------------------------------------
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Figure B.12: Histogram of Residuals: Sulfadoxine NLME Model 3
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Figure B.13: Residuals by Subject ID: Sulfadoxine NLME Model 3
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Figure B.14: QQplot of Residuals: Sulfadoxine NLME Model 3
Random effects
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Figure B.15: QQplot of Random Effects (Subject Level): Sulfadoxine NLME
Model 3
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Figure B.16: QQplot of Random Effects (Phase-within-Subject Level): Sulfa-
doxine NLME Model 3
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Figure B.17: Pairs Plot of Random Effects (Phase-within-Subject Level): Sul-
fadoxine NLME Model 3
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Figure B.18: Pairs Plot of Random Effects (Phase-within-Subject Level): Sul-
fadoxine NLME Model 3
--------------------------------------------------------------------
Example Code for Variance Model
--------------------------------------------------------------------
var5=varConstPower(power=0.9,const=20)
sulf1comp.20=update(sulf1comp.13,weights=var5)
#RANDOM EFFECTS VS. COVARIATES
sulf1comp20.re=ranef(sulf1comp.20,level=1,aug=T)
sulf1comp20.re2=ranef(sulf1comp.20,level=2,aug=T)
sulf1comp20.fe=fixef(sulf1comp.20,level=1,aug=T)
plot(sulf1comp20.re,form=beta0.(Intercept)~trimester+weight+
site+anaem10,control=list(cex.axis=0.7))
plot(sulf1comp20.re,form=beta1~trimester+weight+site+anaem10
,control=list(cex.axis=0.7))
plot(sulf1comp20.re2,form=beta0.(Intercept)~trimester+weight
+site+anaem10,control=list(cex.axis=0.7))
plot(sulf1comp20.re2,form=beta1~trimester+weight+site+anaem10
,control=list(cex.axis=0.7))
plot(sulf1comp20.re2,form=beta2.(Intercept)~trimester+weight+
site+anaem10,control=list(cex.axis=0.7))
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--------------------------------------------------------------------
Random effects vs. Covariates for Model including Variance Function
--------------------------------------------------------------------
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Figure B.19: Occasion-Specific Random Effects for β0 vs. Covariates: Sulfadox-
ine NLME Model 4
--------------------------------------------------------------------
Diagnostic Plots: Sulfadoxine NLME Model 5
--------------------------------------------------------------------
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Figure B.20: Histogram of Residuals: Sulfadoxine NLME Model 5
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Figure B.21: Residuals by Subject ID: Sulfadoxine NLME Model 5
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Figure B.22: QQplot of Residuals: Sulfadoxine NLME Model 5
Random effects
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Figure B.23: QQplot of Random Effects (Subject Level): Sulfadoxine NLME
Model 5
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Figure B.24: QQplot of Random Effects (Phase-within-Subject Level): Sulfa-
doxine NLME Model 5
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Figure B.25: Residuals vs. Fitted Values: Sulfadoxine NLME Model 5
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Figure B.26: Fitted Values vs. Observed: Sulfadoxine NLME Model 5
--------------------------------------------------------------------
Example Code for Figure 3.25
--------------------------------------------------------------------
#CREATING EMPTY DATASET
timenew2=seq(0,42,0.1)
conc_mali2=rep(0,421)
conc_mali_preg2=rep(0,421)
conc_moz2=rep(0,421)
conc_moz_preg2=rep(0,421)
conc_sud2=rep(0,421)
conc_sud_preg2=rep(0,421)
conc_zamb2=rep(0,421)
conc_zamb_preg2=rep(0,421)
newdata2=data.frame(timenew2, conc_mali2,conc_mali_preg2,
conc_moz2,conc_moz_preg2,
conc_sud2,conc_sud_preg2,
conc_zamb2,conc_zamb_preg2)
fixed=fixef(sulf1comp.site6)
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is.vector(fixef(sulf1comp.site6))
#RENAMING VARIABLES OF INTEREST FOR EASE OF USE
beta0mali=fixed[1]
beta1mali=fixed[5]
beta2mali=fixed[6]
beta0malipreg=fixed[1]+fixed[2]
beta1malipreg=fixed[5]
beta2malipreg=fixed[6]+fixed[7]
beta0moz=fixed[1]+fixed[3]
beta1moz=fixed[5]
beta2moz=fixed[6]+fixed[8]
beta0mozpreg=fixed[1]+fixed[3]+fixed[2]
beta1mozpreg=fixed[5]
beta2mozpreg=fixed[6]+fixed[8]+fixed[7]
beta0zamb=fixed[1]+fixed[4]
beta1zamb=fixed[5]
beta2zamb=fixed[6]
beta0zambpreg=fixed[1]+fixed[4]+fixed[2]
beta1zambpreg=fixed[5]
beta2zambpreg=fixed[6]+fixed[7]
beta0sud=fixed[1]
beta1sud=fixed[5]
beta2sud=fixed[6]
beta0sudpreg=fixed[1]+fixed[2]
beta1sudpreg=fixed[5]
beta2sudpreg=fixed[6]+fixed[7]
#FILLING EMPTY DATASET
for (i in 1:nrow(newdata2)) {
newdata2[i,2]=beta0mali*(-exp(-beta1mali*newdata2[i,1])+
exp(-beta2mali*newdata2[i,1]))
newdata2[i,3]=beta0malipreg*(-exp(-beta1malipreg*newdata2[i,1])
+exp(-beta2malipreg*newdata2[i,1]))
newdata2[i,4]=beta0moz*(-exp(-beta1moz*newdata2[i,1])
+exp(-beta2moz*newdata2[i,1]))
newdata2[i,5]=beta0mozpreg*(-exp(-beta1mozpreg*newdata2[i,1])
+exp(-beta2mozpreg*newdata2[i,1]))
newdata2[i,6]=beta0sud*(-exp(-beta1sud*newdata2[i,1])
+exp(-beta2sud*newdata2[i,1]))
newdata2[i,7]=beta0sudpreg*(-exp(-beta1sudpreg*newdata2[i,1])
+exp(-beta2sudpreg*newdata2[i,1]))
newdata2[i,8]=beta0zamb*(-exp(-beta1zamb*newdata2[i,1])
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+exp(-beta2zamb*newdata2[i,1]))
newdata2[i,9]=beta0zambpreg*(-exp(-beta1zambpreg*newdata2[i,1])
+exp(-beta2zambpreg*newdata2[i,1]))
}
#CURVES BY SITE (PREG AND PP)
par(mfrow=c(2,2))
plot(newdata2$conc_mali_preg2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lwd="2", col="blue",font.sub="2",xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)", main="Mali")
par(new=TRUE)
plot(newdata2$conc_mali2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lty="44",lwd="2", col="navy",font.sub="2",xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)")
plot(newdata2$conc_sud_preg2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lwd="2", col="green", font.sub="2",xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)", main="Sudan")
par(new=TRUE)
plot(newdata2$conc_sud2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lty="44",lwd="2", col="forest green",font.sub="2",
xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)")
plot(newdata2$conc_moz_preg2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lwd="2", col="deeppink4",font.sub="2",xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)", main="Mozambique")
par(new=TRUE)
plot(newdata2$conc_moz2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lty="44",lwd="2", col="red",font.sub="2",xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)")
plot(newdata2$conc_zamb_preg2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lwd="2", col="gray",font.sub="2",xlab="Time(Days)",
ylab="Mean Sulfadoxine Concentration (ug/ml)", main="Zambia")
par(new=TRUE)
plot(newdata2$conc_zamb2~newdata2$timenew2,
ylim=range(newdata2$conc_moz_preg2),
type="l",lty="44",lwd="2", col="black",font.sub="2",xlab="Time(Days)",
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ylab="Mean Sulfadoxine Concentration (ug/ml)")
par(xpd=NA)
legend(locator(1), legend=c("Pregnant", "Postpartum"), lty=c(1,44),bty="n",ncol=2)
--------------------------------------------------------------------
Comparison of PK parameters: Sulfadoxine NLME Model 5
(N/D*)= Not determined
--------------------------------------------------------------------
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Model 5 Nyunt et al.
Pregnant Postpartum Pregnant Postpartum
Country Parameter Mean Std. Error Mean Std. Error Mean Std. Error Mean Std. Error
Mali Tmax (days) 0.84 0.27 0.91 0.05 0.38 0.33 0.55 0.37
t1/2 (days) 7.71 0.14 11.48 0.33 7.04 1.34 10.17 1.33
AUC(0 inf) (ug.day/ml) 912.79 24.64 1221.72 45.78 873.07 142.52 1064.86 189.01
Vd/f (ml/kg) 299.85 7.98 342.41 11.64 290.16 36.91 358.95 38.67
Cl/f (ml/kg/day) 26.94 0.74 20.67 0.78 29.51 6.62 24.68 2.97
Cmax (ug/ml) 76.04 2.12 69.83 2.46 83.35 5.44 70.01 9.87
Mozambique Tmax (days) 0.86 0.29 0.94 0.39 0.72 0.86 (N/D*) (N/D)
t1/2 (days) 8.72 0.21 13.87 0.84 8.12 3.55 (N/D) (N/D)
AUC(0 inf) (ug.day/ml) 1144.20 32.69 1653.88 90.90 1091.27 320 (N/D) (N/D)
Vd/f (ml/kg) 270.58 8.00 305.68 12.26 261.94 81.27 (N/D) (N/D)
Cl/f (ml/kg/day) 21.49 0.62 15.27 0.85 24.68 9.08 (N/D) (N/D)
Cmax (ug/ml) 84.88 2.62 78.84 3.25 100.78 74.92 (N/D) (N/D)
Sudan Tmax (days) 0.84 0.27 0.91 0.05 0.98 0.82 (N/D) (N/D)
t1/2 (days) 7.71 0.14 11.48 0.33 6.29 2.28 (N/D) (N/D)
AUC(0 inf) (ug.day/ml) 912.79 24.64 1221.72 45.78 844.64 322.5 (N/D) (N/D)
Vd/f (ml/kg) 299.85 7.98 342.41 11.64 253.99 79.34 (N/D) (N/D)
Cl/f (ml/kg/day) 26.94 0.74 20.67 0.78 30.67 9.75 (N/D) (N/D)
Cmax (ug/ml) 76.04 2.12 69.83 2.46 81.26 18.26 (N/D) (N/D)
Zambia Tmax (days) 0.84 0.27 0.91 0.34 0.3 0.24 0.54 0.45
t1/2 (days) 7.71 0.14 11.48 0.33 8.5 2.83 10.02 1.97
AUC(0 inf) (ug.day/ml) 996.20 27.39 862.22 44.85 745.84 262.48 737.63 107.39
Vd/f (ml/kg) 274.74 16.62 485.17 24.54 426.23 123.85 487.72 54.73
Cl/f (ml/kg/day) 24.68 1.52 29.29 1.54 38.49 16.55 34.72 6.53
Cmax (ug/ml) 82.99 2.38 49.28 2.58 61.3 17.33 50.01 7.14
Table B.3: Comparison of PK parameters by Site and Pregnancy Phase: Sulfadoxine NLME Model 5
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Model 5 Nyunt et al. (Reported)
Pregnant Postpartum Pregnant Postpartum
Country Parameter Mean Std. Error Mean Std. Error Median IQR Median IQR
Mali Tmax (days) 0.84 0.27 0.91 0.05 0.36 (0.04,0.53) 0.46 (0.32,0.80)
t1/2 (days) 7.71 0.14 11.48 0.33 6.83 (6.11,8.00) 9.89 (9.52,10.63)
AUC(0 inf) (ug.day/ml) 912.79 24.64 1221.72 45.78 831.98 (769.21,961.66) 1079.57 (958.38,1156.49)
Vd/f (ml/kg) 299.85 7.98 342.41 11.64 291.05 (274.68,303.99) 353.12 (345.32,392.94)
Cl/f (ml/kg/day) 26.94 0.74 20.67 0.78 28.86 (26.02,33.62) 24.48 (22.41,26.28)
Cmax (ug/ml) 76.04 2.12 69.83 2.46 84.21 (80.78,86.09) 70.57 (63.46,77.07)
Mozambique Tmax (days) 0.86 0.29 0.94 0.39 0.23 (0.15,1.32) (N/D*) (N/D)
t1/2 (days) 8.72 0.21 13.87 0.84 7.79 (6.15,9.79) (N/D) (N/D)
AUC(0 inf) (ug.day/ml) 1144.20 32.69 1653.88 90.90 1045.71 (886.15,1270.09) (N/D) (N/D)
Vd/f (ml/kg) 270.58 8.00 305.68 12.26 270.21 (231.25,301.31) (N/D) (N/D)
Cl/f (ml/kg/day) 21.49 0.62 15.27 0.85 23.14 (19.68,28.14) (N/D) (N/D)
Cmax (ug/ml) 84.88 2.62 78.84 3.25 83.24 (73.70,96.90) (N/D) (N/D)
Sudan Tmax (days) 0.84 0.27 0.91 0.05 1.09 (0.22,1.56) (N/D) (N/D)
t1/2 (days) 7.71 0.14 11.48 0.33 6.72 (5.19,7.38) (N/D) (N/D)
AUC(0 inf) (ug.day/ml) 912.79 24.64 1221.72 45.78 758.75 (622.09,1009.25) (N/D) (N/D)
Vd/f (ml/kg) 299.85 7.98 342.41 11.64 248.61 (217.63,295.44) (N/D) (N/D)
Cl/f (ml/kg/day) 26.94 0.74 20.67 0.78 30.74 (23.87,35.99) (N/D) (N/D)
Cmax (ug/ml) 76.04 2.12 69.83 2.46 83.96 (66.35,90.76) (N/D) (N/D)
Zambia Tmax (days) 0.84 0.27 0.91 0.34 0.35 (0.03,0.43) 0.44 (0.27,0.86)
t1/2 (days) 7.71 0.14 11.48 0.33 7.89 (6.49,10.78) 10.07 (8.24,11.36)
AUC(0 inf) (ug.day/ml) 996.20 27.39 862.22 44.85 743.58 (468.67,911.07) 732.49 (679.03,817.37)
Vd/f (ml/kg) 274.74 16.62 485.17 24.54 457.47 (321.05,518.36) 490.73 (452.06,508.75)
Cl/f (ml/kg/day) 24.68 1.52 29.29 1.54 32.41 (27.60,47.45) 33.87 (29.53,38.45)
Cmax (ug/ml) 82.99 2.38 49.28 2.58 56.94 (47.82,73.37) 50.62 (43.41,54.68)
Table B.4: Comparison of PK parameters by Site and Pregnancy Phase II: Sulfadoxine NLME Model 5
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--------------------------------------------------------------------
Example Code for Single-Level Model (Correlated Random Effects Structure)
--------------------------------------------------------------------
sulf1comp.corr=update(sulf1comp.20,
random=list(pid=pdBlocked(list(pdCompSymm(beta0~preg-1)
,pdCompSymm(beta1~preg-1),pdIdent(beta2~preg-1)))))
summary(sulf1comp.corr)
VarCorr(sulf1comp.corr)
--------------------------------------------------------------------
Example Code for Proportional Random Effects Structure
--------------------------------------------------------------------
#SPECIFYING FUNCTIONS
fm1comp_prop=function(lb0,lb1,lb2,day) {
b0=exp(lb0)
b1=exp(lb1)
b2=exp(lb2)
b0*(-exp(-b1*day)+exp(-b2*day))
}
fm2comp_prop=function(lb1,lb2,lb3,lb4,lb5,day) {
b1=exp(lb1)
b2=exp(lb2)
b3=exp(lb3)
b4=exp(lb4)
b5=exp(lb5)
b2*(-exp(-b1*day)+exp(-b3*day))+b4*(-exp(-b1*day)+exp(-b5*day))
}
#BASIC MODEL (BUILDING FROM SCRATCH)
sulf1comp.propb_scr=nlme(sulfadoxine~fm1comp_propb(lb0,lb1,lb2,day),
data=sulf,
fixed=list(lb0~1,lb1~1,lb2~1),
random=list(pid=pdDiag(lb0+lb1+lb2~1),
preg=pdDiag(lb0+lb1+lb2~1)),
start=list(fixed=c(5,3,0.06)),control=controlS)
summary(sulf1comp.propb_scr)
--------------------------------------------------------------------
Diagnostic Plots for Sulfadoxine NLME Model 7 (Proportional Random Effects
Structure)
--------------------------------------------------------------------
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resid(sulf1comp.prop_scr17, type = "p")
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Figure B.27: Histogram of Residuals: Sulfadoxine NLME Model 7
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Figure B.28: Residuals by Subject ID: Sulfadoxine NLME Model 7
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Figure B.29: QQplot of Residuals: Sulfadoxine NLME Model 7
Random effects
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Figure B.30: QQplot of Random Effects (Subject Level): Sulfadoxine NLME
Model 7
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Figure B.31: QQplot of Random Effects (Phase-within-Subject Level): Sulfa-
doxine NLME Model 7
--------------------------------------------------------------------
Example Code for Mechanistic Models
--------------------------------------------------------------------
#MECHANISTIC MODEL SPECIFICATION
#ADDITIVE SPECIFICATION
#ka, ke, V formulation vs. ka, ke, Cl formulation
fn1=function(day,dose,ka,V,ke) {
((dose*20*ka)/(V*(ka-ke)))*(-exp(-ka*day)+exp(-ke*day))
}
#ka, Cl, V formulation
fn3=function(day,dose,ka,V,CL) {
((dose*20*ka)/(V*(ka-(CL/V))))*(-exp(-ka*day)+exp(-(CL/V)*day))
}
sulf.mech0=nlme(sulfadoxine~fn1(day,dose,ka,ke,V),
data=sulf,
fixed=list(ka~1,ke~1,V~1),
random=list(pid=pdDiag(ke+ka+V~1),
preg=pdDiag(ke+ka+V~1)),
start=list(fixed=c(0.05,0.088,18)),
control=controlS)
summary(sulf.mech0)
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--------------------------------------------------------------------
Diagnostic Plots for Sulfadoxine NLME Model 8 (Mechanistic Model Specifica-
tion)
--------------------------------------------------------------------
resid(sulf.mech3, type = "p")
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Figure B.32: Histogram of Residuals: Sulfadoxine NLME Model 8
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Figure B.33: Residuals by Subject ID: Sulfadoxine NLME Model 8
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Figure B.34: QQplot of Residuals: Sulfadoxine NLME Model 8
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Random effects
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Figure B.35: QQplot of Random Effects (Subject Level): Sulfadoxine NLME
Model 8
Random effects
Qu
an
tile
s o
f s
ta
nd
ar
d 
no
rm
a
l
−2
−1
0
1
2
−0.04 −0.02 0.00 0.02
4
4
ka
−2 −1 0 1
V
Figure B.36: QQplot of Random Effects (Phase-within-Subject Level): Sulfa-
doxine NLME Model 8
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Appendix C
Pyrimethamine Models
--------------------------------------------------------------------
Example Code for Pyrimethamine NLME Model:
--------------------------------------------------------------------
pyr2comp_simple.0=nlme(pyrimethamine~fm2comp(beta1,beta2,beta3,beta4,
beta5,day),
data=pyr,
fixed=list(beta1~1,beta2~1,beta3~1,beta4~1,
beta5~1),
random=list(pid=pdDiag(beta1+beta2+beta3+beta4+
beta5~1)
#,preg=pdDiag(beta2+beta3+beta4+beta5~1)),
start=list(fixed=c(41.16,417.067,1.22,448.43,0.16)),
con rol=controlS)
fixef(pyr2comp_simple.0)
pyr2comp.0=nlme(pyrimethamine~fm2comp(beta1,beta2,beta3,beta4,
beta5,day),
data=pyr,
fixed=list(beta1~1,beta2~1,beta3~1,beta4~1,
beta5~1),
random=list(pid=pdDiag(beta1+beta2+beta3+beta4+
beta5~1),
preg=pdDiag(beta2+beta3+beta4+beta5~1)),
start=list(fixed=c(41,98,1.5,332,0.2)),
control=controlS)
pyr2comp.2=update(pyr2comp.0,
random=list(pid=pdDiag(beta2+beta3+beta4+
beta5~1),
preg=pdDiag(beta2+beta3+beta4+beta5~1)))
summary(pyr2comp.2)
ranef(pyr2comp.2)
--------------------------------------------------------------------
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--------------------------------------------------------------------
Diagnostic Plots for Pyrimethamine NLME Model 1:
--------------------------------------------------------------------
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Figure C.1: Histogram of Residuals: Pyrimethamine NLME Model 1
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Standardized residuals
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Figure C.2: Residuals by Subject ID: Pyrimethamine NLME Model 1
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Figure C.3: QQplot of Residuals: Pyrimethamine NLME Model 1
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Random effects
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Figure C.4: QQplot of Random Effects (Subject Level): Pyrimethamine NLME
Model 1
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Figure C.5: QQplot of Random Effects (Phase-within-Subject Level): Pyrimeth-
amine NLME Model 1
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Scatter Plot Matrix
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Figure C.6: Pairs Plot of Random Effects (Subject Level): Pyrimethamine
NLME Model 1
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Figure C.7: Pairs Plot of Random Effects (Phase-within-Subject Level):
Pyrimeth-amine NLME Model 1
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--------------------------------------------------------------------
Random Effects versus Covariates for Pyrimethamine NLME Model 1 (Subject-
and Occasion-Specific):
--------------------------------------------------------------------
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Figure C.8: Subject-Specific Random Effects for β2 vs. Covariates: Pyrimeth-
amine NLME Model 1
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Figure C.9: Occasion-Specific Random Effects for β2 vs. Covariates: Pyrimeth-
amine NLME Model 1
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Figure C.10: Subject-Specific Random Effects for β3 vs. Covariates: Pyrimeth-
amine NLME Model 1
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Figure C.11: Occasion-Specific Random Effects for β3 vs. Covariates: Pyrimeth-
amine NLME Model 1
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Figure C.12: Subject-Specific Random Effects for β5 vs. Covariates: Pyrimeth-
amine NLME Model 1
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Figure C.13: Occasion-Specific Random Effects for β5 vs. Covariates: Pyrimeth-
amine NLME Model 1
--------------------------------------------------------------------
Diagnostic Plots for Pyrimethamine NLME Model 3:
--------------------------------------------------------------------
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Figure C.14: Histogram of Residuals: Pyrimethamine NLME Model 3
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Figure C.15: Residuals by Subject ID: Pyrimethamine NLME Model 3
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Figure C.16: QQplot of Residuals: Pyrimethamine NLME Model 3
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Figure C.17: Pairs Plot of Random Effects (Subject Level): Pyrimethamine
NLME Model 3
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Figure C.18: Pairs Plot of Random Effects (Phase-within-Subject Level):
Pyrimeth-amine NLME Model 3
--------------------------------------------------------------------
Example Code for Pyrimethamine NLME Model 4:
--------------------------------------------------------------------
pyr2comp.C=update(pyr2comp.2,
fixed=list(beta1~1,beta2~1,beta3~1,beta4~preg,
beta5~1),
random=list(pid=pdDiag(beta4+beta5~1),
preg=pdDiag(beta2+beta5~1)),
start=list(fixed=c(40,100,2,400,70,0.2)),
control=controlS)
pyr2comp.int=update(pyr2comp.2,
fixed=list(beta1~1,beta2~1,beta3~1,beta4~preg*site,
beta5~1),
random=list(pid=pdDiag(beta4+beta5~1),
preg=pdDiag(beta2+beta5~1)),
start=
list(fixed=c(40,100,2,400,70,500,300,10,5,5,5,0.2)),
control=controlS)
anova(pyr2comp.C,pyr2comp.int)
summary(pyr2comp.int)
--------------------------------------------------------------------
Diagnostic Plots for Pyrimethamine NLME Model 4:
--------------------------------------------------------------------
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Figure C.19: Standardized Residuals vs. Fitted Values: Pyrimethamine NLME
Model 4
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Figure C.20: Histogram of Residuals: Pyrimethamine NLME Model 4
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Figure C.21: Residuals by Subject ID: Pyrimethamine NLME Model 4
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Figure C.22: QQplot of Residuals: Pyrimethamine NLME Model 4
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Figure C.23: QQplot of Random Effects (Subject Level): Pyrimethamine NLME
Model 4
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Figure C.24: QQplot of Random Effects (Phase-within-Subject Level):
Pyrimeth-amine NLME Model 4
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Figure C.25: Pairs Plot of Random Effects (Subject Level): Pyrimethamine
NLME Model 4
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Figure C.26: Pairs Plot of Random Effects (Phase-within-Subject Level):
Pyrimeth-amine NLME Model 4
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-----------------------------------------------------------------------------------------------------------------------------
Comparison of PK Parameters by Site and Pregnancy Status: Pyrimethamine NLME Model 4 (Nyunt et al. Reported Values [5])
-----------------------------------------------------------------------------------------------------------------------------
Model 4 Nyunt et al. (Reported) [5]
Pregnant Postpartum Pregnant Postpartum
Country Parameter Mean Std. Error Mean Std. Error Median IQR Median IQR
Mali AUC(0−inf) (ng.day/ml) 2040.28 110.9 1439.23 107.13 1,715 (1,528;1,920) 1,104 (791;1,251)
Cl/f (ml/kg/day) 602.62 32.75 877.3 65.3 717 (620;827) 1,219 (1,019;1,695)
Cmax (ng/ml) 304.07 40.7 250.9 35.96 362 (340;429) 323 (281;371)
Mozambique AUC(0−inf) (ng.day/ml) 3469.98 120.95 3088.15 186 3,277 (2,810;4,237) N/D N/D
Cl/f (ml/kg/day) 354.33 12.35 408.86 24.63 335 (309;466) N/D N/D
Cmax (ng/ml) 489.77 73.18 431.75 51.23 508 (425;631) N/D N/D
Sudan AUC(0−inf) (ng.day/ml) 2583.93 109.62 2441.41 243.73 2,014 (1,626;2,551) N/D N/D
Cl/f (ml/kg/day) 475.83 20.19 517.17 51.63 600 (423;689) N/D N/D
Cmax (ng/ml) 372.92 50.75 359.52 30.66 400 (325;473) N/D N/D
Zambia AUC(0−inf) (ng.day/ml) 1198.46 83.69 1010.82 NaN** 1,047 (868;1,175) 804 (668;1,032)
Cl/f (ml/kg/day) 1025.9 71.64 1249.11 NaN 1,305 (989;1,458) 1,466 (1,325;1,907)
Cmax (ng/ml) 192.54 43.65 161.26 32.4 241 (198;271) 190 (174;231)
Table C.1: Comparison of PK parameters by Site and Pregnancy Phase: Pyrimethamine NLME Model 4
N/D*= Not determined, NaN**= Computation not possible
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Appendix D
Sequential Models
--------------------------------------------------------------------
Example Code for Sequential NLMEModel (Impact of Pyrimethamine predicted
concentrations on Sulfadoxine):
--------------------------------------------------------------------
#BASIC MODEL
seq1comp.0=nlme(sulfadoxine~fm1comp(beta0,beta1,beta2,day),
data=sulfnew,
fixed=list(beta0~1,beta1~1,beta2~1),
random=list(pid=pdDiag(beta0+beta1+beta2~1),
preg=pdDiag(beta0+beta1+beta2~1)),
start=list(fixed=c(70,10,0.07)),
control=controlS)
summary(seq1comp.0)
#COVARIATES
seq1comp.1=nlme(sulfadoxine~fm1comp(beta0,beta1,beta2,day),
data=sulfnew,
fixed=list(beta0~pyr_pred,beta1~1,beta2~1),
random=list(pid=pdDiag(beta0+beta1~1),
preg=pdDiag(beta0+beta1+beta2~1)),
start=list(fixed=c(70,0,10,0.06)),
control=controlS)
summary(seq1comp.1)
--------------------------------------------------------------------
Random Effects versus Covariates for Sequential NLME Model 1:
--------------------------------------------------------------------
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Figure D.1: Occasion-Specific Random Effects for β0 vs. Covariates: Sequential
NLME Model 1
be
ta
1
−10
−5
0
5
10
0 2 3
trimester
Mali Mozambique Sudan Zambia
site
0 1
anaem10
0 50 100 150 200 250
−10
−5
0
5
10
pyr_pred
Figure D.2: Occasion-Specific Random Effects for β1 vs. Covariates: Sequential
NLME Model 1
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Figure D.3: Subject-Specific Random Effects for β2 vs. Covariates: Sequential
NLME Model 1
--------------------------------------------------------------------
Diagnostic Plots for Sequential NLME Model 2:
--------------------------------------------------------------------
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Figure D.4: Histogram of Residuals: Sequential NLME Model 2
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Figure D.5: Residuals by Subject ID: Sequential NLME Model 2
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Figure D.6: QQplot of Residuals: Sequential NLME Model 2
Random effects
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Figure D.7: QQplot of Random Effects (Subject Level): Sequential NLME
Model 2
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Figure D.8: QQplot of Random Effects (Phase-within-Subject Level): Sequen-
tial NLME Model 2
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Figure D.9: Pairs Plot of Random Effects (Subject Level): Sequential NLME
Model 2
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Figure D.10: Pairs Plot of Random Effects (Phase-within-Subject Level): Se-
quential NLME Model 2
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Figure D.11: Fitted Values vs. Observed: Sequential NLME Model 2
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--------------------------------------------------------------------
Diagnostic Plots for Sequential NLME Model 3:
--------------------------------------------------------------------
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Figure D.12: Histogram of Residuals: Sequential NLME Model 3
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Figure D.13: Residuals by Subject ID: Sequential NLME Model 3
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Figure D.14: QQplot of Residuals: Sequential NLME Model 3
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Figure D.15: QQplot of Random Effects (Subject Level): Sequential NLME
Model 3
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Figure D.16: QQplot of Random Effects (Phase-within-Subject Level): Sequen-
tial NLME Model 3
239
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
beta0.(Intercept)
be
ta
1
−5
0
5
−30 −20 −10 0 10 20 30
MOND_008/1
ZAMB_004/1
Figure D.17: Pairs Plot of Random Effects (Phase-within-Subject Level): Se-
quential NLME Model 3
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Appendix E
Simultaneous Models
(Covariate Specification)
--------------------------------------------------------------------
Example Code for Simultaneous NLME Model (Covariate Specification):
--------------------------------------------------------------------
#TRIPLE-EXPONENTIAL: BASIC MODEL
simcov2.basic=nlme(conc~fm2comp(beta1,beta2,beta3,beta4,beta5,day),
data=dta,
fixed=(beta1+beta2+beta3+beta4+beta5~1),
random=list(pid=pdDiag(beta2+beta3+beta4+beta5~1),
preg=pdDiag(beta2+beta3+beta4+beta5~1)),
start=c(beta1=45,beta2=330,beta3=0.2,beta4=100,beta5=1),
control=controlS)
summary(simcov2.basic)
#FITTING DRUG TYPE
simcov2.1=update(simcov2.basic,
fixed=list(beta1~pk_fact,beta2~pk_fact,beta3~pk_fact,
beta4~pk_fact,beta5~pk_fact),
random=list(pid=pdDiag(beta2+beta3+beta4+beta5~1),
preg=pdDiag(beta2+beta3+beta4+beta5~1)),
start=list(fixed=c(45,0,330,0,0.2,0,100,0,1,0)),
control=controlS)
anova(simcov2.basic,simcov2.1)
summary(simcov2.1)
--------------------------------------------------------------------
Diagnostic Plots for Simultaneous NLME Model 1 (Covariate Specification)
--------------------------------------------------------------------
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Figure E.1: Histogram of Residuals: Simultaneous NLME Model 1
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Figure E.2: Residuals by Subject ID: Sequential NLME Model 1
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Figure E.3: QQplot of Residuals: Simultaneous NLME Model 1
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Figure E.4: QQplot of Random Effects (Subject Level): Simultaneous NLME
Model 1
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Figure E.5: QQplot of Random Effects (Phase-within-Subject Level): Simulta-
neous NLME Model 1
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Figure E.6: Pairs Plot of Random Effects (Subject Level): Simultaneous NLME
Model 1
244
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Scatter Plot Matrix
beta2.(Intercept)0
50
100 0 50 100
−100
−50
0
−100 −50 0
beta3.(Intercept)0e+00
5e−11 0e+005e−11
−1e−10
−5e−11
−1e−10−5e−11
beta4.(Intercept)0e+00
1e−07
2e−07 0e+001e−072e−07
−3e−07
−2e−07
−1e−07
−3e−07−2e−07−1e−07
beta5.(Intercept)
0e+00
2e−09 0e+002e−09
−4e−09
−2e−09
−4e−09−2e−09
Figure E.7: Pairs Plot of Random Effects (Phase-within-Subject Level): Simul-
taneous NLME Model 1
--------------------------------------------------------------------
Random Effects vs. Covariates for Simultaneous NLME Model 2 (Covariate
Specification)
--------------------------------------------------------------------
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Figure E.8: Occasion-Specific Random Effects for β3 vs. Covariates: Simulta-
neous NLME Model 2
--------------------------------------------------------------------
Diagnostic Plots for Simultaneous NLME Model 5 (Covariate Specification)
--------------------------------------------------------------------
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Figure E.9: Histogram of Residuals: Simultaneous NLME Model 5
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Figure E.10: QQplot of Residuals: Simultaneous NLME Model 5
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Figure E.11: QQplot of Random Effects (Subject Level): Simultaneous NLME
Model 5
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Figure E.12: QQplot of Random Effects (Phase-within-Subject Level): Simul-
taneous NLME Model 5
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Figure E.13: Pairs Plot of Random Effects (Subject Level): Simultaneous
NLME Model 5
beta2.(Intercept)
be
ta
2.
pk
_f
a
ct
su
lf
−20
−10
0
10
−40 −20 0 20 40
MALI_001/0
ZAMB_023/0
Figure E.14: Pairs Plot of Random Effects (Phase-within-Subject Level): Si-
multaneous NLME Model 5
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Appendix F
Simultaneous Models
(Indicator Specification)
--------------------------------------------------------------------
Example Code for Simultaneous NLME Model (Indicator Specification):
--------------------------------------------------------------------
simcov_indic.16=update(simcov_indic.6,
fixed=list(beta0~preg+sitenew3,beta1~1,beta2~preg,
beta3~1,beta4~preg+site,beta5~1,beta6~1,beta7~1),
random=list(pid=pdBlocked(list(pdDiag(beta0~1),pdDiag(beta3+beta4~1))),
preg=pdBlocked(list(pdDiag(beta0~1),pdDiag(beta3+beta4~1)))),
start=list(fixed=(c(70,0,0,0,10,0.06,0,150,400,70,500,300,50,40,2,0.2))),
control=controlS)
summary(simcov_indic.16)
anova(simcov_indic.14,simcov_indic.16)
--------------------------------------------------------------------
Diagnostic Plots for Simultaneous NLME Model 1 (Indicator Specification)
--------------------------------------------------------------------
250
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
resid(simcov_indic.16, type = "p")
Fr
eq
ue
nc
y
−5 0 5
0
20
0
40
0
60
0
80
0
10
00
12
00
Figure F.1: Histogram of Residuals: Simultaneous NLME Model 1 (Indicator)
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Figure F.2: QQplot of Residuals: Simultaneous NLME Model 1 (Indicator)
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Figure F.3: QQplot of Random Effects (Subject Level): Simultaneous NLME
Model 1 (Indicator)
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Figure F.4: QQplot of Random Effects (Phase-within-Subject Level): Simulta-
neous NLME Model 1 (Indicator)
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